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Abstract 
Mitochondrial DNA (mtDNA) mutations accumulate somatically with age in normal 
individuals causing defects in oxidative phosphorylation (OXPHOS), with no selective 
pressures promoting their accumulation or removal. mtDNA mutations are also inherited 
through the germline causing mtDNA disease. In contrast to somatic mutations, they are lost 
in blood over time, suggesting selective pressure against them. This project aims to further 
investigate the selective loss of inherited mtDNA point mutations in mitotic tissues, using 
gastrointestinal epithelium as a model. 
I have determined the mtDNA mutation load and OXPHOS protein levels in various 
gastrointestinal segments of patients with the inherited m.3243A>G and m.8344A>G mtDNA 
mutations. The data shows selective loss of these mutations in the mitotic epithelium, but not 
the post-mitotic smooth muscle and suggests that the selection occurs in the gastrointestinal 
stem cells.   
I have further characterised a mouse model of mitochondrial disease carrying the inherited 
m.5024C>T mutation and have used them to study potential mechanisms of selective mtDNA 
mutation loss. These mice show: (1) loss of the m.5024C>T in the mitotic spleen and 
gastrointestinal epithelium with age but not in the post-mitotic tissues; (2) the rate of mutation 
loss is related to the rate of epithelial cell turnover; (3) the mutation loss in the intestinal 
epithelium is consistent with maintained levels of OXPHOS proteins with age, in contrast to 
the accumulation of cells with OXPHOS defects in aged wild-type mice; (4) significantly 
upregulated mitochondrial proliferation in the intestinal epithelium. 
These key findings highlight differences in the selective pressures on inherited and somatic 
mtDNA mutations in mitotic tissue, and the contrasting tissue-specific dynamics of inherited 
mtDNA mutations in mitotic and post-mitotic tissues. These findings are important to further 
the understanding of phenotype development, progression and potential treatment of mtDNA 
disease, and the effect of mtDNA mutations on ageing stem cell biology. 
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Chapter 1 Introduction 
1.1 Mitochondria 
Mitochondria are dynamic organelles located in the cytoplasm of all mammalian eukaryotes. 
Their primary function is to supply cellular activities with energy in the form of adenosine 
triphosphates (ATP) through oxidative phosphorylation (OXPHOS) (Hatefi, 1985). 
Mitochondria also contribute to many other processes, such as generation of reactive oxygen 
species (ROS) (Sena and Chandel, 2012), calcium management (Raffaello et al., 2016), iron-
sulphur (Fe-S) cluster biogenesis (Stehling and Lill, 2013) and apoptosis (Wang and Youle, 
2009), which makes mitochondria essential to cellular function and metabolism.   
 
1.1.1 Origin and evolution 
Two theories have been proposed to account for the origin and evolution of mitochondria. The 
earlier “serial hypothesis” describes that endosymbiosis is comprised of two events: the 
formation of the nucleus in Archaebacteria and the subsequent endocytosis of Eubacteria 
(proto-mitochondria) (Margulis, 1971). The alternative theory, “hydrogen hypothesis”, 
describes a simultaneous formation of nucleus and mitochondrion through the integration of 
hydrogen-producing Eubacteria and hydrogen-dependent Archaebacteria (Martin and Müller, 
1998). Both of the hypotheses agree that endosymbiosis occurs and the majority of the 
Eubacterial genes were transported to the host nucleus, which establishes a steady symbiotic 
relationship between them.  
 
1.1.2 Structure 
The first electron micrograph showed oval mitochondria with 1 – 2 µm in length and 0.5 – 1 
µm in diameter (Palade, 1952). However, the shape of mitochondria is changeable, from the 
elongated rod to oval. The size and number of mitochondria are also cell-specific and 
dynamic, largely depending on the metabolic requirement of the cell (Scarpulla, 2011; Chan, 
2012). Mitochondria have a double-membrane structure, comprising an outer and inner 
membrane with the intermembrane space in between (Figure 1.1). The outer mitochondrial 
membrane (OMM) separates mitochondria from the cytosol, whereas the inner mitochondrial 
membrane (IMM) invaginates inwards to form cristae and enclose the matrix (Figure 
1.1)(Palade, 1952). 
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The OMM is a phospholipid bilayer, resembling a normal cell membrane. It is punctuated 
with numerous voltage-dependent anion channels (VDAC, a.k.a. porin), which permits the 
shuttling of small molecules up to 10 kDa (Bayrhuber et al., 2008; Shoshan-Barmatz et al., 
2010). The IMM is a protein-rich lipid bilayer, containing ~75% proteins and ~25% lipidic 
constituents, in particular, cardiolipin (Fleischer et al., 1961; Ardail et al., 1990). This 
structure ensures electrochemical insulation that is crucial for OXPHOS and endows the IMM 
impermeability to polar molecules but not O2, CO2, H2O and NH3. Two components: the 
inner boundary membrane (IBM) and the cristae membrane (CM) form the IMM through the 
connections at cristae junctions (Frey and Mannella, 2000). The IBM is intimately interacted 
with the OMM and is enriched in proteins involved in mitochondrial fusion and import of 
nuclear-encoded proteins (Vogel et al., 2006). The CM is densely folded, providing multi-
subunit OXPHOS complexes with an extensive anchoring surface. The CM is also enriched in 
proteins associated with the transport of mitochondrial translation products and Fe-S cluster 
biogenesis (Vogel et al., 2006). 
The majority of mitochondrial proteins are nuclear encoded and are required to be imported 
into mitochondria to function. Most of these proteins are synthesised as a pre-protein with an 
N-terminal presequence, which are recognised and imported by the translocase of the outer 
membrane (TOM) and the presequence translocase of the inner membrane (TIM23) into the 
matrix to be further cleaved and processed (Wiedemann and Pfanner, 2017). Other machinery, 
such as the sorting and assembly machinery (SAM), mitochondrial import complex (MIM) at 
the OMM and the carrier translocase of the inner membrane (TIM22) at the IMM allow the 
import of peptides without any cleavable presequence (Wiedemann and Pfanner, 2017). In 
addition, the IMM contains abundant transporters termed adenine nucleotide translocator 
(ANT), for the exchange of ATP, ADP and ions between the matrix and the intermembrane 
space (Pfaff and Klingenberg, 1968). 
The mitochondrial matrix encompasses multiple copies of mitochondrial DNA (mtDNA) 
packed in associated proteins to form nucleoids and transcription and translation machinery 
for the expression of mtDNA (Bonekamp and Larsson, 2018). It is also the site of Fe-S cluster 
biogenesis and important intermediary metabolism for OXPHOS, such as the TCA cycle and 
fatty-acid β-oxidation (Llopis et al., 1998). 
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Figure 1.1 Microstructure of a mitochondrion. The mitochondrion is a double-membrane organelle 
containing 2-10 copies of mtDNA combined with proteins as nucleoids in the matrix. Respiratory chain 
complexes that are responsible for producing abundant energy via respiratory chain complexes at the 
inner mitochondrial membrane. 
 
1.2 Mitochondrial Function 
1.2.1 ATP synthesis 
To maintain normal cellular functions, eukaryotic cells consume energy by hydrolysing ATP 
produced by aerobic and anaerobic cellular respiration. Mitochondria play an essential role in 
aerobic respiration to produce the majority of ATP for cellular activities. Resources such as 
monosaccharides, fatty acids and amino acids can all be utilised to generate ATP, in which 
glucose, a type of monosaccharide, is preferable (Smeitink et al., 2001; Koopman et al., 2012; 
Koopman et al., 2013). ATP generation through aerobic respiration takes place in the cytosol 
where glucose is catalysed by a series of enzymes to produce pyruvate and reduced 
nicotinamide adenine dinucleotides (NADH), a crucial electron carrier (Koopman et al., 
2013). If the environment is oxygen-deficient, pyruvate tends to undergo anaerobic respiration 
catalysed by lactate dehydrogenase (LDH) to generate a small number of ATP molecules and 
lactic acid as a metabolite in the cytosol (Koopman et al., 2013). This process is fundamental 
for providing energy for cells that do not contain mitochondria (e.g. erythrocytes) or for 
skeletal muscle fibres for sudden intense activities (Koopman et al., 2013). In an oxygen-
sufficient environment, pyruvate will be transferred into the mitochondrial matrix, and by 
virtue of pyruvate dehydrogenase (PDH), it will be converted to equimolar NADH and acetyl 
coenzyme A (CoA) through pyruvate decarboxylation (Koopman et al., 2013). Acetyl CoA 
serves as the major substrate for the tricarboxylic acid (TCA) cycle (a.k.a. citric acid cycle or 
Krebs cycle) in the mitochondrial matrix, where NADH and another electron carrier, reduced 
flavin adenine dinucleotide (FADH2) are yielded. NADH and FADH2 are subsequently 
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transported to the IMM for OXPHOS, the end stage of aerobic respiration (Figure 1.2) 
(DiMauro and Schon, 2003). 
 
Figure 1.2 The OXPHOS system. The respiratory chain complex I (CI) and complex II (CII) obtain 
electrons from NADH and FADH2 respectively and transport them to complex III (CIII) through 
ubiquinone (Q). Electrons are further transferred via cytochrome c (Cyt c) to complex IV (CIV) and 
employed to reduce oxygen to water. H+ are pumped into the intermembrane space (IMS) at the sites of 
CI, CIII and CIV, the reflux of which are employed by complex V (CV) to synthesise ATP. IMM, inner 
mitochondrial membrane. Dotted arrows indicate the transport route of electrons. 
 
1.2.1.1 OXPHOS system and respiratory chain complexes 
OXPHOS is conducted through five respiratory chain (RC) complexes: complex I, II, III and 
IV (CI, CII, CIII and CIV) together as the electron transport chain (ETC) and the ATP 
synthase (CV) (Hatefi, 1985). In brief, the electron carriers, NADH and FADH2, donate 
electrons to RC complex I and II, which are transported through the ETC (Hatefi, 1985). In 
the course of this process, protons (H+) are pumped from the mitochondrial matrix to the 
intermembrane space at CI, CII and CIV to establish an electrochemical gradient, which is 
subsequently employed by CV to generate ATP (Figure 1.2) (Hatefi, 1985).  
The RC complexes except CII have a transmembrane architecture with multiple subunits 
encoded by both nuclear and mitochondrial DNA (Brière et al., 2005; Koopman et al., 2013). 
The L-shaped CI (a.k.a. NADH: ubiquinone oxidoreductase) is the largest RC complex with 
45 subunits: seven encoded by mtDNA and 38 encoded by nuclear DNA (nDNA). Its 
lipophilic arm is embedded in the OMM whereas the hydrophilic arm projects to the 
mitochondrial matrix (Clason et al., 2010). CII (a.k.a. succinate: ubiquinone oxidoreductase) 
5 
 
is comprised of four subunits: two of them (SDHA and SDHB) protrude into the matrix with 
the base (SDHC and SDHD) anchoring to the OMM. It is entirely encoded by nDNA and is 
also involved in the TCA cycle as succinate dehydrogenase to convert succinate to fumarate 
(Brière et al., 2005). CIII (a.k.a. ubiquinol: cytochrome c oxidoreductase) comprises 11 
subunits, of which one (cytochrome b) is encoded by mtDNA. The terminal of the ETC is 
CIV (a.k.a. cytochrome c oxidase) that incorporates 13 subunits, of which three are mtDNA-
encoded (MT-CO1, MT-COII and MT-COIII; also referred to as COX1, COX2 and COX3). 
ATP is produced at CV (a.k.a. F0F1 ATP synthase) that is composed of two rotary motors: the 
F0 domain spanning the IMM and the F1 domain projecting to the matrix. It comprises 19 
subunits, and two of them in the F0 domain (ATP6 and ATP8) are encoded by mtDNA. 
Information of the subunits in each RC complex is summarised in Table 1.1. 
 
Respiratory 
chain complexes 
Total number 
of subunits 
Number of mtDNA-
encoded subunits 
Subunit-encoding genes in 
mtDNA 
Complex I 45 7 
ND1, ND2, ND3, ND4, 
ND4D, ND5 and ND6 
Complex II 4 0 N/A 
Complex III 11 1 Cytochrome b 
Complex IV 13 3 COXI, COXII and COXIII 
Complex V 19 2 ATP6 and ATP8 
Table 1.1 A summary of mtDNA-encoded subunits in each respiratory chain complex.  
 
During OXPHOS, CI and CII receive the electrons from NADH and FADH2 respectively and 
transport them to ubiquinone (a.k.a. coenzyme Q10; CoQ10) (Figure 1.2). In parallel, CI pumps 
four protons to the intermembrane space. Ubiquinone is ultimately reduced to ubiquinol, both 
of which are lipophilic and can travel freely in the IMM. Electrons from ubiquinol are 
sequentially transferred by CIII to CIV via cytochrome c (Figure 1.2). Concurrently, CIII 
pumps four protons into the intermembrane space through continuous processing of two 
ubiquinol molecules (Hayashi and Stuchebrukhov, 2010). Cytochrome c is a nuclear-encoded 
haemoprotein, which also plays an important role in the mitochondria-dependent intrinsic 
pathway of apoptosis (Hüttemann et al., 2011). Electrons carried by cytochrome c ultimately 
reach CIV, the final acceptor that reduces oxygen to water, which engenders translocation of 
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four protons into the intermembrane space (Figure 1.2). Protons pumped at CI, CIII and CIV 
build up an H+ electrochemical gradient across the IMM (Figure 1.2). The backflow of 
protons through CV drives the rotation of its two sectors to phosphorylate ADP to ATP 
(Figure 1.2) (Okuno et al., 2011; Koopman et al., 2012). OXPHOS can generate 
approximately 30 ATP molecules in an ideal oxygen-sufficient environment with the 
consumption of one glucose molecule, making it the most efficient machinery to produce 
energy in eukaryotes (Rich, 2003). However, its efficiency never reaches 100% due to the 
leakage of protons and electrons (Brand, 1990; Jastroch et al., 2010). 
OXPHOS defects are common in patients with mitochondrial disease, which can occur in a 
single RC complex or in multiple complexes. Isolated CI defect is the most frequent type of 
isolated defects, followed by those in CIV and CV, whereas isolated CII defect is extremely 
rare (Mayr et al., 2015; Alston et al., 2017). Compared with isolated deficiency, combined 
defects in multiple RC complexes is more common in mitochondrial disease, which is 
predominantly caused by mutations in nuclear genes that encode proteins associated with 
mtDNA maintenance and mitochondrial protein synthesis (Mayr et al., 2015). Combined 
defects are also seen in patients with mutations in mt-tRNA genes (Rocha et al., 2015).  
 
1.2.1.2 Respiratory chain supercomplexes 
RC complexes not only exist as single entities but also link each other to form 
supercomplexes (Dudkina et al., 2010), which was revealed by means of blue native 
polyacrylamide gel electrophoresis (BN-PAGE) and electron microscopy (Schägger and 
Pfeiffer, 2000; Schäfer et al., 2006). In mammalian cells, CI associates with CIII, but more 
frequently, it integrates with CIII and CIV together to form supercomplexes termed 
“respirasome” (Winge, 2012). This structure is functional; it is able to complete the ETC in 
the presence of ubiquinone and cytochrome c (Acı́n-Pérez et al., 2004). Assembly of 
respirasomes is organised. An intermediate of CI is initially created as a scaffold for 
subsequent aggregation of CIII and IV, which incorporates the catalytic subunit of CI for the 
final activation of respirasomes (Moreno-Lastres et al., 2012). Lack of any component 
complex would fail the formation of supercomplexes (Acı́n-Pérez et al., 2004). Functional 
respirasomes require intact complex constitutes. Specific mutations in an individual complex 
can cause secondary defects in other components of the supercomplex (Acı́n-Pérez et al., 
2004; Winge, 2012). The formation of supercomplexes is suggested to be advantageous, as it 
can probably enhance OXPHOS efficiency by facilitating electron carriers to targeted 
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enzymes and reducing the leak of protons and electrons (Schägger and Pfeiffer, 2000; Lenaz 
and Genova, 2009). The interactions between RC complexes have a profound implication for 
understanding mitochondrial dysfunction, in particular, combined OXPHOS defects, in 
mitochondrial disease and ageing. 
 
1.2.2 Iron-sulphur cluster biogenesis 
Mitochondria are the main site of haem and Fe-S cluster biogenesis and are essential for iron 
metabolism (Wang and Pantopoulos, 2011). Cellular iron is imported into the mitochondrial 
matrix by mitoferrin located at the IMM for multi-stage Fe-S cluster production (Paradkar et 
al., 2009). Early synthesis machinery includes mitochondrial protein Isu1 (also Isu2 in yeast) 
as a scaffold with sulphide donated by the cysteine desulfurase complex. It is then delivered 
to Grx5 by virtue of chaperone proteins and can be received by specific mitochondrial 
apoproteins or assembled into polypeptide chains to form Fe/S proteins with the aid of Fe-S 
cluster targeting factors (e.g. Nfu1) (Stehling and Lill, 2013; Braymer and Lill, 2017). Fe-S 
clusters primarily contribute to OXPHOS, in which they facilitate electron transport and 
catalytic enzyme reactions in the ETC. They are also involved in the regulation and 
maintenance of iron homeostasis in mitochondria (Schultz and Chan, 2001). 
 
1.2.3 Calcium homeostasis 
Mitochondria are important for regulating intracellular calcium ion (Ca2+) concentrations, 
where the mitochondrial membrane potential established by the ETC could drive the 
accumulation of Ca2+ in the mitochondrial matrix (Rizzuto et al., 2012). Ca2+ crosses the 
OMM through VDAC and is imported into the matrix by the mitochondrial calcium 
uniporters (Kirichok et al., 2004). The outflow of Ca2+ is facilitated by Na+/Ca2+ exchangers 
(Palty et al., 2010). Ca2+ is an important signalling molecule mediating cellular 
communication (Hofer et al., 2000), apoptosis (Orrenius et al., 2003) and ATP production 
(Tarasov et al., 2012) and plays a critical role in a number of physiological activities, such as 
the regulation of muscle contraction, synaptic transmission of signals as well as development 
of neuronal polarity and axonogenesis (Mattson and Partin, 1999; Abramov and Duchen, 
2010; Gehlert et al., 2015). The key role that mitochondria play in the regulation of Ca2+ 
homeostasis further expands their influence on a variety of cellular functions. 
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1.2.4 Generation of reactive oxygen species 
Reactive oxygen species (ROS) are a collective name of superoxide radical anions (O2
-), 
hydroxyl radicals (-OH) and hydrogen peroxide (H2O2), which derive from incomplete 
reduction of oxygen (Hämäläinen, 2016; Tan and Suda, 2017). The commonly believed major 
form of ROS, H2O2 that easily diffuse across membranes, is transformed from O2
- by 
superoxide dismutase (SODs) (Dikalov and Harrison, 2012; Sena and Chandel, 2012). 
Although ROS are produced at multiple sites, it is generated mainly at mitochondrial ETC, in 
particular, CI and CIII, where CIII but not CI can produce ROS into the intermembrane space 
(Sena and Chandel, 2012). ROS are involved in a variety of signalling pathways regulating 
activation of immune cells, autophagy, senescence and apoptosis (Valko et al., 2007; Sena 
and Chandel, 2012). ROS are also crucial for the maintenance of stem cell homeostasis and 
play a role in manipulating cell proliferation and differentiation (Hämäläinen, 2016; Tan and 
Suda, 2017). However, an excessive amount of ROS beyond the load of antioxidant systems 
can be detrimental. They cause cellular oxidative stress and damage biomolecules, such as 
DNA, proteins and lipids, which is believed to contribute to ageing (Forkink et al., 2010; 
Chen et al., 2017).  
 
1.2.5 Apoptosis 
Apoptosis is a delicate programmed process of cell death, which is essential for the 
maintenance of tissue homeostasis (Pellettieri and Alvarado, 2007). In mammalian cells, 
apoptosis is conducted through two pathways: mitochondria-independent extrinsic pathway 
and mitochondria-dependent intrinsic pathway, which display crosstalk and both lead to 
activation of executioner caspases, caspase 3 and caspase 7 to complete the death programme 
(Wang and Youle, 2009; Tait and Green, 2010; Lopez and Tait, 2015). In the intrinsic 
pathway, apoptotic stimuli, e.g. DNA damage, oxidative stress and excessive Ca2+, activate 
pro-apoptotic BH3-only proteins, which further triggers the activation of pro-apoptotic 
effector proteins BAX and BAK, causing mitochondrial outer membrane permeabilisation 
(MOMP)(Cory and Adams, 2002; Pradelli et al., 2010). Anti-apoptotic BCL-2 proteins can 
bind BH3-only proteins and activated BAX and BAK to antagonise this process (Cory and 
Adams, 2002; Lopez and Tait, 2015). Once MOMP occurs, it is irreversible and triggers the 
release of apoptotic proteins cytochrome c from the mitochondrial intermembrane space to the 
cytosol (Lopez and Tait, 2015). Cytochrome c then binds apoptotic protease activating factor 
1 (APAF1), altering its conformation and causing its oligomerisation to form heptameric 
apoptosomes (Wang and Youle, 2009; Tait and Green, 2010; Lopez and Tait, 2015). 
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Subsequently, apoptosomes activate the initiator caspase protein, caspase 9, which cleaves 
and activates the executioner proteins, caspase 3 and caspase 7. In addition to cytochrome c, 
mitochondria discharge other apoptotic proteins, such as SMAC (a.k.a. DIABLO) and OMI, 
to facilitate the ultimate activation of the executioners by counteracting the function of the 
endogenous caspase inhibitor XIAP (Srinivasula et al., 2001; Eckelman et al., 2006; Tait and 
Green, 2010). 
 
1.3 Mitochondrial dynamics and turnover 
1.3.1 Fusion and fission 
Mitochondria are dynamic organelles that constantly undergo fusion and fission, endowing 
them miscellaneous morphology (Chan, 2012). These two processes are also involved in the 
regulation of various mitochondrial functions, including maintenance of mtDNA stability, 
respiration, apoptosis, stress handling and quality control (Chan, 2012).  
Both fusion and fission are mediated by a group of large guanosine triphosphates (GTPase) 
that are members of the dynamin family (Youle and Van Der Bliek, 2012). These proteins are 
highly conserved between different species (Hoppins et al., 2007). Mitochondrial fusion 
involves the coordinated merging of the OMM and the IMM. In mammals, fusion of the 
OMM is mediated by transmembrane proteins Mfn1 and Mfn2 at the OMM and fusion of the 
IMM is regulated by Opa1 (Chen et al., 2003; Cipolat et al., 2004; Chan, 2012; Youle and 
Van Der Bliek, 2012). Mitochondrial fission in mammals is manipulated by a cytosolic 
protein Drp1, which needs to be recruited by secondary proteins, e.g. Mid49, Mid51 and Mff, 
to mitochondria, where it forms spirals to constrict and sever both the OMM and IMM 
(Smirnova et al., 2001; Losón et al., 2013; van der Bliek et al., 2013). 
Fusion and fission are crucial for modulating mitochondrial population and function. Below a 
specific threshold of mitochondrial stress, fusion benefits the maintenance of mitochondrial 
function by compensating damaged mitochondria with comparatively healthy mitochondria 
until they have reached the limit of repair (Nakada et al., 2001; Youle and Van Der Bliek, 
2012). Fission increases mitochondrial population and also segregates severely damaged 
mitochondria, contributing to mitophagy, i.e. selective autophagy of mitochondria, to 
maintain a healthy mitochondrial network (Youle and Van Der Bliek, 2012). Fusion and 
fission are also essential for embryonic development and directly affect embryonic survival 
(Chen et al., 2003). Defects in mitochondrial dynamics are associated with ageing, which 
mainly manifest in the neurons of cases with neurodegenerative disease (Chen and Chan, 
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2006; Seo et al., 2010). Furthermore, fusion and fission are involved in the regulation of stem 
cell homeostasis (Su et al., 2018). Increased fission tends to maintain stem cell self-renewal 
and potency, whereas fusion counteracts the effect of fission and drives stem cell 
differentiation (Chen and Chan, 2017). 
 
1.3.2 Mitophagy 
Mitophagy is a quality control process that selectively removes dysfunctional mitochondria 
by autophagy from mitochondrial populations (Kim et al., 2007). Mitochondrial fission is 
requisite to segregate the impaired portion of mitochondria to facilitate mitophagy (Chan, 
2012; Youle and Van Der Bliek, 2012). Mitophagy is mediated primarily through the 
PINK1/Parkin pathway (Kitada et al., 1998; Valente et al., 2004). In healthy mitochondria, 
PTEN-induced putative kinase protein 1 (PINK1) is imported to the mitochondrial 
intermembrane space and cleaved by protease PARL (Meissner et al., 2011). When 
mitochondria are dysfunctional and uncoupled, the import of PINK1 is blocked, leading to its 
accumulation at the OMM (Narendra et al., 2008). PINK1 then recruits E3 ubiquitin ligase 
Parkin from the cytosol, resulting in ubiquitylation of OMM proteins (Narendra et al., 2008). 
This entails mitochondria to be engulfed by double-membrane vesicles, i.e. autophagosomes, 
which then fuse with lysosomes for degradation (Youle and Narendra, 2011).  
 
1.3.3 Mitochondrial biogenesis 
Mitochondrial biogenesis is a process that aims to increase mitochondrial mass and mtDNA 
copy number to meet the energy demand of cells, which largely depends on delicate 
regulations of a group of nuclear-encoded proteins (Lee and Wei, 2005). Mitochondrial 
biogenesis responds to environmental change (e.g. cold), exercise, calorie restriction and 
oxidative stress (Lee and Wei, 2005; Zhu et al., 2013). Peroxide proliferator activates receptor 
γ coactivator 1 alpha (PCG-1α) is central to mitochondrial biogenesis pathways (Puigserver 
and Spiegelman, 2003; Jornayvaz and Shulman, 2010; Fernandez-Marcos and Auwerx, 2011). 
Major upstream signalling regulators of PCG-1α include AMP-activated protein kinase 
(AMPK), Sirtuin 1 (SIRT1), cAMP responsive element binding protein (CREB) and p38 
mitogen-activated protein kinase (p38 MAPK) (Scarpulla, 2011; Scarpulla et al., 2012; Zhu et 
al., 2013). Under calorie restriction, AMPK detects the fluctuation of AMP/ATP ratio and 
phosphorylates PCG-1α; in addition, SIRT senses the increase in the NAD+ level and 
deacetylates PCG-1α, which both lead to upregulation of PCG-1α (Cantó and Auwerx, 2009). 
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Exercise stimulates PCG-1α expression by activating p38 MARK as well as AMPK 
(Fernandez-Marcos and Auwerx, 2011). Cold, on the other hand, engenders elevation of 
cAMP, which activates protein kinase A (PKA), phosphorylating CREB to further enhance 
PCG-1α expression (Zhu et al., 2013).  
Increased expression of PCG-1α improves mitochondrial biogenesis by upregulating a group 
of proteins, including nuclear respiratory factors NRF1 and NRF 2, oestrogen related receptor 
alpha (ERRα) and peroxisome proliferator activated receptors (PPARs) (Wu et al., 1999; Zhu 
et al., 2013). Enhanced expression of NRFs upregulates mitochondrial transcription factor A 
(TFAM), a vital transcription activator whose level is intimately associated with mtDNA copy 
number (Virbasius and Scarpulla, 1994; Pohjoismäki et al., 2006). 
 
1.4 Mitochondrial genetics 
1.4.1 Mitochondrial genome 
Unlike the nuclear genome, human mitochondrial DNA (mtDNA) is a circular, double-
stranded sequence with a superhelical structure and is absent of introns and histone (Anderson 
et al., 1981). The human mtDNA was initially sequenced in 1981 and reviewed in 1999 
(Anderson et al., 1981; Andrews et al., 1999). With a length of approximate 16.6kb, the 
mitochondrial genome consists of 37 genes, encoding 13 polypeptides as key components of 
the RC complexes, 2 ribosomal RNAs and 22 transfer RNAs (Figure 1.3) (Anderson et al., 
1981). Nuclear-encoded proteins that are synthesised in the cytoplasm and imported to 
mitochondria are indispensable for the maintenance of mitochondrial function along with 
mtDNA-encoded proteins (Schon et al., 2001; Alston et al., 2017). Within the 13 mtDNA-
encoded polypeptides, seven (ND1, ND2, ND3, ND4, ND4D, ND5 and ND6) of them are 
constituents of complex I; one (cytochrome b) is a component of complex III; three (COXI, 
COXII and COXIII) are subunits of complex IV and two (ATP6 and ATP8) are elements of 
complex V, i.e. the ATP synthase (Figure 1.3) (Wallace, 1992).  
Each mitochondrion contains approximately 2 – 10 copies of mtDNA molecules that are 
packed into a cluster of proteins to form complexes termed “nucleoids” (Wang and 
Bogenhagen, 2006; Gilkerson et al., 2013). Many protein components in nucleoids are 
essential for mtDNA replication and expression, such as TFAM, mitochondrial DNA helicase 
(TWINKLE), single-stranded DNA binding protein (mtSSB) and mitochondrial DNA 
polymerase (POLγ) (Gilkerson et al., 2013). The number of mtDNA copies is related to 
cellular energy demand in somatic cells and can substantially vary between different cell 
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types (Shoubridge and Wai, 2007). For example, oocytes carry > 105 copies of mtDNA 
molecules, whereas most of somatic cells contain thousands of mtDNA copies (Shoubridge 
and Wai, 2007). Stem cells can have a lower mtDNA copy number due to the high nuclear: 
cytoplasmic ratio; however, the ratio of mitochondrial mass and cellular mass is estimated 
similar to somatic cells (Birket et al., 2011; Xu et al., 2013). 
The double strands of mtDNA are defined as the heavy (H) strand and the light (L) strand 
based on their differentiated buoyant densities in graded caesium chloride solutions as a result 
of different guanine contents between the two strands (Kasamatsu and Vinograd, 1974). The 
majority of mitochondrial genes are located in the H-strand, except the genes encoding ND6 
and eight tRNAs, which are resident in the L-strand (Figure 1.3) (Anderson et al., 1981; 
Wallace, 1992). MtDNA also contains a triple-strand section named the displacement (D) 
loop with a short sequence complementary to L-strand inserted between the location of heavy 
and light strands, which is the only non-coding sector in the mitochondrial genome (Figure 
1.3) (Anderson et al., 1981; Shadel and Clayton, 1997). The D-loop is critical to mtDNA 
maintenance and expression, as it includes major transcriptional promotors and the site of the 
origin of H-strand replication (Figure 1.3) (Taanman, 1999; Falkenberg et al., 2007).  
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Figure 1.3 The human mitochondrial genome. The double-stranded genome encodes 37 genes, including 
13 polypeptides (complex I genes in blue, complex III gene in purple, complex IV genes in green and 
complex V genes in orange), 22 tRNA (yellow) and 2 rRNA (pink). The sites of the origins of heavy 
(OH) and light (OL) strand replication are shown in the D-loop and the light strand respectively. 
 
1.4.2 Mitochondrial DNA transcription 
Transcription and replication of mtDNA are primarily regulated by the non-coding region of 
the mitochondrial genome. Transcription initiates at promotor domains, where heavy strand 
promoter (HSP) and light strand promotor (LSP) mediates the commencement of H-stand and 
L-strand transcription respectively to opposite directions (Montoya et al., 1983; Falkenberg et 
al., 2007). In detail, H-strand transcription initiates at two sites (HSP1 and HSP2). HSP2 
produces transcripts that encompass information of all genes in the H-strand, whereas HSP2 
only enables the transcription of two rRNAs and two tRNAs (Falkenberg et al., 2007). LSP is 
the only commencing site for L-strand transcription, which produces transcripts for all genes 
in the L-strand. All three sites generate polycistronic transcriptional products (Taanman, 
1999; Clayton, 2000). 
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Mitochondria have elegant transcription machinery containing TFAM, mitochondrial RNA 
polymerase (POLMRT) and mitochondrial transcription factors B1 and B2 (TFB1M and 
TFB2M) (Falkenberg et al., 2002). Transcription is triggered by the binding of TFAM to the 
upstream of promoters, which leads to conformational changes in mtDNA, facilitating the 
incorporation of POLMRT and TFB1M/TFB2M. POLMRT forms a heterodimeric complex 
with either TFM1M or TFM2M to initiate transcription, though TFM2M is more potent than 
TFM1M (Taylor and Turnbull, 2007; Morozov et al., 2014; Morozov et al., 2015). POLMRT 
further conducts the elongation of the transcript assisted by mitochondrial elongation factor 
(TERM). The polycistronic transcriptional chain comprises protein-encoding and rRNA genes 
separated by tRNA genes, which needs to be processed and cleaved by RNAase to produce 
mature mRNA, tRNA and rRNA (Falkenberg et al., 2007). This is proposed as the “tRNA 
punctuation model”. The termination of transcription is mediated by mitochondrial 
transcription termination factors (mTERF) that are found to have four members (mTERF 1 - 
4) (Martin Schmeing et al., 2005; Falkenberg et al., 2007). The entire process of transcription 
is highly accurate, and any minor imprecision may cause severe mitochondrial disease. For 
example, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes 
(MELAS) syndrome is principally caused by the m.3243A>G point mutation in the tRNALeu 
(UUR) gene that is a binding location of mTERF. The mutation has been observed to weaken 
the binding affinity of mTERF to the sequence in vitro (Chomyn et al., 1992a), which may 
impair mitochondrial protein synthesis. 
 
1.4.3 Mitochondrial DNA translation 
Mitochondria have their own translation apparatus to synthesise proteins encoded by mtDNA. 
This is carried out using the 22 mitochondrial encoded tRNA (Anderson et al., 1981; Bibb et 
al., 1981). Despite a smaller size compared with bacterial and cytosolic tRNA, most of them 
still have a classical cloverleaf architecture, comprising an acceptor stem with a CCA triplet, a 
D-loop, a T loop and an anticodon loop with their corresponding stems (Suzuki et al., 2011). 
Mitochondrial translation in mammals occurs at mitoribosomes that are resident in the 
mitochondrial matrix (Smits et al., 2010). Mitoribosomes are composed of a small 28S 
subunit (SSU) and a large 39S subunit comprising 12S and 16S mitochondrial rRNA 
respectively, with in total 82 nuclear-encoded mitochondrial ribosomal proteins (MRPs) 
(Greber and Ban, 2016). Despite similar functions, mitoribosomes have more protein 
components but harbour less rRNA compared with cytosolic ribosomes (Greber and Ban, 
2016).  
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After transcription, mRNA and rRNA that are severed from polycistronic transcripts are 
prepared for mitochondrial translation through polyadenylation by mitochondrial poly (A) 
polymerase (Smits et al., 2010). Mitochondrial translation is unique in many aspects, but it 
still follows the stepwise translation procedure, i.e. initiation, elongation and termination, 
which requires the involvement of nuclear-encoded initiation/elongation/release factors 
(Smits et al., 2010). The mitochondrial translation system also necessitates nuclear-encoded 
aminoacyl-tRNA synthetase to attach amino acids to the CCA triplet of tRNA and methionyl-
tRNA transformylase to formylate tRNAMet, which are both required to commence the 
translational process (Hou, 2010; Smits et al., 2010). As only 22 mitochondrial tRNA are 
available for mitochondrial translation, which is less than the minimum 31 tRNA for nuclear 
translation according to the “wobble hypothesis”, mitochondria change several rules to 
compensate this shortage in translation (Barrell et al., 1980; Smits et al., 2010; Boos et al., 
2016). Typically, mitochondria use a codon pool that is slightly different from the universal 
codes (Xochitl et al., 2008; Boos et al., 2016). For example, AUA is a codon for arginine in 
the universal coding system, and AUU is a codon for isoleucine (Crick, 1966). However, they 
are recognised by formylated tRNAMet to initiate mitochondrial translation (Boos et al., 2016). 
In contrast, nuclear translation commonly initiates at AUG that is the only codon for 
methionine according to the “wobble hypothesis” (Crick, 1966).  
Mitochondrial translation is terminated when mitochondrial the translation release factor 
mtRF1a identifies the termination codons UAA and UAG (Soleimanpour-Lichaei et al., 
2007). However, many mRNA do not carry these stop codons but instead harbour AGA or 
AGG codons (Anderson et al., 1981; Smits et al., 2010). To terminate the translation of these 
mRNA, mitoribosomes can induce a frame shift to facilitate identification of the downstream 
UAG termination codon (Temperley et al., 2010). The integrity of mitochondrial tRNA is 
critical for functional mitochondrial translation. Pathogenic mutations in mt-tRNA genes can 
ubiquitously impair synthesis of mtDNA-encoded protein and RNA products (Kauppila et al., 
2016). 
 
1.4.4 Mitochondrial DNA replication 
Mitochondrial DNA replication is independent of cell cycles, which is termed “relaxed 
replication” (Bogenhagen and Clayton, 1977). The turnover rate of mtDNA is higher in 
mitotic cells compared with that in post-mitotic cells, e.g. neurons (Wang et al., 1997). 
Mammalian mtDNA replication is conducted by mitochondrial replisome that contains three 
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essential proteins: the mitochondrial TWINKLE helicase, the mitochondrial single-stranded 
DNA binding protein (mtSSB) and the mtDNA polymerase (POLγ) (Korhonen et al., 2004; 
Falkenberg et al., 2007; Falkenberg, 2018).  
In mammalian cells, POLγ has a heterotrimeric structure comprising one catalytic subunit 
POLγA and two accessory subunits POLγB (Gray and Wong, 1992). The latter binds to 
double-stranded DNA and improves the catalytic activity and processivity of POLγA (Farr et 
al., 1999; Yakubovskaya et al., 2006). POLγA also contains a 3’ – 5’ exonuclease domain 
that endows it a proofreading ability, ensuring the fidelity of the polymerase (Gray and Wong, 
1992; Longley et al., 2001). The initiation of mtDNA replication at both the origin of heavy 
(OH) and light strand replication (OL) necessitates the RNA primers produced by POLRMT 
that also mediates mtDNA transcription (Chang and Clayton, 1985; Fusté et al., 2010). POLγ 
is unable to use double-stranded DNA as a template, therefore, requires TWINKLE to unwind 
the double strands in the 5’ to 3’ direction ahead of it (Falkenberg, 2018). Once unwound, 
mtSSB binds to the single-stranded DNA to protect it from nucleolysis as well as enhance 
mtDNA synthesis by improving the function of TWINKLE and POLγ (Mignotte et al., 1985; 
Farr et al., 1999; Korhonen et al., 2003). Mitochondrial DNA replication also needs proteins 
in addition to the essential apparatus to function. Paradigms for such proteins include the 
Ribonuclease H1 (RNASEH1) that removes RNA primers at the origins of replication and the 
mitochondrial topoisomerase (TOP1mt) that relieves torsional force of the strands during 
replication (Akman et al., 2016; Falkenberg, 2018). 
The complete mechanism of mtDNA replication has not been determined; however, three 
models for mtDNA replication have been proposed. The “strand-replacement” model (a.k.a. 
the asynchronous model) was the first model proposed in the early 1980s. According to this 
theory, transcription from LSP produces primers that trigger the replication of H-strand at OH. 
When two-thirds of the new H-strand has been synthesised, the origin of L-strand replication 
(OL) is exposed, enabling the continuous synthesis of a nascent L-strand. Once both strands 
are entirely synthesised, they combine to form another copy of mtDNA (Clayton, 1982). In 
the second model, the replication can initiate at multiple sites in a broad zone, where both new 
strands are synthesised simultaneously in opposite directions. More recently, RITOLS 
(ribonucleotide incorporation throughout the lagging strand) model has been proposed as the 
third model of mtDNA replication (Holt et al., 2000; Bowmaker et al., 2003). This model 
suggests that the new leading and lagging strands are not synthesised simultaneously, which is 
analogous to the “asynchronous” model. However, it suggests that the synthesis of the leading 
strand is concomitant with incorporation of RNA intermediates on the lagging strand. In due 
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course, the DNA synthesis of the lagging strand begins, primarily at OL, where the RNA 
intermediates are substituted or converted to DNA (Holt and Reyes, 2012). 
 
1.4.5 Mitochondrial DNA mutagenesis and repair 
Different types of mutations can arise in mtDNA molecules, including mtDNA point 
mutations or DNA rearrangements, such as deletions, insertions and duplications (Schon et 
al., 2012). Mitochondrial DNA point mutations are generally believed to the consequence of 
errors that occur during POLγ-mediated mtDNA replication (Zheng et al., 2006), whereas 
deletions are proposed to arise from slippage replication or during repair of mtDNA with 
double-strand breaks (Krishnan et al., 2008).  
The mutation rate of mtDNA is higher than that of nDNA possibly due to the absence of 
histone and proximity to ROS generated by ETC (Brown et al., 1979; Richter et al., 1988). 
Such difference was also believed to result from a lack of any form of mtDNA repair system 
in the past (Clayton, 1982). However, recent studies show that mitochondria in fact share 
some mechanisms with nuclei for DNA repair, including base excision repair to remove 
damaged bases (e.g. oxidised lesions) (Stierum et al., 1999; Liu et al., 2008) and mismatch 
repair to remove unpaired nucleotide from POLγ replication errors (Liu and Demple, 2010; 
Zinovkina, 2018). In addition, accumulating evidence suggests the existence of homologous 
recombination and non-homologous end joining in the mtDNA repair system for fixing 
double-strand breaks (Liu and Demple, 2010; Zinovkina, 2018). Furthermore, Mitochondria 
can direct damaged mtDNA molecules for degradation to prevent the amplification of 
defective mtDNA (Shokolenko et al., 2009). 
 
1.4.6 Heteroplasmy and threshold effect 
One cell generally contains thousands of copies of mtDNA, with 2-10 copies per 
mitochondria. This property of mtDNA refers to polyplasmy, which is distinct from nuclear 
DNA (Taylor and Turnbull, 2005). A state where all copies of mtDNA have identical 
genotypes is termed homoplasmy. More frequently, the mitochondrial population 
encompasses mtDNA copies with pathogenic mutations or polymorphic variants as well as 
wild-type copies (Holt et al., 1988). This status is referred to as heteroplasmy and is 
commonly expressed as a fraction of the mutated mtDNA copies in tissue/cells. (Larsson and 
Clayton, 1995; Smeitink et al., 2001).  
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A pathogenic heteroplasmic mtDNA mutation does not necessarily cause mitochondrial 
dysfunction and OXPHOS deficiency unless it accumulates to a certain threshold. This 
characteristic is termed as the threshold effect (Figure 1.4) (Sciacco et al., 1994). Biochemical 
thresholds of mutations are affected by multiple factors, such as mutation type, cell types, the 
cellular energy demand and the remaining amount of wild-type mitochondrial genomes. 
Within a variety of pathogenic mutations, mutations in tRNA are generally tolerable 
compared with large-scale deletions. The threshold for tRNA mutations is ~90% (Yoneda et 
al., 1995), but only ~70 – 80% for large-scale deletions in skeletal muscle (Sciacco et al., 
1994). The threshold for point mutations in protein-encoding genes can vary, which is 
specifically tailored for different mutations (Schon et al., 2012). However, once the mutation 
load is above 95%, OXPHOS deficiency will occur for all pathogenic mutations (Schon et al., 
2012). Heteroplasmy and threshold effect have profound implications for the heterogeneous 
phenotypes of mitochondrial disorders. 
 
 
 
Figure 1.4 Mitochondrial threshold effect. Mitochondrial DNA mutations (red circles) can be 
recessive. Cells can maintain normal OXPHOS function by virtue of the compensation of a certain 
level of wild-type mtDNA molecules (blue circles) until the heteroplasmy of mtDNA mutations 
reaches a mutation-specific threshold level (dotted line), at which point OXPHOS function is 
compromised. 
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1.4.7 Maternal inheritance and bottleneck effect 
It is commonly accepted that mtDNA is maternally transmitted, despite a study exceptionally 
reporting a small amount of paternal mtDNA leakage in the offspring of interspecific hybrids 
of two mice strains (Gyllensten et al., 1991). Homoplasmic mutations are transmitted entirely, 
though they do not necessarily develop into congenital diseases. For example, among 
individuals who carry homoplasmic mutations that could cause Leber hereditary optic 
neuropathy (LHON), approximately only half of the males and only one-tenth of the females 
among them will contract the disease (Man et al., 2003). In comparison, heteroplasmic 
inheritance of mtDNA is more frequent and complicated. In addition, the inherited risks for 
different types of mutations are differential. The transmission of single large-scale deletions 
of mtDNA is occasional, even rare, in light of the studies on a large cohort of patients 
(Chinnery et al., 2004). In contrast, transmission of mtDNA point mutations is common, 
predisposing individuals to compromised physical function or even inherited mtDNA diseases 
depending on the number of mutations transmitted through the germline (Falkenberg et al., 
2007). The heteroplasmy levels can notably vary from generation to generation, and an 
unaffected mother possibly gives birth to affected offspring, which makes genetic counselling 
difficult. This is due to the bottleneck effect, where a small number of mutated mtDNA in 
primordial germ cells are substantially amplified through rapid replication, which is 
commonly believed to occur during oogenesis (Stewart and Larsson, 2014). 
       
1.4.8 Clonal expansion 
Clonal expansion refers to a process where a mutated mtDNA molecule clonally amplifies 
and becomes the dominant mitochondrial genotype in a cell (Mita et al., 1989). It is crucial 
for the development of highly heterogeneous biochemical phenotypes of tissue/cells in both 
aged individuals and patients with mtDNA disease. The exact mechanism by which clonal 
expansion occurs remains unknown; however, several hypotheses have been proposed to 
explain this phenomenon.  
The “survival of the smallest” model was proposed first, theorising that a mitochondrial 
genome with large-scale deletions takes advantage of its smaller size to replicate faster than 
the wild-type genome (Wallace, 1989). However, this hypothesis could not apply to the clonal 
expansion of mtDNA point mutations. In addition, a small genome that has lost many genes is 
unlikely to obtain enough ATP for its rapid replication, as it probably cannot produce intact 
proteins to support a functional OXPHOS system (Kowald and Kirkwood, 2000). 
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Alternative theories hypothesise that mutations in protein encoding or tRNA genes could 
cause a change in mitochondrial function to facilitate their clonal amplification (Shoubridge et 
al., 1990; De Grey, 2005). Shoubridge initially proposed that mtDNA defects might induce 
compensatory enhancement of mitochondrial biogenesis, which leads to amplification of the 
defective genome. This is evidenced by identification of ragged red fibres (RRF) with 
proliferated mitochondria in the muscle of some patients with mtDNA disease (Shoubridge et 
al., 1990). Further studies support this hypothesis, showing that non-selective proliferation of 
mtDNA content that contains mutated and wild-type DNA molecules could eventually lead to 
clonal expansion of mutated molecules when the mutation heteroplasmy exceeds a specific 
threshold, though, before the point, mtDNA biogenesis could be beneficial to maintain the 
amount of wild-type mtDNA in a comparatively normal range (Chinnery and Samuels, 1999; 
Durham et al., 2007). An alternative hypothesis proposed by De Grey theorises that defective 
mtDNA has the advantage to elude from quality control systems, as it impairs the function of 
ETC, which diminishes the generation of oxidative stress that damages mitochondrial 
membrane, thus reducing the degradation of the dysfunctional mitochondria (De Grey, 2005). 
These two hypotheses have provided meaningful views that link mitochondrial functions to 
clonal expansion but to some extent overlook mitochondrial dynamics and underestimate 
quality control systems. 
More recently in silico modelling has become a useful tool for studying the clonal expansion 
of mtDNA mutations, and has contributed to the proposal of “random genetic drift” 
hypothesis. Computer simulations suggest that relaxed mtDNA replication and non-selective 
distribution of mtDNA molecules into daughter cells during cell division can solely account 
for the clonal accumulation of mutated mtDNA in mitotic cells, including healthy buccal 
epithelial cells, cancer cells (Coller et al., 2001) and intestinal stem cell populations (Stamp et 
al., 2018). Unbiased replication of mtDNA can also result in a clonal expansion of mutations 
in post-mitotic cells (Elson et al., 2001). Random genetic drift is suggested to take place early 
in life to allow a mutation to expand to a high level in tissue over a long time (Elson et al., 
2001; Greaves et al., 2014).   
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1.4.9 Mitotic segregation 
It is commonly believed that mitochondria are randomly segregated during cell division 
(Tuppen et al., 2010). If a mitotic cell harbours heteroplasmic mutated mtDNA, 
mitotic/vegetative segregation will result in substantial variations in mutation levels between 
daughter cells (Figure 1.5). However, recent in vitro studies challenge the notion of mitotic 
segregation, showing that stem cells might be able to selectively separate aged mitochondria 
during division to maintain stem cell properties in part of the daughter cells (Katajisto et al., 
2015). However, this mechanism might not always be activated in vivo, as computer 
modelling suggests that mitotic segregation leads to clonal expansion of somatic mtDNA 
mutations in dividing cells including colonic stem cell populations (Coller et al., 2001; Stamp 
et al., 2018). On the contrary, patients with mtDNA disease are found to lose specific 
inherited mtDNA mutation in mitotic blood with age, suggesting contrasting fates between 
different types of mtDNA mutations during cell division (Rahman et al., 2001; Grady et al., 
2018) (detailed in 3.1). 
 
 
Figure 1.5 Shift of mutation levels in daughter cells during stem cell division as a result of mitotic 
segregation. Relaxed replication of mtDNA with random segregation during cell division allows stem 
cells with mutated mtDNA molecules (red circle) to produce daughter cells with variable heteroplasmy 
levels. Blue circles are wild-type mtDNA molecules. 
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1.5 Mitochondrial DNA mutations in ageing and disease 
1.5.1 Somatic mtDNA mutations in humans and mice 
1.5.1.1 Somatic mtDNA mutations in normal aged humans 
Normal individuals accumulate OXPHOS deficiency in a variety of tissues with age, 
including post-mitotic skeletal muscle, heart and brain and mitotic blood, epithelium of 
stomach and intestines (Müller-Höcker, 1989; Müller-Höcker, 1990; Cottrell et al., 2001; 
Taylor et al., 2003; McDonald et al., 2008; Gutierrez‐Gonzalez et al., 2009). In colonic 
epithelium, OXPHOS defects increase exponentially with age (Taylor et al., 2003). Crypts 
with COX deficiency are rarely observed in young adult (< 30 years old), whereas the number 
of COX-deficient crypts can rapidly increase afterwards to reach ~15% of the crypt 
population in aged humans (>70 years old) (Taylor et al., 2003). Combined CI, CIII and CIV 
deficiency is the major type of OXPHOS defects in colonic crypts of aged humans, followed 
by isolated CIV deficiency, whereas isolated CI deficiency is a rare form of OXPHOS defects 
in the aged colonic epithelium (Greaves et al., 2010). OXPHOS deficiency can affect the 
function and turnover of colonic epithelial cells, which is discussed in Chapter 6. 
The OXPHOS defects are caused by the accumulation of miscellaneous somatic mtDNA 
mutations, including common mutations that cause mtDNA disease, such as the large-scale 
deletions spanning 4977 nucleotides (Schon et al., 1989), and m.3243A>G and m.8344A>G 
point mutations (Münscher et al., 1993; Zhang et al., 1993). A study using an improved PCR 
technique with higher sensitivity demonstrates that the mutation level of m.3243A>G in the 
skeletal muscle, brain, heart, liver and kidney of middle-aged and elderly adults is 5- to 10-
fold higher compared with infants (Liu et al., 1997). Other studies show that somatic mtDNA 
mutations can occur early in life, which clonal expand to a high level in the soma (Greaves et 
al., 2014).  
The accumulation of somatic mtDNA mutations has a tissue-specific manner. Post-mitotic 
tissue tends to acquire mtDNA deletions (Pallotti et al., 1996; Reeve et al., 2009), whereas 
mitotic tissue tends to obtain point mutations (Taylor et al., 2003). In addition, in mitotic 
tissue that is rapidly renewed by adult stem cells, mutations are likely to occur and 
accumulate in stem cells and expand in the rest of the tissue. Studies have shown a massive 
mtDNA heterogeneity in the clones of CD34+ positive haematopoietic stem cells (HSC) and 
progenitor cells in the bone marrow of adults compared with the clones of CD34+ cells in 
umbilical cord blood (Shin et al., 2004a). Somatic mtDNA mutations are also shown to 
accumulate in gastric and intestinal stem cells that pass down the mutations to all their 
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progeny in gastric glands and intestinal crypts (Taylor et al., 2003; McDonald et al., 2008; 
Gutierrez‐Gonzalez et al., 2009). Furthermore, somatic mtDNA mutations can spread via 
crypt or gland fission in the gastrointestinal epithelium, which is possibly associated with 
stem cell niches (Greaves et al., 2006; McDonald et al., 2008; Gutierrez‐Gonzalez et al., 
2009). The accumulation of somatic mtDNA mutations is intimately associated with ageing 
and age-related disease and cancer, but whether it plays a causal role in these processes is still 
contentious (Khrapko and Vijg, 2009; Baines et al., 2014b).  
 
1.5.1.2 mtDNA-mutator mice 
To date, several mouse models have been developed, showing an accumulation of mtDNA 
mutations with age, such as Mito-Pstl mice, “deletor mice” and mtDNA-mutator mice. The 
mito-Pstl mice are created by induction of mtDNA double-strand breaks, which primarily 
causes mtDNA depletion (Pinto et al., 2016). Accumulation of mtDNA deletions is also 
observed in the brain and muscle of these mice (Pinto et al., 2016). The deletor mice have a 
p.A360T change or a duplication in TWINKLE expression, which correspond to the 
expression of genes with dup352-364 and A359T mutations in patients with PEO (Tyynismaa 
et al., 2005). These changes lead to the accumulation of multiple DNA deletions and 
respiratory chain defects in the brain and skeletal muscle with age (Tyynismaa et al., 2005). 
These mouse models emphasise the accumulation of deletions in post-mitotic tissue rather 
than point mtDNA mutations in mitotic tissue. As this thesis focuses on the dynamics of 
mtDNA point mutations in epithelial cells, the mtDNA-mutator mice with a notable 
accumulation of point mutations in mitotic tissue are discussed in more detail.  
The mtDNA-mutator mice carry a knock-in missense mutation in the exonuclease domain of 
Polg that encodes mtDNA polymerase gamma (Polγ), impairing its proofreading ability, 
which results in an accumulation of somatic mtDNA mutations with age in a variety of mouse 
tissues (Kujoth et al., 2005; Trifunovic et al., 2005). These short-lived PolγAmut/mut mice 
harbour respiratory chain defects in various tissues and display a number of ageing 
phenotypes, including weight loss, kyphosis, hair loss, compromised hearing, reduced 
subcutaneous fat, osteoporosis, muscle loss and sterility (Trifunovic et al., 2004; Kujoth et al., 
2005). The European strain with C57B1/6N background (Trifunovic et al., 2004) displays 
more severe physiological and biochemical defects compared with the American strain with 
C57B1/6J background (Kujoth et al., 2005), highlighting the impact of nuclear regulation on 
the phenotype manifestation. 
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In addition, these mice predominantly accumulate mtDNA point mutations and suffer 
hampered development of mitotic intestine, thymus and testicle (Kujoth et al., 2005). The 
death of these mice is most often due to progressive anaemia that results from defective 
haematopoiesis, suggesting that the accumulation of somatic mtDNA mutations affect HSC 
functions (Trifunovic et al., 2004; Kujoth et al., 2005; Chen et al., 2009). Further research 
showed that the homeostasis of different types of adult stem cells and progenitor cells are 
impeded in these mice (Chen et al., 2009; Norddahl et al., 2011; Ahlqvist et al., 2012; Fox et 
al., 2012; Su et al., 2018). In particular, studies show an altered cell cycle and increased 
apoptosis in the small intestinal crypt of the mutator mice, which is comprised of intestinal 
stem cells (ISC) and transit-amplifying cells (Fox et al., 2012). Impaired growth of the 
organoids (comprising stem cells and Paneth cells) that are developed from isolated crypts is 
also reported (Fox et al., 2012). The functional changes in intestinal stem cells and progenitor 
cells result in extended cell migration, morphological alterations in the intestinal epithelium 
and hampered fat absorption of the mtDNA-mutator mice (Fox et al., 2012). These findings 
together suggest that mtDNA mutagenesis can alter stem cell properties (self-renewal and 
differentiation ability), which could be through impairing mitochondrial functions and 
dynamics (Su et al., 2018). 
 
1.5.2 Selective pressures on mtDNA mutations 
1.5.2.1 Selective pressures on mtDNA mutations during germline transmission 
Mitochondrial DNA mutations can also accumulate in germline (Gustafsson et al., 2016). 
Fortunately, the germline has a purifying selective pressure on extremely pathogenic mtDNA 
mutations, in particular, non-synonymous mutations in protein-encoding genes (Stewart et al., 
2008). Selection against the milder mutations in mt-tRNA genes are relatively less intense, 
but some studies have shown a strong selective pressure against certain mutations in tRNA 
genes during post-fertilisation embryonic development (Stewart et al., 2008; Freyer et al., 
2012). The time point that the germline selection occurs remains elusive. To date, studies 
have indicated that the segregation of mtDNA mutations is unbiased during germ cell 
maturation, and negative selection occurs post-oogenesis (Fan et al., 2008; Stewart et al., 
2008; Freyer et al., 2012). In addition, females with a heavy mutation burden show impaired 
fertility, suggesting that mutations might also be selected against at the organismal level 
(Stewart et al., 2008; Burr et al., 2018). Furthermore, studies have reported a positive 
relationship between the number of mtDNA variants transmitted through the germline and 
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maternal age, suggesting a negative effect of female age on the selective pressure on mtDNA 
variants (Rebolledo-Jaramillo et al., 2014). 
The exact mechanism of the germline selection is unclear; however, several hypotheses have 
been proposed based on the current findings. The bottleneck effect in germline transmission is 
commonly believed to cause a shift of heteroplasmy between generations (Gustafsson et al., 
2016). It is powerful enough to fix a de novo DNA polymorphic variant in a maternal lineage 
within a few generations (Upholt and Dawid, 1977; Olivo et al., 1983). Studies have provided 
evidence that the bottleneck effect changes the heteroplasmy level via stochastic sampling of 
a small number of mtDNA molecules in human and mice (Jenuth et al., 1996; Chinnery et al., 
2000). Nevertheless, this is unable to explain the selective loss of some pathogenic mtDNA 
mutations through germline transmission (Freyer et al., 2012). Studies on Drosophila suggest 
that the negative selective force might result from phenotypically compromised fitness of 
mitochondria, which is possibly mediated by a change in the mitochondrial membrane 
potential (Hill et al., 2014; Ma et al., 2014; Stewart and Larsson, 2014). A recent study has 
suggested that the switch from glycolytic to oxidative metabolism of primordial germ cells 
during their development is able to expose the pathogenicity of mtDNA mutations to facilitate 
their targeting for selective removal (Floros et al., 2018). This study also reported the 
existence of a bottleneck effect in somatic cells during embryonic development, implying that 
mitotic cell populations might share some common mechanisms for the segregation of 
mtDNA molecules (Floros et al., 2018). Despite limited quantity of evidence at present, it is 
hypothesised that the selection against mtDNA mutations within germline transmission can 
take place at the organismal level (compromised female fertility), the cellular level (impaired 
cell division or an inclination to cell death) and the mitochondrial level (unfitness of 
mitochondria) (Stewart et al., 2008; Freyer et al., 2012; Burr et al., 2018; Floros et al., 2018; 
Zhang et al., 2018).  
 
1.5.2.2 The absence of selective pressures on somatic mtDNA mutations 
Mechanisms underlying the accumulation of somatic mtDNA mutations in normal ageing 
populations remains unclear. Harman initially proposed the free radical theory stating that 
impaired respiratory chain produces excessive ROS, which exacerbates mtDNA mutagenesis, 
generating more oxidative stress and forming a “vicious cycle” (Harman, 1972). This theory 
is challenged by some studies showing that the occurrence rate of somatic mtDNA mutations 
is unlikely to change with age (Greaves et al., 2014). On the other hand, in silico modelling 
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suggests that random genetic drift can solely engender the clonal expansion of somatic 
mtDNA mutations in both dividing and non-dividing cells (Coller et al., 2001; Elson et al., 
2004). However, these two hypotheses are not mutually exclusively.  
The mechanism underpinning the accumulation of somatic mtDNA mutations is thought to be 
tailored for specific mutations and tissue/cell types. For example, some mutations are 
proposed to have an advantage for clonal expansion (detailed in 1.4.8). In addition, vegetative 
segregation in mitotic cell populations with perpetual relaxed replication complicate the 
dynamics of mtDNA mutations (detailed in 1.4.8 and 1.4.9) (Stewart and Chinnery, 2015). 
Furthermore, tissue-specific nuclear factors are found to manipulate the segregation of 
mtDNA mutations (Jokinen et al., 2010). 
Mitochondrial DNA mutations can also be inherited through the germline and cause mtDNA 
disease. During transmission, mutations are under strong purifying selective pressures, which 
eliminate those that are highly pathogenic, leaving the comparatively mild mutations/variants 
to pass down to the next generation (Fan et al., 2008; Stewart et al., 2008; Greaves et al., 
2012a). However, the acquired somatic mtDNA mutations in colonic epithelium are 
significantly more pathogenic than the germline variants (Greaves et al., 2012a). In addition, 
the accumulated somatic mutations are randomly distributed in the mitochondrial genome 
(Greaves et al., 2012a). These findings suggest no purifying selection against somatic mtDNA 
mutations. 
 
1.6 Overview of mitochondrial disease 
As mitochondrial function is maintained by proteins encoded by both mtDNA and nDNA, 
pathogenic mutations in either genome can cause mitochondrial disease. The minimum 
prevalence of mitochondrial disorders is estimated at one in 5000 as summarised from 
combined epidemiological data of both children and adults (Schaefer et al., 2004). Recently 
studies show that in adult populations, the prevalence of mitochondrial disease caused by 
mitochondrial and nuclear DNA mutations is approximately one in 4300 (Gorman et al., 
2015). The actual prevalence could be higher as mitochondrial disease is an enormously 
heterogeneous group of disorders with miscellaneous phenotypic expressions in multiple 
systems and broad ages of onset with diverse clinical features, which tremendously hampers 
their diagnosis (Schaefer et al., 2004). The massive heterogeneity of mitochondria disease is a 
result of multifaceted impacts of different factors, including the mutation type, heteroplasmy 
27 
 
and biochemical threshold, bottleneck effect, mitotic segregation and clonal expansion 
(Taylor and Turnbull, 2005). 
Nuclear DNA encodes structural subunits for RC complexes as well as proteins for complex 
assembly, maintenance and expression of mtDNA and mitochondrial dynamics. Pathogenic 
mutations in nDNA can cause a variety of mitochondrial disorders (Lightowlers et al., 2015). 
For instance, mutations in nuclear genes POLG and PEO1, which encodes POLγ and 
TWINKLE respectively, can cause secondary mtDNA depletion and deletions, resulting in 
severe mitochondrial disorders (Spelbrink et al., 2001; Naviaux and Nguyen, 2004; 
Lightowlers et al., 2015). This thesis focuses on mtDNA mutations, in particular, point 
mutations in mt-tRNA genes, which cause primary mtDNA disease. Thus, I will discuss these 
in more detail. 
 
1.6.1 Overview of mtDNA disease 
Pathogenic mtDNA mutations are estimated to be carried by a minimum of one in 200 
individuals (Elliott et al., 2008). Despite the presence of mitochondria in all eukaryotic cells, 
tissue with high energy-consumption like brain, heart, skeletal muscle and retina are more 
susceptible to mitochondrial dysfunction caused by mutations (DiMauro and Schon, 2003). 
Although the clinical manifestations of mtDNA disease are extremely heterogeneous, they 
share several common features, such as lactic acidosis and presence of ragged-red fibres 
(RRF) in skeletal muscles (DiMauro and Schon, 2003). The RRF are termed such for the 
appearance of myocytes with over-accumulated mitochondria at its subsarcolemmal region 
when they are stained using Gomori Trichrome (Cunningham, 1963; Mita et al., 1989). 
Diagnosis of mtDNA disease is facilitated by a variety of histochemical and biochemical 
assays, such as Gomori Trichrome stain, sequential COX/SDH histochemistry and quadruple 
immunofluorescence enormously. These have revealed many typical features of patients’ 
tissue, in particular, muscle fibres, such as RRF, COX deficiency and decreased expression of 
RC complexes (Sciacco et al., 1994; Rocha et al., 2015). Determination of phenotypes is 
normally followed by genetic diagnosis using genome sequencing, with next-generation 
sequencing based techniques becoming prevalent (Alston et al., 2017). 
Though genetic diagnosis is of great potential, the diagnosis of mitochondrial disease is still 
difficult because there is no strict correlation between mutations and their clinical 
manifestations. Moreover, treatment is limited, auxiliary and possibly ineffective at present 
(DiMauro and Schon, 2003; Taylor and Turnbull, 2005). Hence, detection and prevention of 
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the transmission of mtDNA mutations becomes crucial, where prenatal diagnosis and assisted 
reproduction methods including pre-implantation genetic diagnosis (PGD), pronuclear 
transfer and polar body genome transfer are promising strategies (Craven et al., 2010; Wang 
et al., 2014) 
 
1.6.2  Mutations in mtDNA disease 
Mitochondrial DNA mutations, in essence, are a highly heterogeneous group of mutations that 
have distinct nature in many aspects. First, inheritance of mtDNA mutations can be different. 
For example, point mutations are normally transmitted through the germline, whereas single 
large-scale deletions are generally sporadic, arising during oogenesis or early embryogenesis 
and clonally expanding via rapid replication during cell division (DiMauro and Schon, 2003; 
Greaves et al., 2012b; Schon et al., 2012). Moreover, the biochemical thresholds of different 
mtDNA mutations vary (covered in 1.4.6). Furthermore, in contrast to the somatic mtDNA 
mutations that accumulate in mitotic tissue with age and cause OXPHOS deficiency, some 
inherited mutations tend to decrease in mitotic blood and certain epithelial cells with age 
(Larsson et al., 1990; Grady et al., 2018). Such loss is sometimes concomitant with recovered 
symptoms of patients (McShane et al., 1991; Nørby et al., 1994). Specific inherited mtDNA 
mutations are also distributed non-randomly between different tissues, which is intimately 
associated with dividing abilities of the tissue (Chinnery et al., 1999). These intriguing 
phenomena that contrast the permissive accumulation of somatic mtDNA mutations suggest 
potential selective pressures against inherited mtDNA mutations in mitotic tissue, which are 
discussed in detail in Chapter 3. This feature is crucial to the development of tissue-specific 
phenotypes. Studying the mechanism of these features would benefit understanding of 
mtDNA disease progression and development of potential treatment. Therefore, this PhD 
work aims to further investigate the selective loss of inherited mtDNA mutations in mitotic 
tissue. 
Various mtDNA mutations can cause primary mtDNA disease, including mtDNA point 
mutations or rearrangements (Schon et al., 2012). Formation of these mutations is discussed 
in 1.4.5. Single large-scale deletions are the most prevalent form of mtDNA rearrangement in 
mtDNA disease (Schon et al., 2012). Deletions can span the sites of several genes, causing 
severe mitochondrial disorders, such as Pearson syndrome (Rotig et al., 1989), Kearns-Sayre 
syndrome (KSS) (Zeviani et al., 1988) and chronic progressive external ophthalmoplegia 
(CPEO) (Moraes et al., 1989). Point mutations could occur throughout the mitochondrial 
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genome, affecting genes that encode structural proteins of RC complexes, ribosomal RNA 
(rRNA) and tRNA, all of which could cause mtDNA disorders (Taylor and Turnbull, 2005). 
For example, Leber’s Hereditary Optic Neuropathy (LHON), which is the most prevalent 
mitochondrial disorder, is primarily caused by point mutations in MT-ND1, MT-ND4 and 
MT-ND6 that encode subunits of RC complex I (Wallace et al., 1988; Howell et al., 1991; 
Johns et al., 1992; Gorman et al., 2015). A less frequent disorder, NARP (neurogenic 
weakness, ataxia and retinitis pigmentosa) are caused by point mutations at the nucleotide 
8993 in mt-ATP6 gene that encodes CV subunit (Holt et al., 1990; Schon et al., 2001; Schon 
et al., 2012). 
 
1.6.2.1 Point mutations in mitochondrial tRNA genes 
It is of interest that among mtDNA disease, more than half of the cases are caused by 
mutations in mitochondrial tRNA genes, whereas tRNA-coding sequences only occupy 
around 10% of the whole mtDNA coding section (Schon et al., 2012). This phenomenon is 
probably due to a permissive environment for tRNA mutations during oogenesis (Stewart et 
al., 2008). 
Two common pathogenic mt-tRNA mutations m.3243A>G and m.8344A>G are widely 
investigated compared with other mt-tRNA mutations. The m.3243A>G mutation in 
tRNALeu(UUR) gene is also the most common mtDNA point mutation, which is present in 
approximately 1 in 12800 individuals (Gorman et al., 2015). This mutation is associated with 
most MELAS cases (Goto et al., 1990; Goto et al., 1991), though it more often causes the 
milder MIDD (maternally inherited diabetes and deafness) (van den Ouweland et al., 1992). 
The m.8344A>G mutation in the tRNALys gene almost entirely leads to MERRF (myoclonus 
epilepsy and ragged red fibres) syndrome (Shoffner et al., 1990; Schon et al., 2012). 
However, only around one in 143000 individuals are estimated to harbour this mutation, 
suggesting it is generally an uncommon mutation (Gorman et al., 2015). Both m.3243A>G 
and m.8344A>G can impair mtDNA expression, yet the exact mechanism is still being 
investigated (Lightowlers et al., 2015). Pathogenicity of m.3243A>G could be associated with 
impaired termination of mtDNA transcription (discussed in 1.4.2) and/or lack of modification 
at the first position of the anticodon of tRNALeu (Yasukawa et al., 2000b). The m.8344A>G 
mutation is found to result in the unmodified base at the wobble site of the anticodon in the 
tRNALys (Yasukawa et al., 2000a). As well as the common features of mitochondrial diseases 
like lactic acidosis and RRF, patients with MELAS also display symptoms of encephalopathy 
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like seizures and dementia, and those with MERRF may display myoclonus, ataxia and 
seizures (Hirano et al., 1992; Hammans et al., 1993). Heteroplasmy of m.3243A>G and 
m.8344A>G has been found to be related to the clinical manifestations and severity of the 
diseases (Hammans et al., 1993; Whittaker et al., 2009; de Laat et al., 2012). Studies have 
shown that m.3243A>G and m.8344A>G mutations are associated with a defect in one or 
more of the respiratory chain complexes in patients, including CI, CIII and CIV (Berkovic et 
al., 1989; Bindoff et al., 1991; Hirano et al., 1992). In addition, the CI level is more 
susceptible to m.3243A>G mutation compared with CIV (Mariotti et al., 1995; Rocha et al., 
2015).  
 
1.6.3 Mouse models of mtDNA disease 
A number of mouse models of primary mtDNA disease have been established, which benefits 
the investigation of transmission and pathogenesis of disease-causing mtDNA mutations and 
phenotype development of mtDNA disease. 
 
1.6.3.1 Mice with mtDNA large-scale deletions 
Mito-mice with a large-scale deletion of size 4696bp were generated by introducing trans-
mitochondrial cybrids containing somatic mtDNA mutations into mouse zygotes (Inoue et al., 
2000; Nakada et al., 2004). These mice recapitulate certain phenotypes of the patients with 
large-scale deletions, such as hearing loss and lactic acidosis (DiMauro et al., 1985; Larsson 
et al., 1990; Nørby et al., 1994; Inoue et al., 2000; Nakada et al., 2004). They also have a 
shortened lifespan due to severe renal failure, in accordance with markedly reduced COX 
activity in their kidney. Additionally, the skeletal and cardiac muscle fibres of the mito-mice 
show COX defects (Inoue et al., 2000). However, some characteristics of the mito-mice are 
not consistent with those of mtDNA disease. The deletions were stably transmitted through 
germline with a cut-off limit of 90% heteroplasmy level (Inoue et al., 2000), which is rare for 
large-scale deletions in humans (Taylor and Turnbull, 2005). This was thought to be 
associated with a co-existing mtDNA duplication in these mice (Inoue et al., 2000). 
Moreover, unlike the patients with Pearson syndrome who lose the deletions in their blood 
with age (Larsson et al., 1990; McShane et al., 1991; Nørby et al., 1994), no difference in the 
mutation level was found among a variety of mitotic and post-mitotic tissues of these mice, 
regardless of the age (Inoue et al., 2000). Hence, this mouse model is not suitable for studying 
selective pressures on inborn mtDNA mutations. 
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1.6.3.2 Mice with point mutations in rRNA genes 
Attempts to generate the embryos of mice with mtDNA point mutations were made by 
microinjecting stem cells that were fused with cytoplasts carrying pathogenic mtDNA 
mutations into blastocysts (Watanabe et al., 1978; Marchington et al., 1999). The cytoplasts 
with the pathogenic mutations that succeeded in producing chimeric mice originated from 
mouse cell lines with naturally occurring or mutagenized mtDNA mutations (Levy et al., 
1999; Sligh et al., 2000; Kasahara et al., 2006; Fan et al., 2008; Yokota et al., 2010; Freyer et 
al., 2012; Lin et al., 2012; Shimizu et al., 2014; Shimizu et al., 2015). The first mutation 
introduced by this method was a point mutation in the mitochondrial rRNA gene, which 
endows cybrids with resistance to chloramphenicol (CAPR mutation) (Watanabe et al., 1978; 
Marchington et al., 1999). However, only mice with low chimerism were produced, as the 
resident wild-type mtDNA molecules in the stem cells were not eliminated, despite their small 
number (Watanabe et al., 1978; Marchington et al., 1999). This prompted the researchers to 
refine this procedure by pre-treating embryonic stem cells (ESCs) with Rhodamine-6-G (R-6-
G) to deplete their endogenous wild-type mtDNA (Levy et al., 1999; Sligh et al., 2000). 
Using the modified method, chimeric mice with CAPR mutation were successfully created, 
and they showed multiple phenotypes of mtDNA disease (Taylor and Turnbull, 2005), such as 
growth retardation, ophthalmological defects, myopathy and cardiomyopathy (Sligh et al., 
2000). Germline transmission of the CAPR mutation was achieved, and pups with 
homoplasmic or heteroplasmic mutations were generated; however, none of them survived 
through the embryonic or perinatal period (Sligh et al., 2000).  
 
1.6.3.3 Mice with mutations in protein-encoding mtDNA 
Fusing R-6-G pre-treated ESCs with cytoplasts containing pathogenic mtDNA mutations has 
been extensively used for establishing mouse models with mtDNA point mutations in protein-
encoding genes. ESC cybrids were microinjected into embryos, which were then transplanted 
into pseudo-pregnant female mice to produce founder mice (Kasahara et al., 2006). By 
subsequent mating the founder females with wild-type males, a mouse line with a 
homoplasmic m.6589T>C mutation in the COI gene was segregated with stable germline 
transmission (Kasahara et al., 2006). The phenotype of these mice is very mild, only lactic 
acidosis and growth retardation, though biochemical and histochemical examinations revealed 
decreased COX level in the heart, brain, skeletal muscle and liver (Kasahara et al., 2006).  
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Another mouse model with the same missense mutation in the COI gene was created by 
another research group using similar methods (Fan et al., 2008). In addition to the 
homoplasmic COI mutation, some of these mice carried a more severe insertion in the ND6 
gene, causing translational frameshift (Fan et al., 2008). Other mice carried an ND6 revertant 
mutation, correcting the defects caused by the insertion, which enabled the determination of 
the functional changes caused by the mild COI missense mutation (Fan et al., 2008). These 
mice confirmed the COX deficiency caused by m.6589T>C COI mutation and discovered 
complex I deficiency caused by the ND6 frameshift insertion (Fan et al., 2008). These mice 
also showed abnormal mitochondrial proliferation and mitophagy in the heart with 
myofibrillar degeneration (Fan et al., 2008), demonstrating the association between the 
function of mitochondria and somatic cells in disease development. Furthermore, the severe 
frameshift mutation was selectively removed in four generations with evidence that the loss of 
the mutation occurred in proto-oocytes before ovulation, whereas no selection was found 
against the revertant ND6 mutation and the mild COI mutation during germline transmission 
(Fan et al., 2008). These findings improved our understanding of the selective pressures on 
mtDNA mutations with different pathogenicity through germline transmission. Unexpectedly, 
no selective pressure upon the ND6 frameshift mutation was found in the mitotic tissue of 
postnatal animals with age: the mutation was evenly distributed in various mitotic and post-
mitotic tissues in aged trans-mitochondrial mice (Fan et al., 2008), which is not the case in 
patients with certain mtDNA mutations (Chinnery et al., 1999).  
Similar strategies were also used to generate two mouse lines with a stable germline 
transmitted homoplasmic m.13997G>A mutation in the ND6 gene, which were designed for 
modelling the LHON disorder (Yokota et al., 2010; Lin et al., 2012). In the first study, despite 
a marked decline in the complex I level in the brain, kidney and muscle, the examined young 
mice only presented lactic acidosis with no sign of optic nerve atrophy that is a typical 
characteristic of LHON patients (Wallace, 1999; Yokota et al., 2010). This phenotype was 
achieved in the second model, where the aged mice showed a weakened retinal response, 
abnormal retinal ganglion cells (RGCs) and atrophy of optic nerves with abnormal 
morphology and proliferation of mitochondria in RGCs (Lin et al., 2012). These two studies 
highlight the effect of age on phenotype development in disease progression and the 
importance of investigating subjects at different stages of the lifespan. However, as these 
mouse lines harbour homoplasmic mutations in all tissues, they cannot be used to study the 
tissue-specific segregation of pathogenic mtDNA mutations (Yokota et al., 2010; Lin et al., 
2012).  
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1.6.3.4 Mice with mutations in mt-tRNA genes 
More recently, a mouse model with m.7731G>A mutation in the tRNALys gene was 
established using the technique of introducing pathogenic mtDNA mutation via R-6-G pre-
treated ESCs (Shimizu et al., 2014). This mutation is comparable with the m.8328G>A 
mutation and the common m.8344A>G mutation affecting the same tRNA gene in patients 
(Shimizu et al., 2014). These mice showed a transmission threshold of 80% heteroplasmy 
level due to the fatal effect of a higher mutation load (Shimizu et al., 2014). Phenotypically, 
young mice with high heteroplasmy levels displayed short body length and muscle weakness 
with defective OXPHOS in the muscle and kidney (Shimizu et al., 2014), recapitulating 
features of myopathy in patients with mutated tRNALys gene (Houshmand et al., 1999; 
Blakely et al., 2007). Examinations of the aged animals revealed disease progression with age 
(Shimizu et al., 2015). The aged mutants developed new phenotypes including anaemia, lactic 
acidosis and fatal renal failure (Shimizu et al., 2015), some of which are typical 
characteristics of MERRF patients with mt-tRNALys mutation (Fukuhara et al., 1980; Rosing 
et al., 1985; Wallace, 1999). However, these mice had a comparatively normal lifespan and 
showed no ragged red fibres in the muscle (Shimizu et al., 2015), a distinctive metabolic 
feature of MERRF patients (Fukuhara et al., 1980; Rosing et al., 1985). In addition, the 
mutation levels were uniform  among various tissues in both young and old mice (Shimizu et 
al., 2015), unlike MERRF patients who showed consistently lower mutation level in blood 
compared with skeletal muscles (Larsson et al., 1992). Therefore, though these mice carry 
heteroplasmic mutations, they are not a perfect model for studying the tissue heterogeneity of 
mtDNA diseases caused by certain mtDNA mutations.  
The most recent method for generating mouse models of inherited mtDNA mutations was to 
cross mtDNA-mutator females (Polgmut/mut) with wild-type males, followed by continuous 
backcrossing with females to acquire mice with wild-type Polg but germline mtDNA 
mutations (Freyer et al., 2012). The first generated mice carry pathogenic m.5245T>C point 
mutation in the tRNACys gene and m.3875delC in the tRNAMet gene that perturbed the 
expression of the corresponding tRNA (Freyer et al., 2012). The m.5245T>C mutation was 
initially heteroplasmic but quickly expanded to homoplasmy in all organs of the mice (Freyer 
et al., 2012). The m.3875delC maintained heteroplasmy with no offspring harbouring the 
mutation higher than 86% heteroplasmy level (Freyer et al., 2012). The study suggested that 
selection against the m.3875delC mutation occurred during embryonic development after the 
formation of primary germ cells and oocytes (Freyer et al., 2012), giving insights into the 
mechanism of the germline transmission of pathogenic mt-tRNA mutations. Surprisingly, 
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these mice did not show respiratory chain defects in the tissue possibly due to the 
compensatory upregulation of other RNA molecules (Freyer et al., 2012). In addition, the 
heteroplasmy levels of the m.3875delC mutation in different tissues were similar and did not 
change with age (Freyer et al., 2012). These findings contradict those regarding patients with 
certain inherited mt-tRNA mutations (Chinnery et al., 1999; Grady et al., 2018), limiting the 
use of this mouse model for investigating selective pressures upon inherited mtDNA 
mutations. 
As discussed above, none of these mouse models shows clear evidence of losing inherited 
mtDNA mutations in mitotic tissue, thus are not suitable for investigating selective pressures 
against inherited mutations. Recently, a mouse model with an inherited m.5024C>T mutation 
has been developed and serve as a model of mtDNA disease (discussed in detail in Chapter 4) 
(Kauppila et al., 2016). The mice with a high mutation load show a loss of the m.5024C>T 
mutation in blood with age (Kauppila et al., 2016). Further characterisation of these mice is 
necessary to determine whether they are suitable for studying the mechanism underlying the 
selective pressures against inherited mtDNA mutations in mitotic tissue. 
 
1.7 Gastrointestinal tract and GI stem cell populations 
Stem cells are a group of cells that are able to renew themselves and differentiate into 
different progenies by either symmetric division or asymmetric division (Morrison and 
Kimble, 2006). The differentiation potential of different types of stem cells can vary. 
Embryonic stem cells (ESCs) isolated from the inner cell mass of early embryos are 
pluripotent, meaning that they have the capacity to differentiate into all three germ layers that 
will develop into any tissue or organs in animals (Wu and Izpisua Belmonte, 2016). 
Pluripotent stem cells could also be created by reprogramming fibroblasts with defined 
transcription factors. These reprogrammed cells are named induced pluripotent stem cells 
(iPSCs) (Takahashi and Yamanaka, 2006). Adult stem cells (ASCs) (a.k.a. somatic stem cells) 
are multipotent cells, which are able to generate certain types of progenitor cells in order to 
ultimately differentiate and replenish the somatic cells in tissue or organs (Goodell et al., 
2015). They are responsible for haematopoiesis and rapidly renewing various epithelial 
tissues, such as skin and gastrointestinal epithelium (Goodell et al., 2015). These mitotic 
tissues are characterised by sufficient cell proliferation for tissue regeneration and injury 
repair (Campisi and di Fagagna, 2007). In contrast, post-mitotic tissues like the brain or 
different types of muscles (e.g. skeletal muscle, myocardium and smooth muscle) consist of 
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terminally differentiated cells with limited ability to repair and regenerate though some of 
them have quiescent stem cells (Roth et al., 2000; Campisi and di Fagagna, 2007). 
The human alimentary tract consists of two main parts: the upper and lower gastrointestinal 
(GI) tract, which is demarcated by the Ligament of Treitz (Warrell et al., 2003). The upper GI 
tract is composed of the oesophagus, stomach and duodenum and the lower part consists of 
the jejunum, ileum, caecum, colon, rectum and anal canal (Warrell et al., 2003). The 
duodenum, jejunum and ileum constitute the small intestine, while the large intestine is 
composed of the caecum, appendix, colon and rectum (Warrell et al., 2003). The components 
of the GI tract share similar histological features with four general layers: mucosa (containing 
epithelium, lamina propria and muscularis mucosae), submucosa with blood vessels and 
nerves embedded, muscularis externa (including the inner circular and outer longitudinal 
smooth muscle) and serosa, though they still have their own specific features in particular in 
the mucosal layer (James S. Lowe, 2015). It is commonly accepted that gastrointestinal 
epithelium is a mitotic tissue renewed by gastrointestinal stem cells. 
 
1.7.1 Oesophagus 
The epithelium of the oesophagus is comprised of stratified squamous cells with a basal layer 
of cells adjacent to the basement membrane, which is markedly dissimilar to that of the 
digestive tract from stomach to rectum (Figure 1.6) (Treuting and Dintzis, 2011). However, 
the segment of the oesophageal epithelium below the diaphragm has a transition from 
squamous cells to columnar cells as a junction to the stomach. The lamina propria projects 
into the epithelium to form papillae with irregular epithelial borders (James S. Lowe, 2015). 
Moreover, unlike the other components of the GI tract that are encircled by smooth muscle, 
the upper third of oesophagus is encircled by striated muscle for voluntary swallowing (James 
S. Lowe, 2015). After the transition of the middle third part, the lower third section is finally 
encompassed by smooth muscle.  
The regeneration of oesophageal epithelium is believed to initiate at the basal layer of 
epithelium (Figure 1.6) (Eastwood, 1977). It is commonly thought that in GI stem cell 
populations, there is a small portion of dormant stem cells that are only activated to replenish 
the loss of normal stem cells after trauma (Li and Clevers, 2010). However, there seem no 
quiescent stem cell populations in the oesophageal epithelium (Doupé et al., 2012; DeWard et 
al., 2014). Studies show that the cells at the basal layer divide stochastically to produce 
proliferating and differentiated daughter cells approximately twice per week, and wounds 
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caused by physiological or chemical irritations can enhance the regeneration (Doupé et al., 
2012). More recently, Deward et al. found Itgb4High and CD73+ stem cell populations in 
mouse oesophagus that are resident in the basal cell layer of epithelium with transit-
amplifying cells (Figure 1.6) (DeWard et al., 2014). These Itgb4High and CD73+ stem cells 
divide actively, though at a lower frequency compared with amplifying cells (DeWard et al., 
2014). Although the overall turnover of oesophageal epithelium is considered fast, it is still ~5 
times slower than that of intestinal epithelium (Creamer et al., 1961; Squier and Kremer, 
2001).   
 
 
Figure 1.6 Diagram of oesophageal epithelial cells. Oesophageal epithelium consists of stratified 
squamous epithelial cells, which is strikingly different from the gastric or intestinal epithelium. Cell 
regeneration occurs at the basal layer of the epithelium, where stem cells (blue) and transit amplifying 
cells (yellow) actively produce nascent cells that migrate upwards to replace old cells.  
 
1.7.2 Stomach 
Macroscopically, the human stomach is demarcated as four regions: cardia, fundus, corpus 
and antrum (Treuting and Dintzis, 2011), but histologically there are two types of gastric 
mucosa: fundic and pyloric mucosa. Fundus and corpus shares fundic mucosa whereas cardia 
and antrum have pyloric mucosa (Treuting and Dintzis, 2011). Mouse stomach is different 
compared with humans, comprising a forestomach and glandular stomach. The latter is 
histologically similar to human stomach except for lack of cardia and is examined in this 
project (Treuting and Dintzis, 2011). In both species, the fundic epithelium is the major type 
of glandular mucosa (Treuting and Dintzis, 2011).  
Compared with the small and large intestines, the stomach has an extra layer of oblique 
smooth muscle, lying in between the other two muscle layers, in order to mix food with 
gastric acid and digestive enzymes (James S. Lowe, 2015). The epithelium of stomach is also 
unique, containing numbers of gastric units, which are comprised of gastric pits and glands 
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with several glands merged and opened to the base of the pit (Kouznetsova et al., 2011). 
Gastric units are comprised of the pit, downward to the isthmus, the neck and the base 
(Bartfeld and Koo, 2017). The main types of cells in gastric epithelium include mucus cells 
that supply protective mucus, parietal/oxyntic cells that secret acid, chief cells that produce 
pepsin and various enteroendocrine cells (Barker et al., 2010a; Bartfeld and Koo, 2017). The 
pit is lined by mucus-secreting cells, which is the same between the corpus and the pylorus 
(Bartfeld and Koo, 2017). The narrow isthmus region contains a group of proliferative gastric 
stem cell population (Bartfeld and Koo, 2017). The location of the isthmus differs between 
different types of gastric epithelium. In fundic epithelium, the isthmus segment lies in the 
upper third of the unit, whereas it sinks to the lower third of epithelium in the pylorus (Mills 
and Shivdasani, 2011; James S. Lowe, 2015). In addition, the cell component, of the neck and 
the base particularly, is distinct between fundic and pyloric gastric units. The fundic units 
have a typical architecture of gastric units, containing myriads of chief cells and parietal cells. 
In contrast, the pyloric units have abundant mucus-secreting cells with only scattered parietal 
cells and lack chief cells (Treuting and Dintzis, 2011; James S. Lowe, 2015). 
The replenishment of gastric epithelial cells relies on gastric stem cells that are traditionally 
considered to reside at the isthmus mixed with neck mucous cells (Thompson et al., 1990; 
McDonald et al., 2008). Within each gastric unit, multiple stem cells contribute to tissue 
renewal, the progenies of which migrate bilaterally along gastric units (McDonald et al., 
2008). Using lineage tracing in vivo, Barker et al. have reported a second potential stem cell 
population labelled by Lgr5, at the pyloric base of adult mice (Barker et al., 2010b). In 
addition, gastric epithelium regeneration has plasticity. Chief cells labelled by Tnfrsf19 
(encoding TROY) are able to gain stemness and dedifferentiate into actively cycling stem 
cells for tissue regeneration, particularly after injury (Stange et al., 2013). Of note, in addition 
to normal lineage tracing method through the activation of a reporter gene to chromatically 
label all lineages of specific cells, lineage tracing using mtDNA mutations has been validated 
as a convincing method for the biological study of gastrointestinal stem cells (Taylor et al., 
2003; McDonald et al., 2008). However, to date, markers for gastric stem cells have not been 
exhaustively studied (Mills and Shivdasani, 2011). 
Although all cells within a gastric unit are renewed by gastric stem cells, the turnover of 
different cells in the gastric epithelium occurs at a differential rate (Hoffmann, 2008). The 
turnover of surface mucous cells in gastric pits is ~3 days, whereas it can take months to 
renew parietal cells and chief cells in gastric glands (Lee and Leblond, 1985a; Lee and 
Leblond, 1985b; Hoffmann, 2008; Barker et al., 2010a). This leads to different turnover rates 
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between different sections of gastric units and between different types of gastric epithelium 
with distinct cell components (Hoffmann, 2008). For example, the turnover of pyloric 
epithelium is markedly more rapid than that of fundic epithelium (Teir and Rasanen, 1961; 
Hansen et al., 1976; Patel et al., 1993). 
 
1.7.3 Intestines 
The small intestine is the main nutrient-absorptive organ with typical common histological 
characteristics of the GI tract, containing three parts: the duodenum that connects the pylorus 
of the stomach, the jejunum and the ileum that connects to the large intestine (caecum, colon 
and rectum). The jejunum is the main site for nutrition to be absorbed with paradigmatic 
finger-shaped villi to amplify the surface area for absorption. The bases of the villi extend to 
crypts that project into the lamina propria at the mucosa of the small intestines. A variety of 
cells constitute this epithelium (crypts and villi), including enterocytes with microvilli for 
absorption, goblet cells that produce mucus for lubrication, Paneth cells with immune 
function and endocrine cells that secret hormones (Figure 1.7) (James S. Lowe, 2015). 
Intestinal epithelium also contains M (microfold) cells and tuft cells, which are uncommon 
but play an important role in immune defence (von Moltke et al., 2015; Gerbe et al., 2016).  
The histological structure of the large intestine is similar to that of the small intestine. The 
primary difference is that colonic epithelium comprises only crypts with no villi, and crypts 
are more distinct and straight (Figure 1.7) (James S. Lowe, 2015). In addition, due to the 
different function of the colon, which is to reabsorb water and electrolytes to shape faeces, the 
cell components are also distinct from small intestinal epithelium. Columnar cells with 
absorptive ability are the major cell type within colonic crypts. The rest of the cells in crypts 
include goblet (mucous) cells for mucus production in the colon, scattered endocrine cells and 
tuft cells (Figure 1.7) (James S. Lowe, 2015).  
As the intestinal epithelium is rapidly renewed every 3 – 5 days, it serves as a fascinating 
prototype for mitotic tissue (Gehart and Clevers, 2019). In both small and large intestinal 
epithelium, newly differentiated cells migrate upwards to replace apoptotic aged cells during 
intestinal renewal except the Paneth cells that migrate downwards in the crypt of small 
intestines (Potten et al., 1997).  
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1.7.3.1 Intestinal stem cells 
Intestinal stem cells (ISCs) are responsible for replenishing all types of cells in the small and 
large intestines, with more than one ISC involved in this process per crypt (Taylor et al., 
2003; Barker et al., 2007). It is commonly accepted that ISCs are situated at the base of crypts 
(Figure 1.7). In the small intestine, there are two functionally distinct ISC subpopulations 
residing at different positions relative to Paneth cells. Taking advantage of the tritiated 
thymidine labelling, Chen et al. pioneered the identification of ISCs and proposed that the 
crypt base columnar (CBC) cells with stem cell characters are interspersed between Paneth 
cells (Cheng and Leblond, 1974). Barker et al. ultimately confirmed the CBC cells via in vivo 
lineage tracing using the Lgr5-EGFP-ires-cre-ERT2/R26R-lacZ mouse model, showing their 
ability to self-renew and differentiate into all cell lineages of the intestinal epithelium (Barker 
et al., 2007). This study has also revealed Lgr5 as an exceedingly specific marker for CBC 
cells (Barker et al., 2007). In addition, ex vivo culture of fluorescence-activated cell sorting 
(FACS)-isolated Lgr5+ CBC cells from the Lgr5-EGFP reporter mice can develop into self-
maintainable organoids with functional crypts and villi, further corroborating the identity of 
CBC cells (Sato et al., 2009). Olfm4 and Ascl2 were also suggested to be promising 
candidates to label CBC cells (van der Flier et al., 2009; Schuijers et al., 2014). The 
behaviour of CBC cells is substantially regulated by Wnt signalling (Mah et al., 2016). With 
Lgr5 as an important member in Wnt signalling pathway, CBC cells display a marked Wnt 
signature in their gene expression, including many Wnt target genes, such as Sox9, Ascl2, 
EphB2 and Rnf43 (Korinek et al., 1998; Barker et al., 2007; Van der Flier et al., 2007; Muñoz 
et al., 2012). The majority of Lgr5+ cells intersperse between Paneth cells, but some are 
detected above Paneth cells (Figure 1.7) (Barker et al., 2007). For colonic crypts with no 
Paneth cells, the Lgr5+ ISC lie exclusively at the base of crypts (Barker et al., 2007; Barker, 
2014). The WnthighLgr5+ CBC cells actively divide for self-renewal and epithelium 
regeneration under basal conditions and are sensitive to DNA damage caused by 
chemotherapy or irradiation (Yan et al., 2012; Tao et al., 2015). To prevent the catastrophe of 
losing susceptible CBC cells, intestines contain a functionally distinct ISC population, reserve 
stem cells that are able to repopulate CBC cells after injury and in non-pathological 
circumstances (Sangiorgi and Capecchi, 2008a; Tian et al., 2011; Yan et al., 2012; Yousefi et 
al., 2016). These stem cells reside around the +4 position (four cells from the crypt base), 
above Paneth cells but below the transit amplifying cell zone in crypts, and are commonly 
referred to as +4 stem cells (Potten et al., 1997; Medema and Vermeulen, 2011; Gehart and 
Clevers, 2019). Unlike CBC cells, the reserve stem cells are primarily quiescent, damage-
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resistant, injury-inducible and irresponsive to Wnt signalling (Yan et al., 2012; Li et al., 2016; 
Mah et al., 2016; Yousefi et al., 2016; Yousefi et al., 2017). Potential markers for reserve 
stem cell populations include Bmi1, mTert and Hopx; however, the reliability of these 
markers are still debatable, as these markers are not expressed exclusively in +4 stem cells 
(Sangiorgi and Capecchi, 2008b; Montgomery et al., 2011; Takeda et al., 2011; Muñoz et al., 
2012; Grün et al., 2015). 
Unlike the unidirectional grading differentiation in the haematopoietic system, intestinal 
regeneration has plasticity within the hierarchy, where committed cells can dedifferentiate 
back to stem cells to maintain epithelial regeneration after injury-induced loss of CBC cells 
(van Es et al., 2012b; Buczacki et al., 2013; Tetteh et al., 2016; Yan et al., 2017; Yousefi et 
al., 2017). In addition to intestinal stem cells populations, chief cells in the stomach are also 
able to acquire stemness and regenerate gastric epithelium (Stange et al., 2013; Barker, 2018). 
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Figure 1.7 Structure of the epithelium of small intestine and colon. Stem cells (green) are located at the 
base of intestinal crypts. Stem cells differentiate into transit-amplifying cells (yellow) that rapidly divide 
to renew all types of cells in the crypt (pink enterocytes, orange enteroendocrine cells, grey goblet cells 
and purple tuft cells). In the small intestine, stem cells are intercalated with Paneth cells (blue), which 
produce progenies to migrate upwards beyond the crypt to form villus.  
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1.7.3.2 Intestinal stem cell niche 
Stem cells not only need intrinsic signalling to regulate their division and differentiation but 
also require an appropriate microenvironment to maintain their function (Spradling et al., 
2001). The microenvironment where the stem cells are located is defined as the stem cell 
niche (Spradling et al., 2001). In intestines, the proximal epithelial cells and stromal cells 
interact with ISC through a series of intercellular signalling pathways, such as WNT, EGF 
(epidermal growth factor), BMP (bone morphogenetic protein) and Notch signalling, to 
regulate ISC activity and epithelial regeneration (Sato et al., 2010; Barker, 2014; Valenta et 
al., 2016; Gehart and Clevers, 2019). In particular, WNT signalling is indispensable for stem 
cell maintenance and differentiation (Kuhnert et al., 2004; van Es et al., 2012a; Pinto et al., 
2016). Enhanced WNT signalling induces immoderate epithelial proliferation and adenoma 
formation (Moser et al., 1995; Barker et al., 2008), and mutations in WNT signalling are 
exceedingly common (93%) in colon cancer (The Cancer Genome Atlas et al., 2012). At the 
crypt base, WNT and the WNT activator R-spondin are produced by Paneth cells and 
mesenchymal cells (Sato et al., 2010; Aoki et al., 2016; Valenta et al., 2016; Stzepourginski 
et al., 2017). Due to the poor diffusion of the WNT signal, it displays a decreasing gradient 
from the crypt base to the opening of the lumen (Mah et al., 2016; Gehart and Clevers, 2019). 
Opposing to the WNT gradient, BMP signals have the most robust expression at the distal end 
of the crypt, which neutralises the proliferative signals from the stem cell niche and drives cell 
differentiation (He et al., 2004; Kosinski et al., 2007). EGF signals are also critical for 
intestinal epithelium turnover as they control the rate of intestinal stem cell proliferation 
(Gehart and Clevers, 2019). Excessive EGF signalling in the oncogenic Kras mutant mice 
have been shown to accelerate stem cell division, and endow stem cells carrying the mutation 
an advantage to dominate the niche (Snippert et al., 2014). To ensure the strict regulation of 
EGF signalling, CBC cells abundantly express its receptor ERBB1 alongside its inhibitor 
LRIG1 (Wong et al., 2012). Notch signalling plays an important role in intestinal stem cell 
maintenance and the adjustment of secretory to absorptive lineage ratio (Gehart and Clevers, 
2019). In colonic crypts, in the absence of Paneth cells, the deep crypt secretory cells act as 
their alternatives to supply WNT, EGF and Notch signals in the niche (Sasaki et al., 2016). 
Cells in the niche not only communicate with stem cells through signalling pathways but also 
support stem cell metabolism. CBC cells primarily rely on OXPHOS during proliferation and 
differentiation. In contrast, Paneth cells undergo glycolysis and generate lactate that can be 
utilised by CBC cells as a resource for OXPHOS (Rodríguez-Colman et al., 2017).    
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There are multiple stem cells resident in the niche of each crypt; approximately five of them 
are effective stem cells that divide actively for routine epithelial renewal, which results in the 
initial heterogeneous phenotype of each crypt (Winton et al., 1988; Park et al., 1995; Kozar et 
al., 2013; Stamp et al., 2018; Gehart and Clevers, 2019). Unlike general somatic stem cells, 
intestinal stem cells inherently divide symmetrically with identical phenotypes; however, due 
to restricted space in the niche, stem cells are stochastically lost and replaced by other stem 
cells or dominate the niche, resulting in niche succession where a single stem cell and its 
clones entirely occupy the stem cell pool (Figure 1.8) (Lopez-Garcia et al., 2010; Snippert et 
al., 2010; Stamp et al., 2018). As a result, all the cells within the crypt derive from this stem 
cell and its clones, and the crypt inherits the phenotype of this stem cell and displays 
homogenous phenotype, which is termed monoclonal conversion (Figure 1.8). This is initially 
supported by a study reporting the presence of crypts with complete XY genotype or XO 
genotype in XO/XY mosaic patients (Novelli et al., 1996). Further studies show that in the 
R26R-Confetti/Cre recombinase reporter mice that allow the induction of the random 
expression of a variety of fluorescent markers, individual crypts that originally contain 
multiple colours of fluorescence only present monochrome fluorescence after 30 weeks 
(Snippert et al., 2010). In addition, lineage tracing studies where the expression of the reporter 
gene is linked to frameshift mutations during DNA replication show that the number of 
partially-labelled intestinal crypts remains steady with age, whereas the number of wholly-
labelled crypts increases with age (Kozar et al., 2013). Of note, in non-physiological 
circumstances, for example, the occurrence of an oncogenic mutation that increases 
proliferative capacity of a stem cell, the niche competition can be biased, and the mutation-
harbouring stem cell may acquire an advantage over other stem cells to take over the niche 
(Snippert et al., 2014). Monoclonal conversion is not an exclusive feature for intestinal crypts 
but also applies to gastric glands (discussed in Chapter 5 in more detail) (Nomura et al., 1998; 
Bjerknes and Cheng, 2002; McDonald et al., 2008). 
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Figure 1.8 Schematics of (a) the division model of stem cells and (b) niche succession. (a) Immortal 
stem cells only divide asymmetrically for self-renewal. Whereas, in a niche, stem cells undergo either 
asymmetric division or symmetric division (Kim and Shibata, 2002). If a single stem cell symmetrically 
divides into two daughter cells, then this stem cell is lost in the niche. (b) By niche succession, an initially 
heterogeneous crypt can change into a homogeneous crypt, where one of the stem cells dominate the 
niche, and all differentiated cells eventually derive from this stem cell and its clones. The red arrows 
denote the directions of cell migration. ISC, intestinal stem cell.   
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1.8 Overall aims and objectives 
The overall aim of this thesis is to further the understanding of tissue-specific phenotypes and 
distribution of mtDNA mutations during the development of mtDNA disease and more 
specifically, to understand the selective loss of inherited mtDNA mutations in mitotic tissue 
using gastrointestinal epithelium as a model, with a specific focus on intestines. This includes 
three aspects: 
1. Ascertain whether patients with inherited m.3243A>G and m.8344A>G mutations 
selectively lose the mutations in their gastrointestinal epithelium. 
2. Genetically and biochemically characterise tRNAAla mutant mice with an inherited 
m.5024C>T mutation to determine whether they are qualified candidates for the 
investigation of mechanisms underpinning the selective pressures against inherited 
mtDNA mutations in mitotic cell populations. 
3. Using the colonic epithelium of tRNAAla mutant mice to investigate potential 
mechanisms underlying the selective loss of inherited mtDNA mutations with age. 
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Chapter 2 Materials and Methods 
2.1 Equipment and software 
2.1.1 Equipment 
ABI verti-96 well Thermo Cycler Applied Biosystems 
3510 Benchtop pH meter  Jenway 
2100 Antigen Retriever Aptum Biologics 
Aperio CS2 Scanner Leica 
Autoclave Prior Clave 
ChemiDoc Imaging System Bio-Rad 
Eppendorf Thermomixer Eppendorf 
Eppendorf® Refrigerated Microcentrifuge 5417R Eppendorf 
Eppendorf Centrifuge 5418  Eppendorf 
GeneAmp PCR system 9700 Applied Biosystems 
Horizontal gel electrophoresis tank  Peqlab 
IKA™ Aluminum Alloy Basic Magnetic Hotplate Stirrer  Fisher Scientific 
Microflow biological safety hood J. Marston engineers 
Nanodrop ND-1000 Spectrophotometer Labtech International 
A1 Confocal Laser Microscope System Nikon 
OHAUS adventurer® balance  OHAUS 
OTF5000 Cryostat Bright 
PALM MicroBeam Zeiss 
PURELAB® flex ELGA LabWater 
PyroMark Q24 Pyrosequencer Qiagen 
PyroMark Q24 Vacuum Workstation Qiagen 
QBD2 Dry Block Heating System Grant 
UV Cabinet BioAir 
Vortex genie 2 Scientific Industries 
Vwr Microscope Compound Bi Adv V031 VWR 
Zeiss Axio Imager M1 microscope Zeiss 
 
2.1.2 Software 
Aperio ImageScope Leica 
AxioVision Zeiss 
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ImageJ National Institutes of Health 
ImageLab v.4.1 Bio-Rad 
Minitab v17.1.0 Minitab 
ND-1000 software  Labtech International 
NIS-Element AR Imaging Software v4.40  Nikon 
Palm Robo v4.6 Zeiss 
Prism v6.01 GraphPad 
PyroMark Q24 Software 1.0.10 Qiagen 
R v3.3.0 R 
R Studio v0.99.896 RStudio 
ZEN blue Zeiss 
 
2.2 Consumables 
0.2ml Thin-walled PCR tubes STARLAB 
0.5ml Thin-walled PCR tubes STARLAB 
1.5ml Eppendorf Eppendorf 
2ml Eppendorf Eppendorf 
24-Well PCR Plate, Non-Skirted, Elevated Wells, Natural STARLAB 
96-well plate Semi-Skirted with Raised Rim STARLAB 
Colourcoat+ adhesion microscope slides CellPath 
Coverslips (22x40mm and 22x50mm)  VWR 
DNeasy Blood & Tissue Kits QIAGEN 
ErgoOne® Single-channel Pipettes (P10, P20, P200, P1000) STARLAB 
Falcon Tubes (15ml and 50ml) BD Biosciences 
Gloves STARLAB 
MicroAmp® Optical Cap Strips Applied Biosystems 
PEN membrane slides Leica Microsystems 
PIPETMAN P2 Gilson 
PAP Pen Liquid Blocker Newcomer Supply 
Scalples Swann Morton 
SlideRita 5 Mailer CellPath 
Superfrost Plus slides Thermo Scientific 
TipOne® Pipette Tips STARLAB 
Weigh boats VWR 
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Xtra-Clear Advanced Polyolefin StarSeal STARLAB 
 
2.3 Chemicals and solutions 
2.3.1 Chemicals 
2.3.1.1 Tissue processing 
Liquid Nitrogen  BOC 
OCTTM medium Raymond Lamb 
 
2.3.1.2 Histological and histochemical reagents  
Avidin/biotin blocking kit Vector Laboratories 
Catalase Sigma 
Cytochrome c  Sigma  
3,3’ Diaminobenzidine tetrahydrochloride  Sigma  
DPX mounting media  Merck  
Eosin CellPath 
Ethanol  Fisher Scientific 
Ethylenediaminetetraacetic acid (EDTA) disodium salt 
dehydrate 
Affymetrix 
HistoclearTM  National Diagnostics  
Hoechst 33342, Trihydrochloride, Trihydrate Life Technology 
Hydrochloric acid VWR  
Hydrogen peroxide solution 30% (w/w) in H2O Sigma  
Mayer’s haematoxylin TCS Bioscience Ltd. 
Methanol  Merck  
Nitro Blue Tetrazolium Sigma  
Normal goat serum  Sigma  
Paraformaldehyde solution 4% in PBS Santa Cruz Biotechnology  
Phenazine methosulphate  Sigma  
Phosphate buffered saline tablets  Sigma  
Prolong Gold mounting medium Life Technologies  
Sodium azide  Sigma  
Sodium chloride Sigma  
Sodium succinate  Sigma  
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Tri-sodium citrate dihydrate VWR 
Trizma base  Sigma  
Tween-20  Sigma  
 
2.3.1.3 Molecular biology reagents 
Agarose Bioline 
Bromophenol Blue Sigma 
dNTP Mix Promega 
DNA Away Thermo Fisher 
GoTaq polymerase Promega 
PCR Ranger 100 bp DNA Ladder Norgen Biotek Corp 
Proteinase K Invitrogen 
PyroMark Annealing buffer  Qiagen 
PyroMark Binding buffer Qiagen 
PyroMark Gold Q24 Reagents (5 x 24) Qiagen 
PyroMark Wash buffer (x10)  Qiagen 
Streptavidin sepharoseTM high performance beads GE Healthcare 
SYBR Safe DNA Gel Stain Thermo Scientific 
Tris acetate EDTA (10x TAE) Sigma 
TRIS hydrochloride Sigma 
 
2.3.2 Solutions 
Cell lysis buffer  50 mM Tris-HCL pH 8.5 
0.5% Tween-20 
20mg/ml proteinase K 
DNA loading buffer  
 
0.25% (w/v) Bromophenol 
Blue 
30% (v/v) Glycerol 
DNA electrophoresis running buffer (1L)  100 ml 10x TAE  
900ml ultrapure water 
DNA electrophoresis running buffer (1L)  
 
100ml 10x TAE 
900ml ultrapure water 
EDTA antigen retrieval buffer pH 8.0 1 mM EDTA 
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Phosphate buffered saline (PBS) 1 PBS tablet in 100ml 
ultrapure water 
Scott’s tap water  0.2% (w/v) Sodium 
Bicarbonate  
2% (w/v) Magnesium 
Sulphate) 
Sodium citrate antigen retrieval buffer pH 6.0 10 mM tri-sodium citrate 
TBST pH 7.4 
 
5 mM Trizma base 
100 mM Sodium chloride 
0.1% (v/v) Tween®-20 
 
 
2.4 Human samples 
2.4.1 Patients 
Ileum tissue was obtained from patient 1 with m.3243A>G via ileectomy. Gastrointestinal 
tissue specimens were collected from two patients (P2 and P3) with inherited m.3243A>G 
and one patient with m.8344A>G at post-mortem. Details of patients and tissue they provided 
are summarised in Table 2.1.  
 
Patient 
Age  
(years) 
Gender 
MtDNA 
genotype 
Tissue 
Tissue  
component 
P1 30 F m.3243A>G Ileum E and M 
P2 36 F m.3243A>G 
Oesophagus 
E and M Stomach 
Jejunum 
P3 64 F m.3243A>G Colon E and M 
P4 56 M m.8344A>G Colon E and M 
Table 2.1 Information of the patients with inherited mitochondrial point mutations and the tissue thereof. 
E, epithelium; M, muscle. The age indicates the age of the patients when the tissue was collected. 
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2.4.2 Controls 
Control tissue confirmed by histopathologists as “normal” was collected through endoscopy 
from patients who had digestive complaints but showed no evidence of intestinal disease or 
through resection 20cm away from the tumour area of patients with colonic cancer. No 
mitochondrial disorders were reported in any control subjects. Information of the control 
subjects and the tissue thereof is detailed in Table 2.2. 
 
2.4.3 Ethical approval 
Informed consent from all participants was received prior to collecting the tissue. Ethical 
approval for this project was granted from Newcastle and North Tyneside Local Research 
Ethics Committees. 
Control 
Age  
(years) 
Gender 
MtDNA 
genotype 
Tissue 
Tissue  
component 
C1 30 F WT Small intestine E 
C2 31 F WT Small intestine E 
C3 31 F WT Small intestine E 
C4 34 F WT Small intestine E 
C5 37 F WT Small intestine E 
C6 37 F WT Small intestine E 
C7 59 F WT Colon E and M 
C8 61 F WT Colon E and M 
C9 62 M WT Colon E and M 
C10 64 F WT Colon E and M 
C11 64 M WT Colon E 
C12 41 M WT 
Oesophagus 
E 
Stomach 
C13 44 M WT 
Oesophagus 
E 
Stomach 
C14 57 F WT Oesophagus E 
C15 58 F WT Oesophagus E 
Table 2.2 Summary of the control individuals and their tissue. E, epithelium; M, muscle. 
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2.5 tRNAAla mutant mice with m.5024C>T mutation 
All mice were bred by Dr James Stewart and Prof Nils-Göran Larsson, Max Planck Institute 
for Biology of Ageing, Cologne, Germany. A mouse lineage (PolgAmut/+) (Trifunovic et al., 
2005) was used to generate tRNAAla mutant mice (Kauppila et al., 2016), which is a mouse 
model of mitochondrial disease with m.5024C>T point mutation. The former lineage 
(PolgAmut/mut) carries a knock-in mutation in the exonuclease domain of the mtDNA 
polymerase γ (Polg), which compromises its proofreading ability and causes an age-
dependent accumulation of mtDNA mutations (Trifunovic et al., 2005). PolgAmut/mut mice 
have similar germline and somatic mutation load, which is 16 – 20 mutations per molecule 
(Stewart et al., 2008; Ross et al., 2013). To facilitate segregating single mtDNA mutations via 
screening correlated phenotypes, PolgAmut/+ mice that carry approximately 3 mutations per 
mtDNA molecule were employed to generate the new mouse line (Kraytsberg et al., 2009; 
Ross et al., 2013; Kauppila et al., 2016). Male PolgAmut/+ mice were mated with wild-type 
C56Bl/6N (PolgA+/+) females to obtain female PolgAmut/+ mice which had the mutator allele 
but no inherited mtDNA mutations, which were then backcrossed with wild-type PolgA+/+ 
mice to produce females with wild-type mtDNA polymerase that transmitted mtDNA 
mutations (N1) (Figure 2.1) (Kauppila et al., 2016). After breeding these mice for at least 
three generations, the phenotype of the colonic epithelium was screened (Figure 2.1) and 
mouse lineages with no COX-deficient crypts were discontinued (Kauppila et al., 2016). 
Three out of twelve mouse lines showed COX deficiency, which were further subjected to 
whole mtDNA genome sequencing to screen candidate mutations (Figure 2.1) (Kauppila et 
al., 2016). A mouse line (tRNAAla mice) with a stable transmission of m.5024C>T in the 
tRNAAla gene (> 6th generation) was segregated and used for this project (Figure 2.1) 
(Kauppila et al., 2016).  
An ear notch biopsy was taken from mice at ≈3 weeks and its mutation level was measured 
via pyrosequencing by Dr James Stewart, Max Planck Institute for Biology of Ageing, 
Cologne, Germany. Mutant mice in two age groups (~10 weeks and ~ 50 weeks) and their 
age-matched wild-type controls were sacrificed by cervical dislocation and the organs were 
harvested to obtain both frozen and formalin-fixed paraffin-embedded (FFPE) tissue, which 
was performed by Dr Laura Greaves and Dr James Stewart. Each organ was divided in two, 
and one half was snap-frozen in isopentane cooled to -180°C in liquid nitrogen. Frozen tissue 
was then stored at -80°C. The second half was fixed in 10% neutral buffered formalin for 24 
hours, prior to dehydration and embedding in paraffin. Five tRNAAla mice with high ear 
heteroplasmy (>70%) and two mice with intermediately high ear heteroplasmy (60%) in each 
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age group were included in the study. Information of each mouse and acquired organs was 
summarised in Table 2.3. Details of the frozen and FFPE gastrointestinal tissue from 10-week 
and 50-week tRNAAla mice were concluded in Table 2.4 and Table 2.5 respectively.  
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Figure 2.1 Breeding and screening strategy for tRNAAla mutant mice. Rings in blue indicate wild-type 
mtDNA. Rings in red are mtDNA molecules with m.5024C>T mutation. Rings in the other colours are 
mtDNA with different types of pathogenic or non-pathogenic mutations. N indicates the generation. A 
tRNAAla mutant mouse line with stably transmitted m.5024C>T was segregated after the 6th generation 
of the maternal lineage. 
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2.6 Cryosection 
Frozen tissue was mounted on WhatmanTM filter paper with a small amount of OCTTM 
medium (VWR) in liquid nitrogen. Tissue was then placed in OTF5000 Cryostat (Bright) to 
warm to -19°C before sectioning. Sections for histochemical assays were cut at a thickness of 
10 µm using the OTF5000 Cryostat (Bright) and were mounted on Superfrost Plus slides 
(Thermo Scientific). Sections for laser microdissection were cut at 20 µm and mounted on 
polyethylene naphthalate (PEN) membrane slides (Leica Microsystems). Specimens were 
then air-dried for an hour and stored in sealed slide mailers at -80°C until required. 
 
2.7 Histochemistry 
2.7.1 Haematoxylin and eosin staining 
Tissue sections were brought up to room temperature and air-dried for an hour. Sections were 
then submerged into Mayer’s haematoxylin (TCS Bioscience Ltd.) for 5 minutes and rinsed 
with tap water. Sections were subsequently blued in Scott’s tap water (0.2% (w/v) Sodium 
Bicarbonate, 2% (w/v) Magnesium Sulphate) for 30 seconds followed by a wash with running 
tap water. Sections were then immersed in Eosin (CellPath) for 2 minutes and rinsed with tap 
water. Sections were dehydrated through a gradient of ethanol solutions (70%, 95%, and 2x 
100%) for 1 minute in each and cleared in Histoclear (National Diagnostics) twice with 1 
minute in each and mounted in DPX (Merck) with a coverslip. 
 
2.7.2 COX, SDH and sequential COX/SDH histochemistry 
Tissue sections (10 µm) were removed from the freezer and air-dried at room temperature for 
an hour. Sections were then circled in hydrophobic barriers using a PAP liquid blocker pen 
(Newcomer Supply). COX stock solutions (500 µM cytochrome c and 5 mM 
diaminobenzidine tetrahydrochloride (DAB) in 0.2M phosphate buffer, pH 7.0) were thawed 
at 55°C for 5 minutes. COX medium (100 µM cytochrome c, 4 mM DAB in 0.2M phosphate 
buffer, pH 7.0) were prepared by adding a 200 µl cytochrome c to 800 µl DAB with 20 µg/ml 
catalase. Each section was incubated in 100 µl COX medium at 37°C in a humid chamber. 
Tissue sections were then washed with phosphate buffered saline (PBS) for 3 x 5 minutes. 
SDH aliquots (800 µl 1.5 mM nitroblue tetrazolium (NBT), 100 µl 1.5M sodium succinate, 
100 µl 2 mM phenazine methosulphate (PMS) and 10 µl 100 mM sodium azide in 0.2M 
phosphate buffer, pH 7.0) were defrosted at 55°C for 5 minutes and combined to make an 
SDH solution with a final concentration of 1.2 mM NBT, 130 mM sodium succinate, 200 µM 
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PMS and 1 mM sodium azide in 0.2M phosphate buffer, pH 7.0. Each section was covered 
with 100 µl SDH solution and incubated in a humid atmosphere at 37°C, then washed by PBS 
3 x 5 minutes. Optimised incubation times of COX and SDH medium for various tissues were 
listed in the Table 2.6. Sections were subsequently dehydrated through graded ethanol 
solutions (70%, 95% and 2 x 100%) and cleared in two changes of the Histoclear (National 
Diagnostics) for 5 minutes in each, then mounted with DPX (Merck) with coverslips. 
For individual COX or SDH histochemistry, sections were incubated only with COX medium 
or SDH medium and washed with PBS 3 x 5 minutes, then dehydrated and mounted as above. 
For the tissue prior to laser microdissection, sections (20 µm) were subjected to the sequential 
incubation of COX and SDH medium and were dehydrated in the ethanol gradient as above. 
Sections were then air-dried for an hour, sealed in slide mailers and stored at -80°C. 
 
Tissue Species 
COX medium 
incubation time 
(minutes) 
SDH medium 
incubation time 
(minutes) 
Small intestine (E) Human 60 35 
Colon (E) Human 50 35 
Stomach (E) Human 50 35 
Oesophagus (E) Human 60 35 
GI Smooth muscle Human 50 35 
Stomach (fundus) (E) Mouse 5 11 
Stomach (pylorus) (E) Mouse 25 25 
Small intestine (E) Mouse 25 30 
Large intestine (E) Mouse 25 30 
GI smooth muscle Mouse 25 25 
Table 2.6 Optimised incubation time for different types of tissues in COX/SDH medium. E, epithelium; 
GI, gastrointestinal. 
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2.8 Immunofluorescence 
2.8.1 Immunofluorescence on frozen tissue 
Frozen tissue sections were allowed to warm to room temperature and air-dried for an hour. 
Sections were fixed in 4% paraformaldehyde (Santa Cruz Biotechnology) for 10 minutes at 
4°C to preserve morphology. Sections were gently rinsed with distilled water and then washed 
in TBST (5 mM Trizma base, 100 mM Sodium chloride and 0.1% (v/v) Tween®-20) for 10 
minutes. Specimens were further permeabilised in a methanol gradient in sequence: 70% for 
10 minutes, 95% (with 0.3% H2O2 (v/v)) for 10 minutes, 100% for 20 minutes, 95% for 10 
minutes and 70% for 10 minutes. Subsequently, sections were washed by TBST and encircled 
with a hydrophobic pen (Newcomer Supply). To reduce non-specific binding between 
secondary antibodies and endogenous antigens, tissue was incubated with a protein block 
solution for an hour at room temperature. The blocking solution is the diluted serum of the 
animal species for producing the secondary antibody, which is 10% normal goat serum (NGS) 
(Sigma Aldrich) diluted in TBST in this study. A combination of primary antibodies was 
diluted in the 10% NGS to the required concentrations (Table 2.7) and applied to the 
specimens at 4°C overnight in a moist chamber. A no primary control (NPC) corresponding to 
each case was incubated in 10% NGS with no primary antibodies added and was subjected to 
the same subsequent procedure. Sections were then washed 3 x 5 minutes with TBST and 
incubated with a cocktail of diluted secondary antibodies at 4°C for 2.5 hours in a humid 
container in the dark. Sections were then washed 3 x 5 minutes with TBST in dark. When a 
biotinylated secondary antibody was used, a streptavidin-conjugated tertiary antibody was 
diluted and applied to the specimens, followed by 3 x 5 minute wash in TBST. Tissue was 
then mounted with Prolong Gold mounting medium (Life Technologies) and stored at -20°C.  
  
2.8.2 Immunofluorescence on formalin-fixed paraffin-embedded (FFPE) tissue 
FFPE tissue sections at a thickness of 4 µm were deparaffinised and rehydrated by one-hour 
incubation at 60°C, followed by immersion 2 x 10 minute in Histoclear (National 
Diagnostics), an ethanol gradient (2 x 5 minute in 100%, 1 x 5 minute in 95%, 1 x 5 minute in 
70%) and then distilled water for 5 minutes. Specimens were submerged in 1 mM EDTA (pH 
8.0) and placed in 2100 retriever unit (Election Microscopy Sciences) for antigen retrieval. 
Sections were left in the retriever to cool for 40 minutes after the program finished, as a sharp 
change in temperature might detach the tissue from the slide. Tissue was then washed with 
TBST three times with 5 minutes each and incubated in 10% NGS for an hour. Sections were 
then washed 3 x 5 minute with TBST. Endogenous biotin and avidin binding sites were 
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blocked using an Avidin/Biotin blocking kit (Vector Laboratories), when biotinylated 
secondary antibody was used. Sections were covered with the avidin block solution for 15 
minutes at room temperature followed by a 3 x 3 minute wash. Sections were then incubated 
with the biotin block reagent for 15 minutes and washed three times with 3 minutes each. 
Primary antibody cocktails were applied to tissue overnight at 4°C, followed by 3 x 10 minute 
wash. Sections were then incubated with secondary antibodies for 2 hours at 4°C, followed by 
a 3 x 10 minute wash in dark. A streptavidin conjugated tertiary antibody was applied to 
tissue followed by a 3 x 10 minute wash in dark, when a biotinylated secondary antibody was 
included in the cocktail of secondary antibodies. Sections were then mounted with Prolong 
Gold (Life Technologies) using a coverslip and stored at -20°C.  
 
2.8.3 Counterstain Hoechst for immunofluorescence 
Counterstaining sections with Hoechst to label nuclei was performed after washing the last set 
of antibodies. Tissue was incubated with 0.01 mg/ml Hoechst (Life Technology) for 15 
minutes at room temperature in dark followed by a 3 x 5 minute wash. Tissue was then 
mounted with Prolong Gold on a glass slide and stored at 20°C. 
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Primary antibody Host Isotype 
Dilution 
(Human) 
Dilution 
(Mouse) 
Manufacturer Code 
Anti-NDUFB8  M IgG1 1:50 1:50 Abcam ab110242 
Anti-SDHA M IgG1 1:200 1:200 Abcam ab14715 
Anti-
COX4+COX4L2 
M IgG2a 1:200 - Abcam ab110261 
Anti-MTCO1 M IgG2a 1:100 1:100 Abcam ab14705 
Anti-VDAC1 M IgG2b 1:100 1:100 Abcam ab14734 
Anti-β-catenin R IgG 1:100 N/A Abcam ab6302 
Anti-β-catenin M IgG2b N/A 1:300 
Santa Cruz 
Biotechnology 
sc-393501 
Anti-Alpha smooth 
muscle Actin 
R IgG 1:100 N/A Abcam ab5694 
Anti- E-cadherin R IgG 1:400 N/A Abcam ab40772 
Anti-Ki-67  R IgG N/A 1:300 
Cell Signaling 
Technology 
#12202 
Anti-Caspase 3, 
active (cleaved) 
form 
R IgG N/A 1:40 Merck AB3623 
Anti-TOMM20 R IgG N/A 1:100 Abcam ab186734 
Anti-Tom20 M IgG2a N/A - 
Santa Cruz 
Biotechnology 
sc-17764 
Anti-TOMM22 M IgG2a N/A 1:100 Abcam ab57523 
Anti-Tim23 M IgG2b N/A 1:20 
Santa Cruz 
Biotechnology 
sc-514463 
Anti-Parkin M IgG2b N/A 1:50 Merck MAB5512 
Anti-Parkin M IgG2b N/A - Abcam ab77924 
Anti-Parkin M IgG2b N/A - 
Santa Cruz 
Biotechnology 
sc-32282 
Anti-PGC-1 R IgG N/A - Abcam ab3242 
Anti-PINK1 R IgG N/A 1:100 Abcam ab23707 
Table 2.7 Information of primary antibodies and their optimised dilutions for immunofluorescence. M, 
mouse; R, rabbit; "-", failed to be optimised; “N/A”, not used on the tissue. 
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Secondary/tertiary 
antibody 
Target Host 
Dilution 
(Human) 
Dilution 
(Mouse) 
Manufacturer Code 
Biotin-XX 
Mouse 
IgG1 
Goat 1:200 1:400 
Life 
Technologies 
A10519 
Biotin-XX 
Rabbit 
IgG 
Goat 1:200 1:400 Vector Labs BA-1000 
Alexa Fluor 647 
 
Mouse 
IgG1 
Goat 1:200 1:400 
Life 
Technologies 
A21240 
Alexa Fluor 488 
 
Mouse 
IgG2a 
Goat 1:200 1:400 
Life 
Technologies 
A21131 
Alexa Fluor 546 
Mouse 
IgG2a 
Goat 1:200 1:400 
Life 
Technologies 
A21133 
Alexa Fluor 488 
Mouse 
IgG2b 
Goat 1:200 1:400 
Life 
Technologies 
A21141 
Alexa Fluor 546 
Mouse 
IgG2b 
Goat 1:200 1:400 
Life 
Technologies 
A21143 
Alexa Fluor 647 
Mouse 
IgG2b 
Goat 1:200 1:400 
Life 
Technologies 
A21242 
Alexa Fluor 405 
Rabbit 
IgG 
Goat 1:200 1:400 
Life 
Technologies 
A31556 
Alexa Fluor 488 
Rabbit 
IgG 
Goat 1:200 1:400 
Life 
Technologies 
A11008 
Alexa Fluor 546 
Rabbit 
IgG 
Goat 1:200 1:400 
Life 
Technologies 
A11010 
Alexa Fluor 647 
Rabbit 
IgG 
Goat 1:200 1:400 
Life 
Technologies 
A21244 
Streptavidin, Alexa 
Fluor 405 conjugate 
Biotin N/A 1:100 1:200 
Life 
Technologies 
S32351 
Streptavidin, Alexa 
Fluor 488 conjugate 
Biotin N/A 1:100 1:200 
Life 
Technologies 
S32354 
Streptavidin, Alexa 
Fluor 647 conjugate 
Biotin N/A 1:100 1:200 
Life 
Technologies 
S21374 
Table 2.8 Details of secondary/tertiary antibodies and their optimised dilutions used in the study. 
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2.9 Microscopy and image analysis 
2.9.1 Brightfield imaging 
Whole-section scanning was conducted using Aperio CS2 (Leica). Aperio ImageScope 
(Leica) was used for snapshotting and quantifying COX deficiency in gastrointestinal 
epithelium. Using the counter tool in the graphical user interface, the number of COX-
defective gastrointestinal crypts and the total number of crypts on an intact section were 
counted to calculate the COX deficient percentage in the epithelium. For each patient and 
mouse, counting was performed on two serial sections. 
 
2.9.2 Fluorescence microscopy and image analysis 
Fluorescent images were taken by a monochrome camera (AxioCam MRm) integrated in a 
Zeiss Axio Imager M1 microscope at a magnification of 10x. For human and animal studies, 
AxioVision and Zen blue (updated version of AxioVision) were used for controlling the 
microscope respectively. Cubes for filtering fluorescence at a wavelength 405 nm, 488 nm, 
546 nm and 647 nm were selected according to the fluorescent dyes. Exposure time was set 
based on no primary controls to minimize background fluorescence and antibody-treated 
sections with the strongest optical density to avoid pixel saturation, and was kept consistent 
between each subject. Files were saved as .zvi format and exported as tagged image file 
format (TIFF) images for quantitative analysis. Pictures for each channel were then imported 
to ImageJ. Regions of interest (ROI) were selected and the mean fluorescence intensity within 
the ROI was automatically measured by the software. 
 
2.9.3 Confocal microscopy and image analysis 
Sections were imaged using an upright A1+ Confocal Laser Microscope System (Nikon 
Instruments) comprising of a Nikon Ni-E body, confocal scan head laser and detector (PMT / 
GASP detectors) units providing lasers at four wavelengths (405nm, 488nm, 561nm and 
647nm). Images were captured using NIS-Elements Imaging Software (v4.40) (Nikon) 
through an apochromatic lens with x20 magnification, numerical aperture 0.75 and working 
distance 1.0 mm (Nikon). Each section was scanned in a z-stack fashion for 9 steps with 1 µm 
interval between sections. Individual colours were scanned in sequence to reduce ‘cross-talk’ 
between each channel where photons resulting from the excitation of one dye may be 
collected in the channel of another. Laser settings including laser power, photon amplification 
gain (HV) and offset adjustment was tuned according to the brightest image in a set of 
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experiments to avoid pixel saturation, and were maintained identical for each sample. 
Confocal scan settings are summarised in the Table 2.9. Images were saved as .nd2 format for 
analysis using NIS-Element AR Imaging Software (v4.40) (Nikon). Z-stack images were 
integrated to obtain maximum intensity projection at each pixel site. Colonic crypts were 
selected as ROI and were masked with a minimum threshold of pixel intensity to remove the 
lumen area. The masking strategy was remained the same for each case in a set of 
experiments. Mean pixel intensity was measured for each channel. Punctate signals were 
manually counted. 
 
Pinhole size 
(µm) 
Scan size Zoom factor 
Optical 
sectioning 
(µm) 
Pixel size 
(µm) 
Scan speed  
(pixel dwell 
time) 
21.2 1024 x 1024 2 2.83 0.31 2.4 µs 
Table 2.9 Camera settings for confocal imaging. 
 
2.10 DNA extraction and cell lysis 
2.10.1 Laser microdissection 
Sections were air-dried for an hour and loaded on the Zeiss Laser Capture Microdissection 
microscope. Sterile 200 µl PCR tubes were filled with cell lysis buffer (50 mM Tris-HCL pH 
8.5, 0.5% Tween-20, 20mg/ml proteinase K and distilled water) in their caps (10 µl for a 
single crypt or a small area of smooth muscles; 20 µl for a collection of large areas of 
epithelium or muscle from several fields of view) and installed on the motorised rack of the 
microscope. Tissue was selected manually and laser-cut under the mode of “Robo-LPC” using 
Palm Robo v4.6 at 20x magnification. Tissue-specific laser power was optimised until the 
cutting line was thin and smooth. A reagent negative control with no tissue added in the lysis 
buffer was prepared for pyrosequencing (2.11.1). Tissue was then catapulted into the lid of the 
tube and kept on ice to be prepared for cell lysis. 
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2.10.2 Cell lysis and DNA extraction from laser-cut tissue 
Tissue with the lysis buffer (2.10.1) was centrifuged at 14000 rpm for 10 minutes at 4°C, then 
lysed at 55°C for 5 hours, 95°C for 10 minutes to inactivate the proteinase K and held at 4°C 
until being transferred into a -20°C freezer. 
 
2.10.3 DNA extraction from tissue homogenate 
Frozen mouse organs were sectioned at 10 µm in OTF5000 Cryostat (Bright), the morphology 
of which was checked under a Brightfield microscope (VWR). A small piece of tissue was 
then cut and transferred to a sterile freezing 1.5 ml Eppendorf tube in OTF5000 Cryostat 
(Bright). DNA extraction was conducted using a DNeasy Blood & Tissue Kits (QIAGEN) 
following the manufacturer’s instruction. DNA concentration was measured using Nanodrop 
spectrophotometer (Thermo Scientific) with a minimal concentration 2 ng/µl to ensure 
sufficient DNA for the genetic study. Extracted DNA was stored at -80°C. 
 
2.11 PCR and sequencing 
2.11.1  PCR amplification for pyrosequencing 
DNA extracted from the microdissected tissue (2.10.2) and the organ homogenate (2.10.3) 
was used as a template to determine mutation levels in these tissues. A single round of PCR 
was performed using a Thermal cycler (Applied Biosystems) to generate enough PCR 
products for pyrosequencing. A no-template control with no DNA added in the mastermix 
was set for each PCR plate (STARLAB). A lysis-reagent negative control (2.10.1) was run 
together if the DNA was obtained from the micro-dissected tissue. Triplicates were set for all 
samples. Information of primer sequences for the pre-pyro PCR was summarised in Table 
2.13. Details of the mastermix and the PCR programme for each point mutation is described 
in the subsections below.  
 
2.11.1.1 Assay for m.3243A>G 
PCR was performed to amplify a 210 bp PCR fragment spanning the m.3243 mutation locus 
using a forward biotinylated and a reverse primer. The volume of the PCR solution for this 
assay is 25µl: 12.8 µl distilled water, 5 µl 5x GoTaq Reaction buffer (Promega), 2.5 µl 10x 
dNTP (0.2 mM) (Promega), 1.25 µl of each primer (10 µM), 0.2 µl GoTaq polymerase 
(Promega) and 2 µl DNA lysate. Details of PCR programme is summarised in Table 2.10.  
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Step Temperature Duration Cycles 
Initial denaturation 95°C  10 minutes 1 
Denaturation 95°C 30 seconds 
40 Annealing 63°C 30 seconds 
Extension 72°C 30 seconds 
Final Extension 72°C 10 minutes 1 
Hold 4°C ∞  
Table 2.10 PCR condition for expanding PCR fragments at m.3243 locus. 
 
2.11.1.2 Assay for m.8344A>G 
A PCR assay to amplify a 147 bp segment spanning m.8344 mutation site was carried out in a 
25 µl solution containing 12.8 µl distilled water, 5 µl 5x reaction buffer (Promega), 2.5 µl 10x 
dNTP (0.2 mM) (Promega), 1.25 µl of the forward biotinylated and the reverse primer each 
(10 µM), 0.2 µl GoTaq polymerase (Promega) and 2 µl DNA lysate. PCR condition is 
concluded in Table 2.11. 
Step Temperature Duration Cycles 
Initial denaturation 95°C 10 minutes 1 
Denaturation 95°C 30 seconds 
40 Annealing 62°C 30 seconds 
Extension 72°C 30 seconds 
Final Extension 72°C 10 minutes 1 
Hold 4°C ∞  
Table 2.11 PCR condition for the m.8344A>G assay. 
 
2.11.1.3 Assay for mt.5024C>T 
A PCR fragment in a size of 178 bp spanning m.5024 locus was amplified using 1 µl DNA 
lysate and 24 µl mastermix including 13.8 µl distilled water, 5 µl 5x reaction buffer 
(Promega), 2.5 µl 10x dNTP (0.2 mM) (Promega), 1.25 µl of the forward biotinylated and the 
reverse primer each (10 µM) and 0.2 µl GoTaq polymerase (Promega). PCR programme was 
listed in Table 2.12. A wild-type control was set for each plate with DNA extracted from a 
wild-type mouse (by courtesy of Dr Craig Stamp). 
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Step Temperature Duration Cycles 
Initial denaturation 95°C 10 minutes 1 
Denaturation 95°C 30 seconds 
38 Annealing 62°C 30 seconds 
Extension 72°C 30 seconds 
Final Extension 72°C 10 minutes 1 
Hold 4°C ∞  
Table 2.12 Thermal cycler programme for amplifying DNA segments spanning mt.5024 mutation site. 
 
2.11.2 Agarose gel electrophoresis 
PCR products were separated on a 2% (w/v) agarose gel and visualised using SYBR Safe 
DNA Gel Stain (Thermo Scientific) under ultraviolet light. Each PCR product (3 µl) was 
mixed with 1 µl loading dye (0.25% (w/v) bromophenol blue and 30% (v/v) glycerol) and 
loaded in the gel. PCR products were run with 5 µl of PCR Ranger 100 bp DNA Ladder 
(Norgen Biotek Corp). At least one gap was left between the PCR products generated from 
DNA and the no-template negative control to avoid contamination. Gel was immersed in 1x 
TAE buffer (40 mM Tris-acetate and 1 mM EDTA, pH 8.3) (Sigma-Aldrich) and subjected to 
electrophoresis at 100V for 45 minutes. PCR products were visualised using a ChemiDoc 
Imaging System (Bio-Rad). Enough amount of PCR products showing clear bands and 
absence of contamination were confirmed before pyrosequencing (Figure 2.2). 
 
 
Figure 2.2 An image of gel electrophoresis showing PCR products (178bp) spanning m.5024 position 
with no contamination in the reagent negative control (no DNA in the lysis buffer) and the no-template 
negative control (no DNA template added). DNA used for pre-pyro PCR were extracted from small 
intestines of tRNAAla mutant mice. HE, homogenate of epithelium; HSM, homogenate of smooth 
muscle; WT, wildtype; RNC, reagent negative control; Neg, no-template negative control. 
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2.11.3 Pyrosequencing 
PCR products (10 µl) were added into 70 µl mastermix consisting of 29 µl distilled water, 40 
µl PyroMark binding buffer (Qiagen) and 1 µl Streptavidin Sepharose High Performance 
beads (GE Healthcare) to form a total 80 µl solution. The mix was homogenised on a shaker 
for 10 minutes to facilitate PCR products binding to the beads. Samples were then transferred 
to a PyroMark Q24 Vacuum Workstation (Qiagen) equipped with a hedgehog head connected 
to a 2511 Dry Vacuum Pump/Compressor (Welch). Samples was aspirated using the 
hedgehog head and beads bound with PCR products were filtered and collected at the tip of its 
probes, which were then flushed successively through 70% ethanol for 5 seconds, 
denaturation solution (0.2M NaOH) for 5 seconds, 1x PyroMark wash buffer (Qiagen) for 10 
seconds. Beads were then released from the probes into a 25 µl annealing solution consisting 
of 0.75 µl sequencing primers (Table 2.13) and 24.25 µl PyroMark annealing buffer (Qiagen), 
and were placed on a QBD2 Dry Block Heating System (Grant) to denature at 80°C for 2 
minutes. Samples were then placed in the PyroMark Q24 Pyrosequencer (Qiagen) and 
annealed at room temperature for at least 5 minutes to allow the primers to bind to PCR 
amplicons. PyroMark Gold Q24 Reagents (Qiagen), including dNTPs, enzyme compounds 
(DNA polymerase, ATP sulfurylase, luciferase and apyrase) and substrate compounds 
(adenosine 5’ phosphosulfate and luciferin), were loaded in a PyroMark Q24 Cartridge 
(Qiagen) in volumes calculated by PyroMark Q24 Software 1.0.10 (Qiagen) according to the 
sample size. Pyrosequencing was performed on PyroMark Q24 Pyrosequencer (Qiagen) 
equipped with the PyroMark Q24 Cartridge (Qiagen) following the corresponding assays 
selected for each mutation. Raw data were exported and analysed using the allele 
quantification algorithm in PyroMark Q24 Software 1.0.10 (Qiagen). WT controls were 
included to ensure the stringency of the assay with errors less than 3%. Final mutation levels 
of each sample were the mean value of triplicates.    
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2.12 Statistical analyses 
2.12.1 R statistical analysis for immunofluorescence 
Raw data exported from imageJ (2.9.2) was processed through an R-script written by Dr John 
Grady (Rocha et al., 2015). Optical density (OD) for each channel in sections treated with 
primary antibodies was subtracted by OD in the NPC for each case to remove the background 
caused by non-specific binding of secondary antibodies, which was then normalised by 
logarithm transformation. Normal populations were established by randomly sampling equal 
numbers of measured items from each control. The number was defined according to the 
control with the smallest size. Mean and standard deviation (SD) of normal populations were 
obtained as estimates for calculating z-scores of patient and control cohorts with or without 
normalisation of mitochondrial mass markers. Boundaries for categorising levels of OXPHOS 
subunits were set according to statistical confidence levels (Table 2.14) and specified in 
individual result chapters. Levels of mitochondrial mass (Tom20) or nuclear encoded 
mitochondrial markers (SDHA and COX4) were classified as “very low” (z-score < -3), 
“low” (-3 ≤ z-score < -2), “normal” (-2 ≤ z-score ≤ 2), “high” (2 < z-score ≤ 3) and “very 
high” (z-score > 3). 
 
Z-score (SD) Confidence level 
< -2 or > 2 95% 
< -2.6 or > 2.6 99% 
< -3 or > 3 ≈99% 
< -3.3 or > 3.3 99.9% 
Table 2.14 Confidence levels corresponding to significant z-scores defined as the number of SD that a 
sample is away from the mean of a population. 
 
2.12.2 General data analysis 
Immunofluorescence data was formatted using Minitab v17.1.0 before being exported for R 
analysis. Prism v6.01 was used for the remaining statistical analyses and generating figures. 
Normality tests were performed on data sets and sample sizes were taken into account for 
selecting corresponding parametric or non-parametric tests. 
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Chapter 3 Inherited mtDNA mutations in the gastrointestinal tract from 
patients with mitochondrial disease 
3.1 Introduction 
3.1.1 Somatic mtDNA mutations in normal individuals during ageing 
In normal ageing humans, OXPHOS deficiency has been found in both mitotic (Taylor et al., 
2003; McDonald et al., 2008; Gutierrez‐Gonzalez et al., 2009; Greaves et al., 2010) and 
post-mitotic tissues (Müller-Höcker, 1989; Müller-Höcker, 1990; Cottrell et al., 2001). 
Mitochondrial DNA mutations, some of which are highly pathogenic, have been shown to 
accumulate clonally to high levels of heteroplasmy or to homoplasmy in individual cells, 
resulting in a respiratory chain defect (Taylor et al., 2003; Kraytsberg et al., 2006; Greaves et 
al., 2010). These somatic mtDNA mutations are associated with ageing (Khrapko and Vijg, 
2009; Baines et al., 2014b), age-related disease (Cha et al., 2015) and cancer (Popadin et al.; 
Chatterjee et al., 2006), though whether these mutations play a causal role in ageing and the 
development of these diseases remains unknown. Adult stem cells responsible for regular 
tissue regeneration contribute to the accumulation of somatic mtDNA mutations in mitotic 
tissue. Studies have shown that the accumulation of somatic mtDNA mutations occurs in stem 
cells, particularly haematopoietic (Shin et al., 2004a; Shin et al., 2004b) and intestinal stem 
cells (Taylor et al., 2003). In addition, stem cell niches are involved in the spread of these 
mutations in gastric and colonic epithelium (Greaves et al., 2006; McDonald et al., 2008). 
Limited numbers of studies on human samples show the functional changes caused by the 
accumulated somatic mtDNA mutations in stem cells and their progenies, and their findings 
are controversial (McDonald et al., 2008; Gutierrez‐Gonzalez et al., 2009; Nooteboom et 
al., 2010). Mouse models with mtDNA mutagenesis show a typical ageing phenotype, with 
the homeostasis of either stem cells per se or downstream precursors severely affected 
(Trifunovic et al., 2004; Kujoth et al., 2005; Wang et al., 2013b; Pinto et al., 2016). These 
studies suggest a strong association between age-dependent mtDNA mutagenesis and stem 
cell ageing, yet the underlying mechanism is unclear (Su et al., 2018).  
The mechanism by which somatic mtDNA mutations occur and clonally expand within 
individual cells with age is largely unknown. Somatic mtDNA mutations may be generated in 
a tissue-specific way: in neurons with a high demand of energy, mutations are thought to 
occur through repairing the mtDNA molecules that are damaged by ROS (Krishnan et al., 
2008), whereas in mitotic tissue, mutations originate from replication errors (Reeve et al., 
2009). Clonal expansion of the somatic mtDNA mutations can be entirely explained by a 
model of random genetic drift in both dividing and non-dividing cells (Coller et al., 2001; 
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Elson et al., 2001; Stamp et al., 2018), but this does not rule out the traditional free radical 
hypothesis where respiratory chain defects produce excessive ROS to damage mtDNA, which 
in turn causes more oxidative stress to form a vicious cycle (Harman, 1972; Vincent et al., 
2018). Somatic mtDNA mutations in a variety of mitotic tissue, such as the epithelium of 
colon, small intestine, stomach and prostate, and bladder urothelium are not subjected to any 
purifying selection as in germline transmission, since comparing different spectra of mtDNA 
mutations show that the somatic mtDNA mutations are remarkably more pathogenic 
compared to variants transmitted through germline in general populations (Greaves et al., 
2012a; Baines et al., 2014a). To date, little is known about the dynamics of the accumulation 
of somatic mtDNA mutations during ageing and the mechanism underlying the absence of 
negative selection against them.  
 
3.1.2 Inherited mtDNA mutations in patients with mitochondrial disease 
In addition to the somatic mutations discussed above, mtDNA mutations can also be inherited 
through the germline or occur sporadically during oogenesis or embryogenesis and cause 
mitochondrial DNA disease (DiMauro and Schon, 2003; Taylor and Turnbull, 2005). Large-
scale deletions and mtDNA point mutations are the two most frequent causes of primary 
mtDNA disorders (Alston et al., 2017). Despite only about 10% of the mtDNA genome being 
tRNA genes, more than half of the inherited pathogenic point mutations are in tRNA 
encoding sequences, the two most prevalent of which are m.3243A>G in the tRNALeu gene 
and m.8344A>G in the tRNALys gene (Schon et al., 2012; Gorman et al., 2015).  
In contrast to the somatic mtDNA mutations that accumulate with age, patients with mtDNA 
disease have been shown to lose specific mtDNA mutations in specific mitotic tissues, with 
some evidence suggesting the involvement of stem cells (Su et al., 2018). For example, 
patients with Pearson syndrome caused by single large-scale deletions suffer from fatal 
pancytopenia as the mutation severely affects the haematopoietic progenitor cells in the bone 
marrow (Pearson et al., 1979; Rotig et al., 1989). However, patients can gradually recover 
from the abnormal haematopoiesis and show a normal blood phenotype and a marked lower 
mutation load in blood than in muscle, but they may then develop Kearns-Sayer syndrome 
that predominantly affects post-mitotic tissue (Larsson et al., 1990; McShane et al., 1991; 
Nørby et al., 1994). For mtDNA point mutations, the loss of the mutation was first suggested 
by a contrast in the distribution of the mutation across different tissues in affected foetuses 
and adult patients. During foetal development (12 – 25 gestation weeks), the inherited 
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mtDNA point mutations are uniform across tissues, regardless of whether they are mitotic or 
post-mitotic (Matthews et al., 1994; Cardaioli et al., 2000; Monnot et al., 2011). In contrast, 
non-random distribution of the mutation was reported in adult patients, with the mutation load 
in post-mitotic skeletal muscle higher than that in several mitotic tissues, such as hair 
follicles, buccal mucosa and blood (Chinnery et al., 1999). Furthermore, both cross-sectional 
and longitudinal studies show a decrease in the mutation level in blood with age in 
symptomatic patients and asymptomatic carriers with the germline m.3243A>G mutation (t 
Hart et al., 1996; Rahman et al., 2001; Frederiksen et al., 2006; de Laat et al., 2012; Grady et 
al., 2018). This was also shown to be the case in a few samples containing mitotic cells, 
including urine, buccal mucosa and cervical smears (Olsson et al., 2001; Frederiksen et al., 
2006; de Laat et al., 2012; Grady et al., 2018). In contrast, the mutation level of m.3243A>G 
in post-mitotic muscle was shown to be stable with age with no correlation between them 
(Frederiksen et al., 2006; Grady et al., 2018). As mitotic tissue is regularly renewed by 
somatic stem cells, this contrast in the behaviour of the inherited mtDNA mutation between 
mitotic and post-mitotic tissue implies that stem cells might be involved in the loss of the 
mutation.  
The loss of inherited mutations in blood with age suggests a selective pressure against them, 
which is in contrast to the accumulation of somatic mtDNA mutations during ageing in stem 
cell populations with no evidence of any selective pressure on them (Greaves et al., 2012a). 
This highlights the difference in the organismal response to mtDNA mutations under ageing 
and pathogenic mitochondrial conditions, which is likely associated with stem cell biology. 
Investigating the age-related behaviour of inherited mtDNA mutation in mitotic tissue and 
more specifically, somatic stem cells, is crucial, as it benefits the understanding of both 
ageing and mitochondrial disease. Intestinal epithelium with a rapid turnover rate has proved 
to be a good model for stem cell research (Barker, 2014). With all cells in a crypt originating 
from the stem cells at its base, it can go through a process termed monoclonal conversion 
where the stem cell niche of an individual crypt is dominated by a single stem cell (Novelli et 
al., 1996; Kim and Shibata, 2002; Snippert et al., 2010; Kozar et al., 2013). These traits make 
each crypt monoclonal, which is a good representative of the characteristics of the mother 
stem cell.  
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3.2 Aims 
Although studies have suggested selection against inherited mtDNA mutations in blood as 
well as a few types of epithelial cells, such as those in the buccal mucosa, urine and cervix, it 
is unknown whether this is generic to other mitotic tissue, where the selection occurs in the 
tissue and what effect it is on tissue phenotype. Using gastrointestinal (GI) tissue from 
patients with inherited mtDNA mutations, I aimed to: 
1. Determine the heteroplasmy of inherited mtDNA mutations in the epithelium of 
different GI segments and compare this with post-mitotic tissue in the same patient. 
2. Determine whether the selection against inherited mtDNA mutations occurs in 
intestinal stem cell populations by analysing isolated intestinal crypts. 
3. Determine the effect of a decrease in heteroplasmy on OXPHOS function in the 
mitotic epithelium.  
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3.3 Methods 
3.3.1 Tissue samples 
Post-mortem GI tissue was obtained from two patients with m.3243A>G (patient 2 and 
patient 3) and one patient with m.8344A>G (patient 4). An ileum sample was collected from 
patient 1 by ileectomy. Control tissue with no evidence of pathology was collected from age-
matched normal individuals for biochemical assays. Details of the patients and controls with 
the samples they provided are tabulated in Table 2.1 and Table 2.2 respectively. The case 
history is described in the Appendix 8.1. The study was approved by Newcastle and North 
Tyneside Local Research Ethics Committees. 
 
3.3.2 Sequential COX/SDH histochemistry 
Frozen tissue from patients subjects was sectioned (detailed in 2.6) for histochemical assays. 
Tissue sections from controls 12 – 15 (Table 2.2) were provided by Dr Stuart A.C. 
McDonald. Sections were subjected to haematoxylin and eosin staining (2.7.1) to assess the 
morphology. Sequential COX/SDH histochemistry for determining the COX activity was then 
performed on patients’ tissue sections and two to four control samples as a reference for tissue 
with normal and defective COX activity (described in 2.7.2). The percentage of COX 
deficiency in the tissue was determined as the number of the COX-deficient intestinal crypts 
or gastric pits by the total number of the crypts/pits. The counting was performed on two 
sections to prevent loss of information from the imperfect morphology of the tissue due to 
post-mortem degradation or sectioning. Only crypts/gastric pits with no COX activity in blue 
were counted to quantify the level of COX defects, as this is the method to quantify COX 
deficiency caused by the accumulation of somatic mtDNA mutation in normal ageing 
individuals in the published data (Taylor et al., 2003). In addition, it is imprecise to define the 
tissue with partial COX deficiency labelled as bluish brown, as differentiating the hue of blue 
in brown pigment by eye is very subjective. Therefore, though this histochemical assay is 
advantageous for determining the functional defects in enzymes, the immunofluorescence 
assay described below is required, which allows for an exact quantification of the protein 
level of the respiratory chain complexes. 
  
77 
 
3.3.3 Immunofluorescence 
Antibodies for the immunofluorescence assay were always optimised prior to final 
experiments. Details of primary and secondary/tertiary antibodies with their optimised 
concentrations are summarised in Table 2.7 and Table 2.8 respectively. Antibody cocktails 
used in the formal experiments were listed in Table 3.1. The optical density of each intestinal 
crypt/gastric unit was measured using ImageJ. For oesophageal epithelium and muscle, the 
optical density of the section was measured by dividing it into small areas of similar sizes (≈ 
50000 µm2) as a unit in multiple fields, as it was not feasible to include the whole section in 
one field of view. Fluorescence data of all subjects were background corrected according to 
the no primary controls. The number of age-matched controls for each patient and the number 
of the examined intestinal crypts/gastric units in each subject is listed in Table 3.2. The 
detailed procedure of the immunofluorescence assay and image analysis are described in 
section 2.8.1 and 2.9.2. Z-scores of the optical density in each examined unit were calculated 
using data from the control population established by random sampling of the same number of 
units from each control subject (detailed in 2.12.1) and categorised as follows: for NDUFB8 
labelling the respiratory chain complex I and COX1 marking the complex IV, the subunit 
level was classified by z-scores as “negative” (< -3SD), “Intermediate” (-3SD ~ -2SD) and 
“positive” (> -2SD); for the non-mtDNA encoded proteins COX4 and SDHA, the level was 
categorised as “low” (< -2SD), “normal” (-2SD ~ 2SD) and “high” (> 2SD).  
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 Primary antibody Secondary antibody Tertiary antibody 
Combination 
one 
Anti-NDUFB8 
(ab110242) 
Biotin-XX (A10519) 
Streptavidin, Alexa 
Fluor 488 conjugate 
(S32354) 
Anti-COX4+COX4L2 
(ab110261) 
Alexa Fluor 546 Mouse 
IgG2a (A21133) 
N/A 
Anti- E-cadherin 
(ab40772) 
Alexa Fluor 647 Rabbit 
IgG (A21244) 
N/A 
Combination 
two 
Anti-MTCO1 
(ab14705) 
Alexa Fluor 488 
Mouse IgG2a (A21131) 
N/A 
Anti-SDHA (ab14715) 
Alexa Fluor 647 
Mouse IgG1 (A21240) 
N/A 
Anti- E-cadherin 
(ab40772) 
Alexa Fluor 546 Rabbit 
IgG (A11010) 
N/A 
Table 3.1 Antibody combinations used for formal experiments. Details of the primary and 
secondary/tertiary antibodies with their optimised concentrations on human tissue are summarised in 
Table 2.7 and Table 2.8 respectively. 
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Tissue 
Patient ID & 
the number of 
controls 
The number of units for 
the examination of 
NDUFB8 and COX4 
The number of units for 
the examination of 
MTCO1 and SDHA 
Patient Controls Patient Controls 
Ileum E 
Patient 1 with  
4 controls 
70 128 20 83 
Oesophagus E 
Patient 2 with  
3 controls 
n/a n/a n/a n/a 
Stomach E 
Patient 2 with  
2 controls 
6 36 7 44 
Small intestine E 
Patient 2 with  
3 controls 
28 48 30 47 
Colon E 
Patient 3 with  
3 controls 
20 91 20 79 
Colon M 
Patient 3 with  
3 controls 
n/a n/a n/a n/a 
Table 3.2 The summary of the number of age-matched controls for each patient and the number of 
crypts/gastric units included for fluorescence quantification. n/a = the epithelium of the oesophagus and 
the colonic smooth muscle on a whole section were included for the measurement. 
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3.3.4 Pyrosequencing  
Gastrointestinal epithelium and muscle were randomly selected and collected by laser 
microdissection (Figure 3.1) (detailed in 2.10.1) and subjected to cell lysis (2.10.2) to extract 
DNA. Five crypts/gastric glands were collected and pooled. The oesophageal epithelium in a 
whole field of view and muscles were divided into areas of similar sizes and collected as a 
unit (≈ 50000 µm2). DNA extracted from the tissue was then subjected to PCR amplification 
(described in 2.11.1). Enough amount of PCR product was visualised by DNA electrophoresis 
(detailed in 2.11.2) and used for pyrosequencing described in 2.11.3 to measure the mutation 
load of the tissue.  
 
 
Figure 3.1 Laser microdissection of the intestinal crypts and smooth muscle. The left panel shows the 
laser-microdissected intestinal crypts before and after collection. The middle and the right images show 
the smooth muscle before and after microdissection. Tissue was randomly selected regardless of the 
COX activity. Scale bar: 50µm. 
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3.4 Results 
3.4.1 Heteroplasmy levels of mitotic and post-mitotic tissue in the alimentary canal 
The mutation level in the homogenate of different segments of the alimentary canals from two 
patients with the m.3243A>G point mutation was reported to be lower than that in smooth 
muscle (Betts et al., 2008). As the homogenate contains all types of tissues in the segment, 
including epithelium, connective tissue as well as smooth muscle, this finding suggests that 
the epithelium and/or connective tissue might have a lower mutation load that depresses the 
average. To determine whether this is due to the decrease in the mutation load in the GI 
epithelium, I collected the mucosal epithelium and smooth muscle from different GI segments 
of three patients with the inherited m.3243A>G mutation (patient 1 - 3) and one patient with 
the m.8344A>G mutation (patient 4) by laser microdissection and lysed them to obtain their 
DNA. I further performed pyrosequencing using the DNA to measure heteroplasmy in the 
tissue. The pyrosequencing technique provides a rapid and accurate measurement for the 
heteroplasmy of mtDNA point mutations based on the “sequencing by synthesis” principle, 
where it quantifies the light signal generated when a nucleotide is incorporated to the DNA 
template strand (Ronaghi et al., 1998). The Newcastle Wellcome Centre pyrosequencing 
assay for the m.3243A>G and m.8344A>G mutations have been validated to be highly 
sensitive and specific and proved capable of precisely measuring the heteroplasmy of the 
mutations in small areas of tissue and even in single cells (Chrysostomou et al., 2015; de Laat 
et al., 2016). The sensitivity of the assay suggests that any measurements showing 
heteroplasmy levels lower than 2% should be considered as “no detectable mutation”, which 
is confirmed by comparing to the wild-type control. The dissected tissue was randomly 
selected regardless of its COX activity to ensure the measured mutation level objectively 
reflects the true heteroplasmy of the tissue.  
The mutation level was significantly lower in the mitotic epithelium compared with that in the 
post-mitotic muscle fibres in the oesophagus (p < 0.0001, Mann-Whitney U test); the stomach 
(p < 0.0001, unpaired t-test); the small intestines (SI) (p < 0.05 for patient 1 and p < 0.0001 
for patient 2, unpaired t-test and Mann-Whitney U test respectively); and the colon (p < 0.005, 
unpaired t-test) (Figure 3.2). For the patient with the m.8344A>G mutation, the heteroplasmy 
level was also markedly lower in the colonic crypts compared with the smooth muscle (P < 
0.0001, unpaired t-test) (Figure 3.2).  
The data show a substantial variation in the heteroplasmy level between different crypts/areas 
of the oesophageal epithelium in contrast to the tight distribution within the muscle of the 
patients (Figure 3.2). The variance in the gastric glands was smaller compared with the other 
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epithelial tissues (Figure 3.2C). In addition, some intestinal crypts and oesophageal 
epithelium carried no detectable mutation (< 2% is considered as no mutation) (Figure 3.2A 
and 2B). Furthermore, each epithelial tissue shows an upper limit for the heteroplasmy level. 
Neither crypts harbouring an m.3243A>G% higher than 86% nor gastric glands with 
m.3243A>G% higher than 89% were observed. The oesophageal epithelium shows a lower 
limit (51%) for the m.3243A>G mutation. The upper limits for m.3243A>G and m.8344A>G 
were similar in the colonic epithelium, which was ~80%. The upper limit of the mutation in 
the epithelium was always lower than the average heteroplasmy level in the muscle of the 
same GI segment in the patients with high levels of the mutation in muscle (patient 2, 3 and 
4). In patient 1 who had an intermediate mutation load (< 80%) in the muscle, the upper limit 
of m.3243A>G in the epithelium (77%) was higher than the mean mutation load in the muscle 
and was similar to the highest mutation level in the muscle (78%). 
 
Figure 3.2 Heteroplasmy in the epithelium and the smooth muscle of different parts of the digestive 
tracts from patients with inherited m.3243A>G and m.8344A>G point mutations. The DNA for each 
replicate was extracted from 5 intestinal crypts/gastric glands/areas of oesophageal epithelium or 
muscle. P1 SI (ne=10, nm=10), P2 oesophagus (ne=10, nm=10), P2 stomach (ne=10, nm=10), P2 SI 
(ne=10, nm=9), P3 colon (ne=10, nm=10), P4 colon (ne=20, nm=10). *, P<0.05, **, P<0.005 and ****, 
P<0.0001.  
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3.4.2 COX activity in the gastrointestinal tract 
The m.3243A>G mutation is pathogenic, and once it reaches a heteroplasmy threshold, it 
causes OXPHOS deficiency in both mitotic and post-mitotic tissue (Hämäläinen et al., 2013). 
To investigate whether the reduction of the mutation load in the GI epithelial tissue makes any 
difference to the OXPHOS level, I performed sequential COX/SDH histochemistry and 
quantitative immunofluorescence on the tissue to determine the COX activity and protein 
levels of the respiratory chain subunits respectively. Haematoxylin and eosin staining was 
first carried out on sections of the patients’ GI tract to assess the morphology of the tissue. 
Sequential COX/SDH histochemistry was then performed on patients’ GI tissue, which allows 
visualisation of the in situ enzyme activity of cytochrome c oxidase (COX) and succinate 
dehydrogenase (SDH) in the tissue. In this assay, the electron donor, 3,3’-diaminobenzidine 
(DAB) will be oxidised by COX with normal enzyme activity to form brown polymer 
compounds saturating the cells and preventing the subsequent reactions of the SDH assay. 
When a cell contains dysfunctional COX that fails to produce polymer precipitates, the 
electron acceptor, nitroblue tetrazolium (NBT) will be reduced to blue formazan products, 
allowing visualisation of the SDH activity within the cell.  
The ileum sample from patient 1 was very well preserved with intact morphology (Figure 
3.3). Post-mortem tissue from patients 2 – 4 had various degree of degradation. The 
epithelium of the colon samples from patients 3 and 4 was poorly preserved and failed to be 
labelled by the SDH (Figure 3.4) and COX assay (Appendix 2, Figure 8.2) respectively. The 
COX and SDH assays were optimised separately on the epithelium and muscle of the GI 
tissue from patients 1 and 2 with comparatively good morphology (Figure 3.3 and Figure 3.5 
respectively).  
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Figure 3.3 Haematoxylin and eosin staining, COX and SDH assay on the ileum from patient 1 with 
inherited m.3243A>G. Haematoxylin and eosin staining revealed the intact morphology of the tissue. 
The middle and right panel shows the optimised COX and SDH assay respectively on the epithelium 
and smooth muscle. Scale bar: 200µm. 
 
 
Figure 3.4 Haematoxylin and eosin staining, COX and SDH assay on the colon of patient 3 with the 
m.3243A>G mutation. H&E staining revealed fragmented colonic crypts with severe post-mortem 
degradation (indicated by the black arrows). SDH histochemistry failed the optimisation due to the poor 
morphology. Scale bar: 200µm. 
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Figure 3.5 Haematoxylin and eosin staining, optimised COX assay and SDH assay on the epithelium 
and muscle of the oesophagus, stomach and jejunum (small intestine) from patient 2 with m.3243A>G. 
The morphology of the oesophageal epithelium was comparatively better than the gastric and intestinal 
epithelium. Many gastric pits, as well as the villi of the small intestine, were degraded. Scale bar: 200µm. 
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Sequential COX/SDH histochemistry revealed numerous blue COX-defective muscle fibres 
along the GI tract, whereas almost no COX deficiency was observed in the epithelium (Figure 
3.6). To confirm this observation, all intestinal epithelial crypts and gastric pits in a whole 
section were examined, and COX deficiency was quantified as the ratio of the COX-defective 
crypts/gastric pits and all crypts/gastric pits on the section. It shows zero to very low levels of 
COX deficiency in each epithelial tissue (Table 3.3).  
These results indicate that the COX activity was mainly preserved in the mitotic GI epithelial 
tissue from the patients, despite the pathogenicity of the m.3243A>G mutation shown by the 
severe COX deficiency in the post-mitotic muscle. 
 
Patient (m.3243A>G) Tissue (epithelium) COX deficiency 
P1 Ileum 1.25% 
P2 
Stomach 2.67% 
Jejunum 0.00% 
P3 Colon 2.59% 
Table 3.3 COX deficiency in the epithelial tissue of patients with the inherited m.3243A>G mutation. 
COX deficiency was quantified as the number of the COX-deficient intestinal crypts/gastric pits over 
the total number of the crypts/pits on a section. The counting was performed on two sections and 
averaged as the final result. 
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Figure 3.6 Sequential COX/SDH histochemistry on the epithelium and muscle of the GI segments from 
all three patients with inherited m.3243A>G mutation. Tissue with COX activity was labelled brown, 
and that with COX deficiency was in blue. A control section was used as a reference for the pigment. 
The black and red arrow refers to the COX-normal and COX-deficient crypt respectively. Scale bar: 
50µm. 
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3.4.3 Optimisation of immunofluorescence and verification of mitochondrial markers 
The histochemical results have demonstrated the preservation of the COX function in 
accordance with the decreased mutation load in the epithelial cells. To further investigate 
whether the OXPHOS level was influenced by the loss of the inherited mtDNA mutations, 
immunofluorescence was carried out on the GI tissue from three patients with the 
m.3243A>G mutation. The poor morphology of the tissue due to the post-mortem degradation 
was a significant challenge and required considerable time and effort to optimise the 
antibodies. Antibodies were incubated on tissue in a gradient of dilutions, and the antibody 
concentration that gave the optimal optic effect under the identical imaging exposure time was 
selected for the formal experiment (an example is shown in Figure 3.7A). Epithelial tissue and 
muscle were identified by labelling with antibodies for E-cadherin and Actin respectively 
(Figure 3.7, A and B). The E-cadherin marker nicely labelled the crypts in the ileal resection 
of patient 1 but failed to label some of the crypts in the post-mortem intestines of patient 2 
(Figure 3.7C) and patient 3. Despite this, it helped me differentiate the epithelial tissue in the 
fluorescence imaging. Another intestinal epithelium marker, beta-catenin, also failed to mark 
the post-mortem epithelium.  
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Figure 3.7 (A) E-cadherin optimisation as an example to show the optimisation strategy for antibodies 
used in immunofluorescence. Epithelial tissue was marked by E-cadherin in a dilution gradient, in which 
the one (1:200) that had the best labelling effect was chosen for the final experiment. (B) Identification 
of muscle using actin with no labelling of the epithelial marker (E-cadherin). (C) E-cadherin failed to 
label the epithelium in the post-mortem tissue. The images in the top and middle row show the clear 
labelling of SDHA, E-cadherin and COX1 on the control and the ileum section of patient 1 from 
resection respectively. The bottom row shows that E-cadherin failed to label a few intestinal crypts taken 
from patient 2 at post-mortem. Scale bar: 50µm. 
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Labelling tissue with a nuclear-encoded mitochondrial marker that is not affected by mtDNA 
mutations is necessary as it enables the OXPHOS deficient tissue to be visualised and selected 
for quantification in fluorescence imaging. In addition, as mitochondrial proliferation was 
reported in patients with mtDNA mutations (Egger et al., 1981; Moraes et al., 1992), it is 
important to investigate whether the loss of the inherited mtDNA mutation has any impact on 
nuclear-encoded mitochondrial components. Porin is a nuclear-encoded protein that 
constitutes the ion channel at the outer membrane of mitochondria, and was firstly used as a 
mitochondrial marker. However, the antibody of porin failed to label the epithelium of the 
post-mortem GI tissue (Figure 3.8). SDHA and COX4, the nuclear-encoded subunits that 
proved to be preserved in tissue with mtDNA defects (Betts et al., 2008; Chrysostomou et al., 
2015), were used as alternatives. Although they are encoded by nDNA, they are subunits of 
the respiratory chain complexes and might be disabled by the inherited mtDNA mutation, 
despite a low possibility. To verify SDHA and COX4 as mitochondrial markers, I performed 
an immunofluoresence assay to examine their protein level together with porin in the ileum 
section of patient 1 that was obtained by ileectomy. Z-scores of the optical density in 
individual intestinal crypts were calculated based on the control population for each marker to 
normalise the inherent difference in the level of each protein. Neither of them showed any 
deficiency in the patient when compared with four age-matched controls, and their protein 
level was as steady as that of the porin (Figure 3.9). This proves that COX4 and SDHA are 
appropriate mitochondrial markers for immunofluorescence assay. 
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Figure 3.8 Porin failed to label the mitochondria on the post-mortem section of patient 2. The white 
arrows indicate some intestinal crypts showing no fluorescent signal of the porin marker that labels the 
mitochondria but strong signals of the respiratory chain complex IV (marked by COX1 antibody). The 
top panel shows the normal labelling of the porin and COX1 antibodies in the colonic crypts of a control. 
Scale bar: 50µm. 
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Figure 3.9 Verification of SDHA and COX4 as mitochondrial markers. (A) Immunofluorescence images 
of SDHA, porin and COX4 in a combination on the ileum section of patient 1. SDHA and COX4 show 
clearer borders of the intestinal crypts than porin. Scale bar: 50µm. (B) Immunofluorescence 
quantification of porin, SDHA and COX4. Fluorescence of individual crypts was quantified using 
ImageJ. Z-scores were calculated using the raw data and categorised according to the control population. 
Crypts: n (control) = 40 from four age-matched individuals, n (patient) = 30. Z-scores were classified 
as “low” (< -3SD), “normal” (-3SD ~ 3SD) and “high” (> 3SD).   
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3.4.4 Level of the respiratory chain complexes I and IV in gastrointestinal tract 
Respiratory chain complexes I (CI) and IV (CIV) contain subunits that are encoded by 
mtDNA and are predisposed to mtDNA mutations (James et al., 1996; Rocha et al., 2015). To 
determine whether the loss of the inherited mtDNA mutation in the GI epithelium has any 
influence on the protein levels of these complexes, I performed quantitative 
immunofluorescence to measure the level of complexes I and IV using the antibodies against 
NDUFB8, a subunit of complex I that is critical to the complex assembly and often lost when 
there is a respiratory chain defect, and COX1, a mitochondrial encoded subunit of complex 
IV, respectively (Perales-Clemente et al., 2010; Rocha et al., 2015; Guerrero-Castillo et al., 
2017). Nuclear-encoded mitochondrial markers, COX4 and SDHA, were verified (3.4.3) and 
co-labelled with NDUFB8 and COX1 respectively to visualise tissue with a loss of complex I 
or IV subunits (Figure 3.10 and Figure 3.12 respectively). Raw data of the optical density was 
transformed to z-scores based on the control population and categorised according to different 
confidence levels.  
No CI-deficient epithelium was found in any GI segments of any of the three patients with the 
inherited m.3243A>G mutation, including the oesophagus, stomach, small intestine and colon 
(Figure 3.10 and Figure 3.11). In contrast, half of the muscle fibres in the colon of patient 3 
were complex I-deficient (Figure 3.10 and Figure 3.11). Except for the oesophageal 
epithelium of patient 2, which had a higher mean CI level than controls, the average CI level 
in patients’ GI epithelium was similar to controls (Figure 3.11B).  
In the epithelium of the oesophagus, stomach and small intestine of the patients, complex IV 
level was normal compared with controls (Figure 3.12 and Figure 3.13). A low level of COX1 
deficiency (5%) was detected in the colonic epithelium of patient 3 (Figure 3.13). 
Surprisingly, no COX1 deficiency in the colonic muscle was observed (Figure 3.12 and 
Figure 3.13). The mean COX1 level in the epithelium of the oesophagus was higher than that 
in the control, though it was still within the normal range (z-score ≈ 2) (Figure 3.13B).   
These results demonstrate that the protein levels of complex I and IV were preserved in the 
epithelium of the GI tracts from the patients, which is consistent with the normal COX 
activity and the low m.3243A>G mutation level in the epithelium discussed in 3.4.2 and 3.4.1. 
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Figure 3.10 Immunofluorescence images of complex I (marked by NDUFB8 green) co-labelled with the 
mitochondrial marker COX4 (red) on the oesophageal and small intestinal epithelium, and the colonic 
smooth muscle from patients with m.3243A>G mutation compared with age-matched controls. The 
merged image is shown in the right panel. Scale bar: 50µm. 
95 
 
 
Figure 3.11 Quantification of complex I in the epithelium along the GI tract and the colonic smooth 
muscle of patients with m.3243A>G and controls. (A) Categorised z-scores of complex I (NDUFB8). 
The optical density of the tissue was measured using ImageJ, which was transformed to z-scores 
according to the control population. Categorisation of the z-scores was based on the 95% and 99% 
confidence levels: “negative” (< -3SD), “Intermediate” (-3SD ~ -2SD) and “positive” (> -2SD). (B) An 
overview dot plot showing the mean and distribution of the CI data. Individual intestinal crypts/gastric 
pits were selected for optical quantification. The oesophageal epithelium and colonic smooth muscle on 
the whole section were selected and quantified as areas of similar sizes. The number of selections for 
measurement: n (P1 SI) = 70; n (control) =128; n (P2 SI)= 28, n (control) = 48; n (P2 stomach) = 6, n 
(control) = 36; n (P3 colon)=20, n (control) = 91. Patients were compared with two controls for the 
stomach, three controls for the colon, the oesophagus and the small intestine of the patient 2, and four 
controls for the SI of the patient 1. SI, small intestine; E, epithelium; M, muscle.  
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Figure 3.12 Example pictures showing combined COX1 (green) and SDHA (red) labelling on the 
epithelium of the oesophagus and the stomach, and the muscle of the colon from patients with 
inherited m.3243A>G in comparison to controls. The right panel shows the merged image. Scale bar: 
50µm. 
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Figure 3.13 Quantification of COX1 (labelling complex IV) in the GI epithelium and the colon muscle 
of patients with m.3243A>G in comparison to controls. (A) Classification of the z-scores was set 
corresponding to the 95% and 99% confidence levels: “negative” (< -3SD), “Intermediate” (-3SD ~ -
2SD) and “positive” (> -2SD). (B) A summary of the z-scores of the COX1 level showing the mean and 
the distribution of the data. The COX1 level was measured in individual crypts/gastric units and areas 
of the oesophageal epithelium and smooth muscle in the whole section. The number of analysed 
subjects: n (P1 SI) = 20; n (control) = 83; n (P2 SI)= 30, n (control) = 47; n (P2 stomach) = 7, n (control) 
= 44; n (P3 colon)=20, n (control) = 79. Two controls were included for the stomach, three controls for 
the colon, the oesophagus and the small intestine of patient 2, and four controls for the SI of patient 1. 
SI, small intestine; E, epithelium; M, muscle. 
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3.4.5 Level of nuclear-encoded mitochondrial markers 
The nuclear-encoded respiratory chain subunit COX4 showed increased levels in the 
epithelium of the small intestine (8.57% of the tissue with a high level of COX4 in patient 1 
and 14.29% in patient 2) and the oesophagus (40.91%) but not the muscle from the patients 
with the inherited m.3243A>G mutation (Figure 3.14A). The average level of COX4 in 
patients’ GI epithelium and muscle were within the normal range (z-scores between -2 to 2), 
except a marked upregulation in the oesophageal epithelium (Figure 3.14B). SDHA, a subunit 
of complex II that is entirely encoded by nDNA, was also elevated in the epithelium of 
patients’ GI segments, including the oesophagus (47.62%), stomach (14.29%), and small 
intestine (10%) (Figure 3.15A). It also augmented in the colonic muscle of the patient 3 
(27.27%) (Figure 3.15A). The mean level of SDHA was notably higher in the oesophageal 
epithelium and the smooth muscle of the patients compared with controls, but it was still 
below the threshold of abnormality (<2) (Figure 3.15B). Of note, both of the mitochondrial 
markers was increased in the epithelium of the oesophagus and the small intestine of the 
patients compared to controls(Figure 3.14 and Figure 3.15). 
Surprisingly, 5% and 15% of the crypts in the small intestine of patient 1 and the colon of 
patient 3 respectively showed low SDHA expression (95% confidence level) (Figure 3.15A), 
though none of them dropped below -3 (99% confidence level) (Figure 3.15B). A slight 
increase in the mitochondrial markers was noticed in the epithelium of different GI segments 
from controls, which might be a compensatory response to age-related OXPHOS deficiency 
(Figure 3.14 and Figure 3.15).     
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Figure 3.14 Z-scores of COX4 levels in the epithelium and muscle of the GI tract from the patients with 
the inherited m.3243A>G mutation and controls. (A) Categorised z-scores based on the control 
population: “low” (< -2SD), “normal” (-2SD ~ 2SD) and “high” (> 2SD). (B) An overview of the 
distribution and the average level of the data. Patients were compared with 2 controls for the stomach, 
3 controls for the colon, the oesophagus and the small intestine (P2), and 4 controls for the SI (P1). The 
number of crypts/gastric pits/oesophageal epithelium or muscle areas for analysis: n (P1 SI) = 70; n 
(control) =128; n (P2 SI)= 28, n (control) = 48; n (P2 stomach) = 6, n (control) = 36; n (P3 colon)=20, 
n (control) = 91. SI, small intestine; E, epithelium; M, muscle.  
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Figure 3.15 The level of SDHA in the epithelial and muscle tissue of patients with m.3243A>G 
compared with controls. (A) The raw optical density data was transformed into z-scores and categorised 
according to the control population: “low” (< -2SD), “normal” (-2SD ~ 2SD) and “high” (> 2SD). (B) 
The plot showing the mean and the variation of the data. Two controls were used for the stomach, three 
controls for the colon, the oesophagus and the small intestine (P2), and four controls for the SI (P1). The 
number of analysed crypts/gastric pits/areas of the oesophageal epithelium or smooth muscles: n (P1 SI) 
= 20; n (control) = 83; n (P2 SI)= 30, n (control) = 47; n (P2 stomach) = 7, n (control) = 44; n (P3 
colon)=20, n (control) = 79. SI, small intestine; E, epithelium; M, muscle. 
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3.4.6 Correlation between the level of complex I/IV and mitochondrial markers  
Linear regression and correlation analysis were performed to determine whether the 
maintenance of complex I and IV in patients’ GI epithelium was associated with the nuclear-
encoded mitochondrial markers, COX4 and SDHA respectively. Both patients and controls 
showed positive correlations between complex I and COX4 in the epithelium and muscle 
(Figure 3.16). The linear models are of good fitness for most of the tissue (Table 3.4). The 
slope of the linear model for the epithelium of the small intestine, the oesophagus and the 
colon in patients is not different from controls (Figure 3.16 A, B, D and E, and Table 3.4), 
indicating the level of complex I in the patients increased with COX4 at the same speed as in 
controls. In regards to the gastric epithelium and the smooth muscle, the slope of the patients’ 
model is significantly steeper compared with controls, meaning that complex I increased 
faster with the elevation of COX4 in patients compared with controls (Figure 3.16 C and F, 
and Table 3.4).  
COX1 had a strong positive correlation with SDHA in the epithelium of the small intestine, 
oesophagus and stomach in both patients and controls, but it showed no correlation with 
SDHA in the colonic epithelium of patient 3 (Figure 3.17 A-E and Table 3.5). COX1 was also 
significantly correlated with SDHA in the smooth muscle of both patients and controls 
(Figure 3.17F and Table 3.5). For all epithelial tissues with the correlation between COX1 
and SDHA, the slope of the linear model is the same between patients and controls with a 
good fit of the data to this model indicated by the high R2 value (Figure 3.17 A-D and Table 
3.5). 
These data suggest that in most of the epithelial tissue in the GI tract and the colonic smooth 
muscles, the levels of complex I and IV are positively correlated with the level of 
mitochondrial markers.  
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Figure 3.16 Linear modelling showing the correlation between complex I (marked by NDUFB8) and 
the nuclear encoded COX4 in the epithelium of (A) the small intestine of patient 1, (B) the oesophagus, 
(C) the stomach and (D) the small intestine of patient 2, (E) the colonic crypts and (F) the smooth muscle 
of patient 3 compared with controls. Each dot represents a single crypt/gastric pit or an area of the 
oesophageal epithelium and the smooth muscle. Equations of the linear models in each tissue: (A) 
patient, Y = 0.5824*X - 0.7855; controls, Y = 0.7916*X - 0.02390; (B) patient: Y = 0.7884*X + 0.9989; 
controls, Y = 0.7121*X - 0.01499; (C) patient: Y = 1.542*X - 1.584; controls, Y = 0.7189*X - 0.04683; 
(D) patient, Y = 0.8860*X - 1.217; controls, Y = 0.8642*X - 4.883e-008; (E) patient, Y = 0.8234*X + 
0.01112; controls, Y = 0.9118*X - 4.140e-010; (F) patient, Y = 4.236*X - 7.986; controls, Y = 0.4476*X 
- 0.01741. Patient 1 was compared with 4 controls. Patient 2 was compared with 2 controls for the 
stomach and 3 controls for the oesophagus and the small intestine. Patient 3 was compared with 3 
controls. The number of crypts/gastric pits/areas of oesophageal epithelium and muscle for analysis: n 
(P1 SI) = 70; n (control) =128; n (P2 SI)= 28, n (control) = 48; n (P2 stomach) = 6, n (control) = 36; n 
(P3 colon)=20, n (control) = 91. SI, small intestine. 
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Figure 3.17 Linear regression showing the correlation between complex IV (labelled by COX1) and 
mitochondrial marker, SDHA in the GI tract of patients with the m.3243A>G mutation and controls. 
Equations of the linear relationship: (A) small intestine epithelium: patient 1, Y = 0.6608*X + 1.327; 
four controls, Y = 0.8109*X + 0.005016; (B) oesophageal epithelium: patient 2, Y = 1.024*X + 0.4491; 
three controls, Y = 1.001*X - 0.1228; (C) gastric epithelium: patient 2, Y = 0.7077*X + 0.5981; two 
controls, Y = 0.6882*X - 0.004174; (D) small intestinal epithelium: patient 1, Y = 0.6608*X + 1.327; 
three controls, Y = 0.8109*X + 0.005016; (E) colonic epithelium: patient 3, Y = -0.2840*X - 0.8434 
(P> 0,05, no linear correlation); three controls, Y = 0.3824*X + 0.0006270; (F) colonic smooth muscle: 
patient 3, Y = 0.8107*X - 0.5503; three controls, Y = 0.9494*X - 0.008117. The number of crypts/gastric 
pits/areas of the oesophageal epithelium or smooth muscles for the analysis: n (P1 SI) = 20; n (control) 
= 83; n (P2 SI)= 30, n (control) = 47; n (P2 stomach) = 7, n (control) = 44; n (P3 colon)=20, n (control) 
= 79. SI, small intestine. 
 
Tissue 
Patient Controls 
Any difference 
between P & C (P 
value)? 
P value R2 P value R2 Slope Intercept 
SI E (P1) 0.0001 0.5624 < 0.0001 0.7186 No < 0.0001 
Oesophagus E < 0.0001 0.9505 < 0.0001 0.5641 No < 0.0001 
Stomach E 0.0090 0.7065 < 0.0001 0.5954 0.0305 N/A 
SI E (P2) 0.0019 0.3135 < 0.0001 0.7469 No < 0.0001 
Colon E < 0.0001 0.7021 < 0.0001 0.8314 No No 
Colon M < 0.0001 0.6062 0.0020 0.1692 < 0.0001 N/A 
Table 3.4 Parameters of the linear regression of complex I and COX4 in the epithelium and the muscle 
of patients’ GI segments compared with controls. P, patient; C, controls. 
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Tissue 
Patient Controls 
Any difference 
between P & C (P 
value)? 
P value R2 P value R2 Slope Intercept 
SI E (P1) < 0.0001 0.9420 < 0.0001 0.6540 No < 0.0001 
Oesophagus E < 0.0001 0.9766 < 0.0001 0.8542 No < 0.0001 
Stomach E 0.0022 0.8701 < 0.0001 0.4690 No 0.0372 
SI E (P2) < 0.0001 0.8456 < 0.0001 0.8451 No No 
Colon E >0.05 0.05700 0.0011 0.1298 0.0128 N/A 
Colon M 0.0053 0.3282 < 0.0001 0.8957 No < 0.0001 
Table 3.5 Parameters of the linear models of COX1 and SDHA in the epithelium and muscle of the GI 
segments from patients with m.3243A>G and controls. P, patient; C, controls. 
 
3.4.7 The difference in the OXPHOS level between gastric pits and glands 
A difference in the OXPHOS level between the gastric pits and glands in the stomach from 
patient 2 was observed as a secondary finding. In contrast to the well-preserved OXPHOS 
function in the gastric pits (discussed in 3.4.2, 3.4.4 and 3.4.6), sequential COX/SDH 
histochemistry revealed COX deficiency in the gastric glands (Figure 3.18). In addition, the 
quantitative immunofluorescence assay demonstrated lower levels of complex I and IV in the 
gastric glands compared with controls (Figure 3.19A and B). Furthermore, the level of the 
nuclear-encoded mitochondrial markers COX4 and SDHA decreased in the gastric glands 
compared with controls (Figure 3.19C and D), which was not the case in the gastric pits 
(discussed in 3.4.5). No correlation was found between the levels of complex I and COX4 in 
the gastric glands (P-value = 0.4294, R2 = 0.1617) (Figure 3.19E), though the level of 
complex IV was still positively correlated to SDHA (P < 0.0001, R2 = 0.8067) (Figure 3.19F). 
The linear relationship between complex IV and SDHA in the gastric glands of the patient is 
the same compared with controls (P = 0.3836 for the slope and P = 0.5715 for the intercept). 
However, as a secondary discovery, these data are still preliminary due to the small sample 
size. To draw a comprehensive conclusion, more gastric glands should be included for 
analysis in future work. 
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Figure 3.18 The COX activity in the gastric glands of patient 2 compared with controls. Haematoxylin 
and eosin staining, a COX assay, an SDH assay and sequential COX/SDH histochemical assay were 
performed on the gastric gland sections of patient 2. The black arrows indicate the COX-defective 
glands.  
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Figure 3.19 Categorical z-scores of the level of (A) complex I (marked by NDUFB8), (B) complex IV 
(marked by COX1), (C) COX4 and (D) SDHA in the gastric glands of patient 2 in comparison to two 
age-matched controls. Classification for NDUFB8 and COX1: “negative” (< -3SD), “Intermediate” (-
3SD ~ -2SD) and “positive” (> -2SD). Hierarchy for nuclear encoded COX4 and SDHA: “low” (< -
2SD), “normal” (-2SD ~ 2SD) and “high” (> 2SD). (E) Linear regression of NDUFB8 and COX4 in the 
gastric pits of the patient and controls. Equations of the linear models: patient, Y = -0.3097*X - 3.170 
(P > 0.05, R2 = 0.1617); controls, Y = 0.8963*X - 0.07408 (P < 0.0001, R2 = 0.8028). (F) Correlation 
between COX1 and SDHA in the glands of the stomach from the patient and controls. Linear formulas: 
patient, Y = 1.110*X + 0.7457 (P < 0.0001, R2 = 0.8067); controls, Y = 0.8337*X + 0.1424 (P < 0.0001, 
R2 = 0.5499). 
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3.5 Discussion 
Understanding the behaviour of mtDNA mutations in various tissues is crucial to 
understanding the development of both ageing and primary mitochondrial disorders. In 
contrast to the somatic mtDNA mutations that accumulate under no selective pressures with 
age (Greaves et al., 2012a), patients with mitochondrial disease lose certain inherited 
mutations in mitotic blood (McShane et al., 1991; Rahman et al., 2001; Grady et al., 2018). 
However, the age-related behaviour of the inherited mtDNA mutations in other mitotic tissue 
remains mostly unknown. Here I have investigated whether the loss of the inherited mtDNA 
mutations also occurs in mitotic gastrointestinal epithelium and whether it has any impact on 
the biochemical defect caused by the mutation. 
Previous studies have shown that the m.3243A>G mutation was uniformly distributed in 
various tissues of foetuses, regardless of whether they are mitotic or not (Matthews et al., 
1994; Cardaioli et al., 2000; Monnot et al., 2011). In contrast, this study shows a lower 
m.3243A>G mutation load in the mitotic epithelium compared with the post-mitotic muscle 
in different GI segments from the patient group (age ranging from 36 years to 64 years). 
Given that there is no evidence the mutation load in muscle changes with age (Frederiksen et 
al., 2006; Grady et al., 2018), this contrast suggests a loss of the mutation in the patients’ GI 
epithelial tissue, which is consistent with previous studies on epithelial cells in the buccal 
mucosa, urine and cervical smears (Olsson et al., 2001; Frederiksen et al., 2006; de Laat et 
al., 2012; Grady et al., 2018). 
The intestinal epithelium is a good model for stem cell research as each crypt is an 
independent unit with all cells deriving from the stem cell at the crypt base. In addition, 
intestinal crypts often undergo niche succession where a single stem cell dominates the stem 
cell pool, and monoclonally produces daughter cells in a crypt (Novelli et al., 1996; Kim and 
Shibata, 2002; Snippert et al., 2010; Kozar et al., 2013). Given the monoclonal attribute of the 
intestinal crypt, the considerable variation in the heteroplasmy level between different crypts 
with some of the crypts carrying no m.3243A>G mutation suggests that the loss of the 
inherited mtDNA mutation occurs in intestinal stem cells. This is consistent with a previous 
study where in silico simulations suggest that the loss of m.3243A>G mutations in blood 
occurs in haematopoietic stem cells (Rajasimha et al., 2008). However, the analysis of the 
clinical data in this study also shows that the level of m.8344A>G mutation does not tend to 
decrease with age in patient blood (Rajasimha et al., 2008), despite a consistent slightly lower 
heteroplasmy level in the blood compared with that in the muscle of the patients shown in the 
other study (Larsson et al., 1992). The results here demonstrate that the heteroplasmy level of 
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m.8344A>G is significantly lower in the colonic epithelium of the patient compared with the 
muscle with a large variation in different crypts, which suggests that the selection against the 
m.8344A>G mutation may be stronger in the intestinal epithelium than blood. Nevertheless, 
due to the shortage of tissue samples, the results need to be confirmed when tissue specimens 
from more patients are available. 
My results also show an upper limit of heteroplasmy level in the GI epithelium of the patients, 
which is likely tissue-specific, as in the same patient, the limit in the oesophageal epithelium 
is substantially different from that in the gastric or intestinal epithelium. The upper limit of 
the heteroplasmy level could also be individual-specific and might be associated with the 
overall mutation burden in the patient, since the limit in the small intestinal epithelium of 
patient 1 with an intermediate mutation load in the muscle is approximately 10% lower 
compared with patient 2 with a high mutation burden in the muscle. The upper cut-off limit of 
the mutation level in patients’ GI epithelium suggests that once cells have reached this level 
of mutation load, they might be eliminated or activate some pathways to remove the mutation. 
The upper limits for m.3243A>G and m.8344A>G are similar in the colonic epithelium from 
the patients with comparable mutation burdens in the muscle; however, due to the small 
sample size, the factors that determine the limit of the mutation are still unknown. 
Whether the loss of the inherited mtDNA mutations influences the phenotype of the tissue has 
not been documented in previous research on blood or epithelial cells, given the technical 
difficulties in examining the biochemical level in these tissues. Defective respiratory chain 
complex I and complex IV caused by mtDNA mutations are frequently reported (Hämäläinen 
et al., 2013; Rocha et al., 2015). In this study, I have demonstrated that the loss of the 
inherited mtDNA mutation in the mitotic GI epithelium of the patients corresponds to the 
well-preserved COX activity and protein levels of complexes I and IV in the epithelium. By 
contrast, the patients had a severe COX defect and complex I deficiency in accordance with 
the high mutation load in the post-mitotic muscle. Since studies indicate that high levels of 
m.3243A>G mutation can cause severe COX and complex I deficiency in mitotic intestinal 
epithelium as well as post-mitotic muscle and neurons (Hämäläinen et al., 2013), the finding 
here suggests that the biochemical defects in the patients’ GI epithelium might be reversible 
with the loss of the inherited mtDNA mutations. The data here also shows that the colonic 
smooth muscle with severe complex I deficiency displays a relatively normal level of 
complex IV, together with previous studies (James et al., 1996; Hämäläinen et al., 2013; 
Rocha et al., 2015), suggesting that complex I is more susceptible to m.3243A>G mutation 
than complex IV. 
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This study also shows that the nuclear-encoded subunits COX4 and SDHA are as stable as 
porin as a mitochondrial marker for the patient cases with the m.3243A>G mutation, which is 
consistent with previous studies (Chrysostomou et al., 2015). The results have revealed 
increased levels of COX4 and SDHA in the epithelium of different GI segments from patients 
compared with controls, which has a strong positive correlation to the level of complex I and 
complex IV respectively in most of the GI epithelial tissues of the patients. These data suggest 
an adaptive response of the nuclear-encoded subunits to inherited mtDNA mutations, which 
might improve the phenotype of the tissue and buffer the OXPHOS deficiency caused by the 
mutation. Such compensation was also observed in the smooth muscle of patient 3, which is 
in accordance with previous research on skeletal muscles (Moraes et al., 1992). No increase in 
either of the mitochondrial markers was observed in the colonic epithelium of patient 3 (64y, 
the oldest among all the cases). In addition, the tissue has a low level of COX1 deficiency 
with no correlation between COX1 and SDHA. These data suggest a limit in the 
compensatory response that might be associated with ageing, yet the mechanism remains 
unknown. The gradient of the linear models between the mitochondrial markers and 
NDUFB8/COX1 in most of the patients’ tissue is the same as for controls, suggesting that the 
rising rate of NDUFB8/COX1 concomitant with the increase in the mitochondrial markers in 
patients are the same compared with controls. For gastric pits and colonic smooth muscle, 
NDUFB8 rises faster with the elevation of COX4 in patients compared with controls, 
indicating some adaptability in the relationship. The correlation between COX1 and SDHA is 
robust in the epithelium of different GI segments from patient 1 and 2, indicated by the 
consistent high R2 value. NDUFB8 and COX4 are also strongly correlated in the GI 
epithelium of the patients, but the correlation is comparatively weaker than that between 
COX1 and SDHA. Nevertheless, whether COX1 is more associated with mitochondrial mass 
than NDUFB8 needs to be confirmed by correlating them with the same mitochondrial mass 
marker. 
In this study, despite severe COX deficiency shown by sequential COX/SDH histochemistry 
in the colonic smooth muscle of the patient, the level of COX1 determined by 
immunofluorescence is unexpectedly normal compared with controls. One possibility is that 
the COX deficiency indicated by the histochemical assay is exaggerated by the overpowering 
labelling of the upregulated SDH activity to some extent. Moreover, as the histochemical 
assay determines the enzyme activity of complex IV, whereas the immunofluorescence assay 
quantifies the protein level, a more likely explanation is that the muscle contains 
dysfunctional complex IV even though the protein expression is unaffected by the mtDNA 
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mutation. This has also been reported in other studies (Hämäläinen et al., 2013), suggesting 
that for clinical diagnosis or laboratory examination of the OXPHOS function, the 
histochemical assay should not be replaced by techniques that solely examine the protein level 
of complex IV. Another explanation is that COX1 fails to mark the true level of complex IV 
for cases with m.3243A>G mutations. This is unlikely, as the mtDNA-encoded subunit COX1 
has been well documented to be an ideal marker for the respiratory chain complex IV in 
patients with the m.3243A>G mutation (Rocha et al., 2015).  
The findings in this study also reveal tissue specificity in the rate of losing the inherited 
mtDNA mutations. The mutation level of m.3243A>G in the oesophageal epithelium is 
notably lower compared with that in the gastric or intestinal epithelium from the same patient, 
which is concomitant with the significant upregulation of complex I/IV and the mitochondrial 
markers. The reason why the epithelium of the oesophagus loses the mutation much faster 
than other parts of the alimentary tract remains unknown, but the data here suggests that the 
rate of losing the mutation is unlikely to be solely determined by the tissue turnover rate under 
normal physiological conditions, as the normal renewal speed of the oesophageal epithelium 
is much slower than that of the intestinal epithelium (Creamer et al., 1961; Squier and 
Kremer, 2001). On the other hand, it might be associated with the increased cell proliferation 
during wound healing in the oesophageal epithelium (Doupé et al., 2012), considering that it 
is often exposed to the high temperature and hardness of food, which predisposes it to more 
damage compared with the other part of the GI tract. 
The gastric epithelium is composed of numerous gastric units that comprise gastric pits and 
glands (James S. Lowe, 2015). A noticeable difference in the OXPHOS level between the 
gastric pits and glands of the same patient was observed as a secondary finding, which 
highlights the specificity within epithelial tissue. Although gastric stem cells at the neck zone 
of a gastric unit produce daughter cells that undergo a bidirectional migration to form all the 
cells within the unit, gastric pits and glands are distinct in terms of the cell composition and 
function (Kouznetsova et al., 2011; James S. Lowe, 2015). Thus, they may have different 
demands for energy, and their sensitivity and response to the m.3243A>G mutation may be 
different accordingly. Another possibility is that the gastric pit and gland may have different 
levels of the mutation, which suggests an involvement of amplifying or differentiated cells in 
altering the load of the inherited mtDNA mutation within a gastric unit. Unfortunately, in this 
study, no gastric pits were available for the pyrosequencing measurement to determine the 
heteroplasmy level. In addition, the interpretation is only based on the data of one patient with 
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a limited number of gastric units being analysed. Hence, the hypotheses above need to be 
confirmed when tissue specimens from more patients become available in the future.  
The limitations of this study are due to the quality of the tissue and the small sample size. The 
tissue from only four patients was available. The severe post-mortem degradation of the tissue 
was a challenge in all of the assays for DNA or protein analysis. DNA extracted from a single 
intestinal crypt/gastric gland was not sufficient for genetic analysis. Thus five pooled 
crypts/glands were used for the measurement of the mutation load, which might compromise 
the interpretations. The poor morphology of the tissue generally compromised the protein 
assays and incapacitated the antibodies of the ideal mitochondrial mass marker porin and 
several epithelial markers. The poor tissue quality and the lack of GI stem cell markers for 
humans restrict the study to stem cell progenies rather than stem cells per se. In addition, this 
is not a longitudinal study, and the age-related changes in the mutation level in the patients are 
extrapolated based on previous literature. These limitations make it necessary to confirm the 
findings using tissue from more patients when it is available and to use animal models for 
mechanistic studies. 
 
3.5.1 Future work 
There are still many questions in regards to the loss of inherited mtDNA mutations in mitotic 
tissue. Here only the two common mtDNA-tRNA mutations were investigated, and it is 
necessary to expand the sample size. Furthermore, studies have reported that for two 
mutations at the site m.8993 in a protein-encoding gene mt-ATP6, there is no tissue-specific 
segregation or age-related changes in the mutation load in blood (White et al., 1999). To gain 
the understanding of the biological features of pathogenic mtDNA mutations and the 
phenotype of mitochondrial disease, it would be beneficial to determine whether the age-
dependent loss of the mutation in the GI stem cell populations is generic to other types of 
inherited mtDNA mutations. Longitudinal studies show that, despite a possibility that the 
mutation might have been lost before the examination, not all subjects with the inherited 
m.3243A>G lose the mutation in blood (Grady et al., 2018). There was a large variance in the 
change in the mutation level with age between individuals, and the mutation level in some of 
the subjects drifted slightly up or was sustained as a plateau (Grady et al., 2018). This seems 
not to be the case here, and more samples need to be examined to consolidate the conclusion. 
Studying the variance in the heteroplasmy in different segments of GI epithelium would 
possibly reveal the difference in the selective pressure against inherited mtDNA mutations 
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between different stem cell populations. Answering all these questions requires tissue from 
more patients and carriers with inherited mtDNA mutations. 
The interpretations in regards to GI stem cell populations in this study is based on the 
extrapolation from the stem cell progenies and the presumption of monoclonal conversion of 
the intestinal crypt. It would be valuable to confirm the findings on stem cells per se. Isolating 
intestinal stem cells will also benefit mechanistic studies. Available techniques that allow 
isolation of intestinal stem cells from fresh biopsies of patients have been published recently, 
though it requires validation (Jung et al., 2015). However, it is challenging to acquire such 
tissue in the clinic.  
Investigating the mechanism underlying the loss of the inherited mutation in mitotic tissue is 
still at an early stage. Although there is a visible upper limit in the mutation load of different 
intestinal crypts from patients, the pattern of the data appears to resemble the distribution 
caused by random genetic drift. Investigating the distribution of the mutation level in crypts is 
very important to understanding the mechanism of the age-related loss of the inherited 
mtDNA mutations. Verifying whether the variation in the mutation load of different crypts is 
due to random genetic drift could be achieved by either statistically comparing the data in this 
study with known distributions caused by random genetic drift or establishing in silico 
simulations. 
The ultimate question is why only inherited but not somatic mtDNA mutations that 
accumulate in normal ageing are under negative selective pressures. Due to the limitations of 
the human study, the investigation of the mechanism requires the use of animal models. A 
mouse model of mitochondrial disorders (tRNAAla mutant mice) carrying hereditary 
m.5024C>T was established recently (Kauppila et al., 2016), which may be of use in further 
investigating selective pressures. Full characterisation of the mouse model is indispensable for 
determining whether this mouse model is suitable for the mechanistic study. This will be 
discussed in Chapter 4 and Chapter 5. 
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3.6 Conclusion 
In this study, I have presented genetic and biochemical evidence for the selective loss of the 
inherited mtDNA mutations in the mitotic GI epithelium. The substantial variation in the 
mutation load of different intestinal crypts with some of them carrying no inherited mutation 
suggests that the selection against the mutation occurs in intestinal stem cells. This study 
benefits the understanding of the phenotype and the progression of mtDNA disease. It also 
highlights the contrast in the selective pressures on inherited and somatic mtDNA mutations. 
Investigating the mechanism underlying this difference would be valuable in the 
understanding of both ageing and mitochondrial disorders.  
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Chapter 4 Genetic characterisation of a tRNAAla mutant mouse model for 
investigating selective pressure on inherited mtDNA mutations 
4.1 Introduction 
Mitochondrial diseases characterised by mitochondrial dysfunction are highly heterogeneous 
(Alston et al., 2017). Patients with mitochondrial disorders can carry identical genetic 
mutations but present various tissue-specific phenotypes and symptoms with different ages of 
onset (Alston et al., 2017). mtDNA diseases are a primary group of mitochondrial disorders 
caused by germline mtDNA mutations (Taylor and Turnbull, 2005). Many factors are 
believed to be involved in the heterogeneity of mtDNA diseases, including heteroplasmy 
level, clonal expansion, the biochemical threshold and tissue specificity with mitotic 
segregation (Taylor and Turnbull, 2005); however, the exact mechanism underlying disease 
heterogeneity remains uncertain. Studying the dynamics of mtDNA mutations in different 
tissues with age is critical to understanding the factors accounting for the diversity of mtDNA 
diseases. In addition, it is important to understanding ageing, ageing-related degenerative 
disease and cancer that are intimately related to the age-dependent accumulation of acquired 
somatic mtDNA mutations. However, it is difficult to study these using human samples, due 
to the invasive sampling methodology. Developing mitochondrial models of ageing and 
mtDNA disease and comparing normal aged individuals with those with mtDNA disease 
regarding the dynamics of mtDNA mutations would be enormously helpful to understanding 
mtDNA disease and ageing. A mouse model of ageing (mtDNA-mutator mouse) has been 
established, which recapitulates the accumulation of somatic mtDNA mutations during ageing 
(Kujoth et al., 2005; Trifunovic et al., 2005). These mice carry a knock-in mutation in the 
mtDNA polymerase γ (Polg) sequence, which impairs proofreading during mtDNA synthesis, 
predisposing them to acquired mtDNA mutations with age (Kujoth et al., 2005; Trifunovic et 
al., 2005). The mtDNA-mutator mice have been ubiquitously utilized to study the association 
between mtDNA mutations and ageing (Su et al., 2018); however, establishing reliable 
models of mtDNA disease is a considerable challenge for mitochondrial researchers. 
A breakthrough was the creation of rho zero (ρ0) cells, a cell line depleted of mtDNA through 
exposure to ethidium bromide (King and Attardi, 1989). These cells were fused with 
cytoplasts with exogenous mtDNA to form trans-mitochondrial cybrids, enabling the study of 
different introduced mutant mtDNAs in the same nuclear background (King and Attardi, 
1989). This model has proved valuable for studying the effect of heteroplasmy level on 
cellular function and phenotype (Hayashi et al., 1991; Chomyn et al., 1992b), the genetic 
causes of mitochondrial disorders (Tiranti et al., 1995; Taanman et al., 1997) and the 
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influence of nuclear factors on the dynamics of pathogenic mtDNA mutations in cells 
(Dunbar et al., 1995). 
Another cell model of mitochondrial disease has been established with the development of 
stem cell research where induced pluripotent stem cells (iPSCs) were generated through 
reprogramming fibroblasts from patients with mtDNA disease (Hämäläinen et al., 2013). This 
technique enables the generation of teratomas containing different types of tissues with 
similar heteroplasmy levels and the same nuclear background from the iPSCs, and it also 
allows the monitoring of biochemical changes in the respiratory chain and the mtDNA 
dynamics during stem cell differentiation (Hämäläinen et al., 2013). This model has proved 
useful for studying the influence of cell-specific factors and tissue development on the 
progression of mtDNA disease (Hämäläinen et al., 2013). 
 
4.1.1 Mouse models of mDNA disease 
Although these in-vitro models are beneficial to the understanding of the pathogenesis of 
mtDNA disorders, mammalian models that simulate the actual in-vivo environment are 
undoubtedly the ultimate models of mtDNA disease. Mice are commonly utilised for disease 
modelling given their high genetic and physiological homology to humans, fast reproductive 
rate and manageable breeding strategy. Mouse models of mtDNA disease would be hugely 
advantageous to research into the mechanisms underlying the germline transmission as well 
as the pathogenesis of specific mtDNA mutations, and in particular, the progression of disease 
with age. It is difficult to investigate mtDNA disease progression at the tissue level in human 
patients due to the invasive nature of obtaining samples. Therefore, having a mouse model 
allows the study of the age-related phenotype development and the tissue heterogeneity 
through tissue sampling of mice at serial stages of the lifespan. This could potentially inform 
on prevention, diagnosis and treatment of mtDNA diseases. With continuous effort, 
researchers have succeeded in generating several mouse models of mtDNA disorders carrying 
different types of mtDNA mutations, including large-scale deletions, point mutations in 
protein-encoding and rRNA sequences and mutations in tRNA genes (Watanabe et al., 1978; 
Levy et al., 1999; Marchington et al., 1999; Inoue et al., 2000; Sligh et al., 2000; Nakada et 
al., 2004; Kasahara et al., 2006; Fan et al., 2008; Yokota et al., 2010; Freyer et al., 2012; Lin 
et al., 2012; Shimizu et al., 2014; Shimizu et al., 2015; Kauppila et al., 2016). These mouse 
models are reviewed in detail in 1.6.3 of Chapter 1. The mouse models of mtDNA disease 
mentioned above have given useful insights into the germline transmission as well as the 
pathogenesis of mtDNA mutations. However, none of them has proven suitable for studying 
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the tissue-specific distribution of mtDNA mutations and the selective loss of mutations in 
mitotic tissue of patients (Chinnery et al., 1999; Grady et al., 2018). Some of them carry 
homoplasmic mutations consistently in all organs (Kasahara et al., 2006; Yokota et al., 2010; 
Freyer et al., 2012; Lin et al., 2012), and the rest of them show uniformly distributed 
heteroplasmic mutations among different tissues, regardless of the age (Inoue et al., 2000; Fan 
et al., 2008; Freyer et al., 2012; Shimizu et al., 2015). Therefore, the establishment of a 
mouse model with heteroplasmic mtDNA mutations that shows age-related and tissue-specific 
segregation of the mutation is in demand to comprehensively investigate the development of 
tissue-specific phenotypes during the progression of mtDNA disease. 
 
4.1.2 Mice with m.5024C>T mutation in the tRNAAla gene 
Most of the existing mouse models of mtDNA disease were created by introducing 
pathogenic mutations that naturally occurred or mutagenized in a cell line into embryonic 
stem cells (ESC), which were subsequently microinjected into mouse embryos (Levy et al., 
1999; Sligh et al., 2000; Kasahara et al., 2006; Fan et al., 2008; Yokota et al., 2010; Lin et 
al., 2012; Shimizu et al., 2014; Shimizu et al., 2015). Recently, a phenotypic-driven 
methodology has been developed, which avoids the laborious manipulation of ESCs and 
ensures the stable maternal transmission of the mutation (Kauppila et al., 2016). This 
approach involves the use of the Polgmut/+ (heterozygous mtDNA-mutator) mice with lower 
burdens of somatic and germline mtDNA mutations compared with the Polgmut/mut mice (Ross 
et al., 2013). The Polg heterozygous male mice were mated with wild-type females to 
produce Polg heterozygous females with reintroduced germline wild-type mtDNA, which 
were then backcrossed with wild-type males for three generations (N3) (Kauppila et al., 2016) 
(Figure 4.1). Due to the permissive environment for clonal expansion of pathogenic mtDNA 
mutations in colonic crypts (epithelium), mouse colonic crypts were collected from N3 mice 
and screened for COX deficiency (Kauppila et al., 2016) (Figure 4.1). Mouse lines with 
normal COX activity were halted, and those with defective COX in their colonic epithelium 
were screened genetically via complete mitochondrial genome sequencing (Kauppila et al., 
2016) (Figure 4.1). The qualified candidates with pathogenic mtDNA mutations were 
reproduced for more than six generations to segregate the mouse lineage (Kauppila et al., 
2016) (Figure 4.1). Via this approach, a mouse line was generated carrying a pathogenic 
m.5024C>T mutation in their mitochondrial tRNAAla gene and a non-pathogenic 
m.13715C>T mutation in the ND6 polymorphic sequence (Kauppila et al., 2016). The 
pathogenic m.5024C>T mutation locates in the same base pair as the m.5650G>A mutation 
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which causes mitochondrial myopathy in patients (Finnilä et al., 2001; McFarland et al., 
2008). These mice demonstrated reduced body mass and cardiomyopathy with respiratory 
chain defects in the heart and the colonic smooth muscle that were highly correlated with the 
heteroplasmy level (Kauppila et al., 2016). This mutation also impaired the translation of all 
mitochondrial encoded proteins (Kauppila et al., 2016). The m.5024C>T mutation was stably 
transmitted through the germline with a maximum of 80% mutated mtDNA molecules 
transmitted to the offspring (Kauppila et al., 2016). Although the mutation level in various 
tissues appeared to be similar in 20-week mice, the heteroplasmy level of the mitotic colonic 
epithelium was around 20% lower than that of the post-mitotic smooth muscle in the old mice 
(> 40 weeks) (Kauppila et al., 2016). In addition, a loss of the mutation was observed with 
age in the blood of the mice with a high mutation load (>60%) but not in those with a low to 
intermediate mutation load (<60%) (Kauppila et al., 2016), suggesting selective pressures 
against the pathogenic m.5024C>T mutation in the blood as in patients with other mt-tRNA 
mutations (Rahman et al., 2001; Grady et al., 2018). Therefore, this mouse model can 
potentially be a good model for the mechanistic study of the tissue-specific segregation of 
mtDNA mutations. However, it remains unclear whether the selective loss of the mutation 
also occurs in other mitotic tissue, for example, gastrointestinal epithelium, as reported in 
patients with mt-tRNA mutations (Chapter 3) and how the mutation is segregated in different 
types of tissues with age. A thorough characterisation of this mouse lineage to answer these 
questions would determine whether they are suitable for studying the development of tissue-
specific phenotypes and the mechanism of the selective pressure upon the inherited mtDNA 
mutations in mitotic tissue, which would also be useful for understanding the absence of 
selection against somatic mtDNA mutations during ageing. 
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Figure 4.1 Establishment of the mouse line with inherited m.5024C>T mutation in the tRNAAla gene. 
Polg heterozygous females accumulate a multitude of somatic mtDNA mutations in the germline over 
generations. The previous heavy mutation burden must be removed from the germline of the Polg 
heterozygous females to facilitate the segregation of individual mutations. To this end, Polg 
heterozygous males were mated with Polg wild-type females to obtain Polg heterozygous females with 
reintroduced wild-type germline mtDNA. The newly generated females that accumulated a small 
number of age-related mutated mtDNA molecules in the germline were then backcrossed with Polg 
wild-type males to acquire Polg wild-type females with inherited mtDNA mutations. Mice were 
sacrificed after three generations to examine the COX deficiency in the colonic epithelium using 
sequential COX/SDH histochemistry (COX-defective crypts in blue and COX-normal crypts in brown). 
The breeding of the mice with no OXPHOS defects was discontinued. Tail biopsies were collected from 
the mice with defective COX activity in the colonic crypts, which were subjected to whole mitochondrial 
genome sequencing to identify the mutations in mtDNA. Qualified candidates with inherited 
m.5024C>T point mutation in the tRNAAla gene were bred for at least six generations to segregate the 
mouse lineage with the stable maternal transmission. Rings in red signifies mtDNA molecules with the 
m.5024C>T mutation and those in other colour indicate molecules with various pathogenic mutations 
or polymorphism. 
 
4.2 Aims 
The tRNAAla mutant mice show a loss of the m.5024C>T mutation in blood over time and a 
lower mutation load in colonic epithelium compared with the smooth muscle when they age. 
To date it is the only mouse model that has shown potential selective pressure against the 
inherited mtDNA mutation somatically, similar to patients with mtDNA disease.  
This study aimed to genetically characterise the dynamics of the m.5024C>T mutation with 
age in the tRNAAla mutant mice and determine whether these mice are a suitable model for 
studying the mechanism of the selection against the inherited mtDNA mutations. The 
characterisation included: 
1. Determine whether there is any tissue-specific and age-related segregation of the 
m.5024C>T mutation by measuring the heteroplasmy levels of multiple tissue/organ 
homogenates from the young and old tRNAAla mutant mice. 
2. Determine whether the m.5024C>T is lost in gastrointestinal epithelium with age and 
whether GI stem cells are involved in this process through single crypt/gastric unit 
analysis. 
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4.3 Methods 
4.3.1 Mice with m.5024C>T mutation in the mitochondrial tRNAAla gene 
All the tRNAAla mutant mice were bred by Dr James Stewart and Nils-Göran Larsson, Max 
Planck Institute for Biology of Ageing, Cologne, Germany. Figure 4.1 illustrates the breeding 
strategy, which was expatiated in 2.5. The young (≈ 10 weeks) and old mice (≈ 50 weeks) 
were culled, and their organs were collected and frozen by Dr Laura Greaves and Dr James 
Stewart for the subsequent genetic analysis. The number of mice included for the examination 
of different tissue homogenates is summarised in Table 4.1. An ear notch was collected for 
each mouse at weaning (three weeks of age), of which the heteroplasmy level was measured 
by Dr James Stewart using pyrosequencing as a reference of the initial mutation load in each 
animal. 
 
4.3.2 Quantification of the heteroplasmy level in tissue homogenates 
A small tissue block was cut from the frozen organs of the tRNAAla mutant mice and was 
homogenised for DNA extraction (detailed in section 2.10.3). In regards to the homogenate of 
the GI epithelium and muscle, sections were labelled via sequential COX/SDH 
histochemistry. Then large areas of the epithelial tissue and smooth muscles spanning a 
couple of fields of view (≈ 5 x 105 µm2 in total) were laser-microdissected and collected 
(described in 2.10.1), followed by cell lysis to acquire the DNA (detailed in 2.10.2). A 
pyrosequencing assay designed to quantify the heteroplasmy level of the m.5024C>T 
mutation was performed (delineated in section 2.11) using the extracted DNA described 
above. The number of mice included for the statistical analysis of each tissue is summarised 
in Table 4.1. 
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Tissue/organ homogenate N (10-week mutants)  N (50-week mutants) 
Ear notch 7 7 
Gastric smooth muscle 7 7 
SI smooth muscle 7 6 
Heart 7 7 
SKM 7 7 
Brain 7 7 
Kidney 7 7 
Pancreas 6 7 
Lung 6 7 
Liver 7 7 
Spleen 7 7 
Fundic epithelium 7 6 
Pyloric epithelium 3 3 
SI epithelium 7 5 
Table 4.1 The number of the 10-week and 50-week mice included for the analysis of the heteroplasmy 
level in each tissue/organ. Ear notches of the mice were collected at weaning (three weeks). N, number; 
SI, small intestine; SKM, skeletal muscle. 
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4.3.3 Genetic analysis of single intestinal crypts/gastric units 
Tissue was sectioned in a cryostat at a thickness of 20 µm (specified in section 2.6). Single 
intestinal crypt/gastric units and small areas of GI smooth muscles (≈ 50000 µm2 as a unit) 
were laser-microdissected and collected in PCR tubes (detailed in 2.10.1), which were lysed 
(2.10.2) for pyrosequencing to measure their heteroplasmy levels (2.11). The number of 
crypts/gastric units/muscle areas for the statistical analysis is concluded in Table 4.2. 
 
ID 
Small intestine Stomach 
N of crypts N of muscles 
N of fundic 
unit 
N of pyloric 
unit 
N of muscles 
B933 10 10 n/a n/a n/a 
B934 10 10 n/a n/a n/a 
B945 10 9 n/a n/a n/a 
B948 10 10 n/a n/a n/a 
B952 10 10 n/a n/a n/a 
B949 10 10 n/a n/a n/a 
365 10 10 10 10 10 
353 10 9 10 10 10 
370 12 10 10 - 10 
369 15 12 10 - 10 
373 10 10 10 - 10 
351 12 15 10 - 10 
372 n/a n/a n/a 10 10 
Table 4.2 The number of intestinal crypts/gastric units of fundus or pylorus/areas of smooth muscles 
included for statistical analysis. B933, B934, B945, B948, B952, B949 were sacrificed at 10 weeks. 365, 
353, 370, 369, 373, 351 and 372 were culled at 50 weeks. “n/a” indicates the tissue that was not used in 
the study. “-” designates the tissue that was unavailable. 
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4.4 Results  
4.4.1 Variations in the mutation level between tissues/organs in young and old mice 
No discernible difference in the m.5024C>T mutation level was observed between seven 
tissues/organs, including the blood, spleen, skeletal muscle, heart, kidney, liver and the tail, 
within each 20-week tRNAAla mutant mice (Kauppila et al., 2016). To determine whether 
there is any tissue-specific age-related changes in the mutation load, I measured the 
heteroplasmy levels of the homogenates of various tissues/organs of the 10-week and 50-
week tRNAAla mutant mice, including the mitotic tissue, such as gastrointestinal epithelium 
and spleen; post-mitotic tissue including GI smooth muscle, heart, skeletal muscle and brain; 
and the organs that contain a mixture of mitotic and post-mitotic tissue or have limited 
regeneration under normal physiological conditions, such as kidney, pancreas, lung and liver 
(Benigni et al., 2010; Kotton and Morrisey, 2014; Forbes and Newsome, 2016; Zhou and 
Melton, 2018). The heteroplasmy level of the post-mitotic ear notch measured by Dr James 
Stewart, Max Planck Institute for Biology of Ageing, Cologne, Germany, at 3 weeks of age, 
was included as a reference of the initial mutation burden of each mouse. Only mice with high 
mutation burden in the ear notch (60% - 80%) were used in this study since the loss of the 
mutation was not found in the blood of the mice with intermediate-low tail heteroplasmy (< 
60%) (Kauppila et al., 2016).  
The mutation was evenly distributed in different tissues/organs of the 10-week mutant mice (p 
= 0.1267, one-way ANOVA) (Figure 4.2A). This is in contrast to the case of the 50-week 
mutant mice (p < 0.0001, one-way ANOVA), where the mutation level in the small intestinal 
epithelium was significantly lower compared with those in all the other tissues except for the 
spleen and pyloric epithelium of the stomach (p < 0.01, one-way ANOVA) (Figure 4.2B). The 
heteroplasmy level in the spleen was found to be lower than that in the ear notch and the 
gastric smooth muscle (p < 0.05, one-way ANOVA) (Figure 4.2B). To determine the change 
in the m.5024C>T heteroplasmy in each type of the tissue with age, I compared the mutation 
level of each tissue from the 10-week and 50-week tRNAAla mutant mice. This revealed a 
decline in the mutation load in the small intestinal epithelium in the 50-week mutants 
compared with the 10-week mutants (p < 0.01, unpaired t-test) (Figure 4.3). However, no 
significant difference in the heteroplasmy level was observed in the other tissues between the 
10-week and 50-week mice (Figure 4.3). 
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Figure 4.2 Mutation levels in different tissues/organs of (A) 10-week and (B) 50-week tRNAAla mutant 
mice. Tissues/organs were categorised into “mitotic”, “combination” and “post-mitotic” based on the 
general thoughts of the cell component and the renewal ability of the tissue/organ. Frozen tissue was 
homogenised and subjected to DNA extraction, which was used for pyrosequencing assay to measure 
the heteroplasmy level. The gastric epithelium was classified into fundic and pyloric epithelium 
because of the different cellular components and functions. All the mice in this study carried high 
levels of m.5024C>T mutation in the three-week ear notch (% m.5024C>T ranging from 60% to 
80%). The number of mice included for analysing the data of each tissue is concluded in Table 4.1. SI, 
small intestine; SM, smooth muscle; E, epithelium; SKM, skeletal muscle. For the small intestinal 
epithelium of the 50-week mutants, p < 0.0001 compared with the ear notch (3 weeks) and gastric 
smooth muscle, p < 0.001 compared with the intestinal smooth muscle, kidney, pancreas and heart, p < 
0.01 compared with the skeletal muscle, brain, lung, liver and gastric fundic epithelium; for the spleen 
of the 50-week mutants, p < 0.05 compared with the ear notch and gastric smooth muscle, determined 
by Tukey’s multiple comparison test for one-way ANOVA. 
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Figure 4.3 Comparison of the m.5024C>T mutation level in different tissues/organs between 10-week 
and 50-week tRNAAla mutant mice. The heteroplasmy level of each tissue homogenate was measured 
by pyrosequencing. The number of mice for the analysis is tabulated in Table 4.1. SI, small intestine; 
SM, smooth muscle; E, epithelium; SKM, skeletal muscle. **, P < 0.01. 
 
4.4.2 Assay verification and data normalisation 
The data in this study show that the mutation level in the majority of the tissues was lower 
than that of the ear notch from the tRNAAla mutant mice (Figure 4.2); however, previous 
studies have shown that the heteroplasmy of various tissues was often higher than that of the 
tail obtained at three weeks (Kauppila et al., 2016). As the mutation level of the ear notch was 
measured by the pyrosequencing assay in the Max Planck Institute for Biology of Ageing, 
Cologne, Germany, whereas the data in this study were acquired using the assay of the 
Newcastle Wellcome Centre, this difference could be due to the variation between different 
Pyrosequencers and assays. To verify the pyrosequencing assay used in this study, I measured 
the heteroplasmy level in the ear notch using the same DNA that was used in the previous 
study and compared it to that measured by the Cologne assay. The mutation level in the ear 
notch of each mouse quantified by the Newcastle assay was consistently slightly lower than 
that quantified by the Cologne assay (Figure 4.4), which explains the difference in the 
findings (mean of difference with standard deviation: 3.71 ± 1.13; p < 0001, paired t-test). 
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The other concern is that the difference in the initial mutation burden of the mice might affect 
the comparison of the heteroplasmy level in different tissues between the 10-week and 50-
week mutant mice. In the blood of the patients with different mutation burdens, a substantial 
variation was observed in the age-related change in the m.3243A>G heteroplasmy (Grady et 
al., 2018). In addition, the loss of the m.5024C>T mutation in the blood of the tRNAAla 
mutant mice was notably different between the mice with high and low tail heteroplasmy 
level (Kauppila et al., 2016). Although the mice at different ages that were examined in this 
study all carried high levels of the mutation in their ear notch (putative original mutation 
level), the remaining variations in the heteroplasmy of the ear notch may still affect the 
analysis. Therefore, I normalised the data by subtracting the heteroplasmy level of the three-
week ear notch from the mutation level of each tissue collected when they were culled, which 
was then compared between each mouse (Figure 4.5). In this way, the mutation level of the 
tissue from each mouse was normalised relative to its own initial heteroplasmy level.  
 
 
Figure 4.4 Comparison of the pyrosequencing assays used in the Max Planck Institute for Biology of 
Ageing, Cologne, Germany and the assay used in Wellcome Centre for Mitochondrial Research, 
Newcastle, UK. The same DNA was used for both assays, which was extracted from the three-week ear 
notch of seven 10-week tRNAAla mutant mice by Dr James Stewart.  
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Figure 4.5 Diagram of the normalisation methodology of the initial mutation burden. For each tRNAAla 
mutant mouse, the heteroplasmy level in each tissue relative to the initial mutation burden (∆mut% 10 
weeks or 50 weeks) was normalised by subtracting the mutation load in the three-week ear notch from 
that in each tissue. The change in the mutation level from 10 weeks to 50 weeks in each tissue was 
calculated by subtracting the “∆mut% 10 weeks” from the “∆mut% 50 weeks”. 
  
130 
 
4.4.3 Changes in the mutation loads in different tissues over time 
The mutation level of each tissue collected from different tRNAAla mutant mice at 10 weeks 
and 50 weeks relative to their ear notch heteroplasmy was determined and compared (Figure 
4.6), from which the change in the mutation load in each tissue with age was calculated 
(Figure 4.5 and Figure 4.7). This revealed a significant age-related decline in the 
heteroplasmy level in some canonical mitotic tissues, such small intestinal epithelium (-
13.5%, p < 0.001), the pyloric epithelium (-7.2%, p < 0.05) and the spleen (-3.37%, p < 0.05) 
(unpaired t-test) (Figure 4.7). In contrast, the mutation load slightly drifted up in the kidney 
(3.6%) and the gastric smooth muscle (3.83%) (p < 0.05, unpaired t-test) (Figure 4.7). The 
heteroplasmy levels in the other tissues/organs, including the post-mitotic heart, skeletal 
muscle, intestinal smooth muscle and brain remained stable from 10 weeks to 50 weeks 
(Figure 4.7). Surprisingly, the mutation level in the putatively mitotic epithelium of the gastric 
fundus did not decrease with age (Figure 4.7).  
 
 
Figure 4.6 Comparison of the mutation levels in various tissues/organs of 10-week and 50-week tRNAAla 
mutant mice relative to the heteroplasmy of their three-week ear notches. The number of mice for the 
analysis is concluded in Table 4.1. SI, small intestine; SM, smooth muscle; E, epithelium; SKM, skeletal 
muscle. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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Figure 4.7 Changes in the mutation level in different tissues/organs of the tRNAAla mutant mice from 10 
weeks to 50 weeks. Tissues/organs were classified into “mitotic”, “combination” and “post-mitotic” 
based on the main cell type in the tissue/organ and the general beliefs in their regeneration capability. 
The number of mice for the analysis is summarised in Table 4.1. SI, small intestine; SM, smooth muscle; 
E, epithelium; SKM, skeletal muscle. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
 
4.4.4 Distribution of the m.5024C>T mutation in intestinal crypts and smooth muscles 
To determine the distribution of the m.5024C>T mutation in the intestinal crypts and the 
smooth muscle of the tRNAAla mutant mice and whether it mimics that in the patients with 
mt-tRNA mutations (Chapter 3), I laser-microdissected individual crypts and patches of the 
smooth muscle fibres from the tRNAAla mutant mice and measured their heteroplasmy levels 
using pyrosequencing. Mice aged 10 weeks and 50 weeks were investigated, and each age 
group included two mice with intermediate-high (60% - 70%) and four mice with high (79% - 
80%) mutation loads in the ear. Statistical analysis confirmed the match of the heteroplasmy 
level in the intestinal smooth muscle (no difference in the mean and variation between two 
populations, unpaired t-test) (Figure 4.8). 
The study of the individual mice showed that in the 10-week tRNAAla mutant mice, the 
average mutation level of the intestinal crypts was similar to or slightly lower than that of the 
smooth muscle (mean difference ≈ 10%) (Figure 4.9), whereas, in 50-week mutant mice, the 
mean heteroplasmy level in the crypts was significantly lower compared with the smooth 
muscle (mean difference ranging from 16.84% to 25.70%) (Figure 4.10). This is consistent 
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with the results of the tissue homogenate (Figure 4.2). In addition, the single crypt analysis 
showed that the variation in the mutation level of each crypt in individual 50-week mouse 
(SD ranging from 5.4 to 8.2) (Figure 4.10) was markedly larger compared with that in 
individual 10-week mutant mice (SD ranging from 2.4 to 3.8) (Figure 4.9). The statistical 
analysis on the pooled data of all the 10-week and 50-week mice confirmed the findings of 
the individual mouse investigation discussed above showing (1) a notable decrease in the 
heteroplasmy level in the intestinal epithelium from 10 weeks to 50 weeks (mean difference = 
14.67%, p < 0.0001, one-way ANOVA with Tukey’s multiple comparison test); (2) a tight 
distribution of the mutation in individual crypts of the 10-week mice and (3) a scattered 
mutation distribution in the 50-week crypts (difference in SD = 10.78, p< 0.0001, unpaired t-
test with F-test) (Figure 4.8). The mutation load of some crypts dropped to 3% in 50-week 
mice, but no crypts harbouring the mutation higher than 83% heteroplasmy was found in mice 
at either age (Figure 4.8). The same maximum threshold also applied to the smooth muscles 
(Figure 4.8).  
Of note, in two 10-week mice with intermediate-high mutation level in the ear, the 
heteroplasmy levels in single crypts followed a normal distribution with the means similar to 
the mutation load in their smooth muscle and the three-week ear notch, indicating that the 
heteroplasmy level drifted evenly in both directions (Figure 4.9, E and F). In contrast, in 10-
week mice with high mutation load in the ear, the populations of the crypt heteroplasmy 
deviated from the muscle heteroplasmy (Figure 4.9, A-D), which became obvious in all 50-
week mice (Figure 4.10). This difference in the distribution of the mutation between the 10-
week mice with different initial mutation burdens prompted me to investigate the association 
between the rate of the losing the m.5024C>T mutation in the intestinal epithelium and the 
original mutation burden in the tRNAAla mice. The former factor was reflected by the 
difference in the mutation level between the intestinal epithelium and the three-week ear 
notch of each mouse. However, no correlation was found between the loss rate of the 
mutation and the initial mutation burden in either 10-week (p = 0.36) or 50-week (p = 0.75) 
tRNAAla mice (Spearman’s rank correlation analysis) (Figure 4.11).  
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Figure 4.8 Comparison of the distribution of the m.5024C>T mutation in individual crypts and smooth 
muscle areas of the small intestines from the 10-week and 50-week tRNAAla mutant mice. Single crypts 
and small areas of smooth muscles of the small intestines were laser-cut, collected and lysed to extract 
DNA. Pyrosequencing was performed using the DNA to measure the mutation level in the tissue. n (10-
week crypts) = 60, n (50-week crypts) = 69, n (10-week muscle areas) = 59, n (50-week muscle areas) 
= 66; ****, P < 0.0001. 
 
Figure 4.9 Quantification of the m.5024C>T heteroplasmy level in individual small intestinal crypt/areas 
of smooth muscles of each 10-week tRNAAla mutant mice. The number of the crypts/muscle areas for 
the analysis is summarised in Table 4.2. *, P < 0.05; **, P < 0.01. 
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Figure 4.10 Quantification of the m.5024C>T heteroplasmy level in individual small intestinal 
crypt/areas of smooth muscles of each 50-week tRNAAla mutant mice. The summary on the number of 
the crypts/muscle areas for the analysis is in Table 4.2. *, P < 0.05; **, P < 0.01. 
 
 
Figure 4.11 Associations between the initial mutation burden and the rate of losing the m.5024C>T 
mutation in the (A) 10-week and (B) 50-week tRNAAla mutant mice. The loss rate of the mutation in 
each mouse is specified as the difference in the heteroplasmy level between the epithelium of the small 
intestine and the ear notch obtained at 3 weeks. Each square represents an individual mouse. n (10-week 
mice) = 7, n (50-week mice) = 6. 
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4.4.5 Distribution of m.5024C>T mutation in gastric units and smooth muscles 
As the heteroplasmy level changed differently in the homogenate of the fundic and the pyloric 
epithelium of the stomach from the tRNAAla mutant mice (Figure 4.7), I investigated the 
distribution of the mutation in the gastric epithelium of the 50-week mutant mice by 
quantifying the heteroplasmy in laser-microdissected single units of the gastric fundus and 
pylorus using pyrosequencing. Analysis of individual mice showed no difference in the mean 
heteroplasmy level between the fundic epithelium and gastric smooth muscle (Figure 4.12), 
confirming the previous study on tissue homogenate (Figure 4.2B). In addition, it revealed 
that the m.5024C>T mutation was tightly distributed in the fundic units,  regardless of the 
initial mutation burden of the mice (Figure 4.12), with notably less variation compared with 
that in the pyloric units (Figure 4.13, Figure 4.14A and B) and intestinal crypts (Figure 4.10). 
The highest heteroplasmy level in the fundic units was 86% (Figure 4.14C), which is higher 
than that in the pyloric units (82%) and intestinal crypts (83%) (Figure 4.14C and Figure 4.8), 
indicating different tolerance to the mutation even in the same type (epithelial) of the tissue. 
Analysis of the collective data of all 50-week tRNAAla mutant mice confirmed (1) a trend of a 
lower mutation level in the pyloric epithelium compared with the fundic epithelium and (2) a 
significant larger variation in the distribution of the mutation in individual pyloric units 
compared with that in individual gastric units of the fundus (difference in SD = 7.70, p< 
0.0001, unpaired t-test with F-test) (Figure 4.14). It is worth mentioning that there were only 
three mice containing pyloric epithelium in their tissue sections and more mice should be 
included in the further study of this topic. 
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Figure 4.12 Heteroplasmy levels in individual fundic units compared with the smooth muscle fibres of 
the stomach from the 50-week tRNAAla mutant mice. The number of the analysed gastric units of the 
fundus and the smooth muscle areas is summarised in Table 4.2. E, epithelium. 
 
 
Figure 4.13 The m.5024C>T mutation level in individual pyloric units of the stomach and gastric 
smooth muscle of tRNAAla mutant mice. The quantity of the analysed gastric units of the pylorus and 
the smooth muscle areas is concluded in Table 4.2. **, P < 0.01. 
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Figure 4.14 Comparison of the heteroplasmy level between individual fundic and pyloric units, and 
gastric smooth muscles of the 50-week tRNAAla mutant mice. (A) (B) show the data of two mice with 
both fundic and pyloric epithelium in the tissue samples. Figure (C) shows the pooled data of all 50-
week mice whose stomachs were examined. n (fundic units) = 60, n (pyloric units) = 30, n (smooth 
muscle areas) = 70; *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
 
4.5 Discussion 
The establishment of the mt-tRNAAla mutant mouse model with the heteroplasmic pathogenic 
m.5024C>T mutation is crucial to the investigation of the mechanism and the pathogenesis of 
mtDNA disorders. In addition, a selective loss of the inherited m.5024C>T had been 
previously reported in the mitotic blood of the mice with high mutation load in the tail, 
suggesting this mouse model could be potentially valuable for studying the dynamics of 
mtDNA heteroplasmy in mtDNA disease progression, including age-related mitotic 
segregation and tissue-specific distribution of mtDNA mutations. Furthermore, these mice 
could be useful for studying the mechanism of selection against inherited mtDNA mutations, 
which might reveal the cause of the difference in the selective pressure on inherited and 
somatic mtDNA mutations, and benefit our understanding of stem cell physiology and ageing. 
All of these potential applications need to be substantiated through a thorough genetic 
characterisation of the tRNAAla mutant mice in terms of the dynamics of mtDNA 
heteroplasmy with age. In this study, I have accomplished this by determining the 
heteroplasmy level in different tissues/organs of the tRNAAla mutant mice at two stages of 
lifespan and investigating the distribution of the m.5024C>T mutation in monoclonal 
intestinal crypts and gastric units that are regularly renewed by gastrointestinal stem cells.  
The m.5024C>T is homogeneously distributed in various tissues/organs of the young (10-
week) tRNAAla mutants, which becomes more heterogeneous with age, showing a detectable 
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lower mutation level in some mitotic tissues/organs, such as the spleen and the small 
intestinal epithelium, compared with the post-mitotic tissue in the 50-week mice. This is 
consistent with the reports of the non-random distribution of the m.3243A>G and the 
m.8344A>G mutation in different tissues of the adult patients (Larsson et al., 1992; Chinnery 
et al., 1999). The difference in the distribution of the mutation in tissue between the young 
and old mice is able to account for the effect of age on the development of the phenotypes in 
patients with mtDNA disease, where more symptoms involving mitotic tissues are observed 
in paediatric patients compared with adult patients who have symptoms mainly in post-mitotic 
organs (Taylor and Turnbull, 2005). Moreover, in both young and old tRNAAla mutant mice, 
the high mutation loads in the kidney, pancreas, lung and liver that are similar to those in 
post-mitotic muscle and brain correlate with the renal, endocrinal, respiratory and hepatic 
symptoms in patients with mtDNA disease (Taylor and Turnbull, 2005). 
The comparison between the young and the old tRNAAla mutant mice regarding the 
heteroplasmy level in each tissue that is normalised by the initial mutation burden reveals a 
steady mutation level in the majority of the post-mitotic tissues with age, including the brain, 
heart, skeletal muscle and intestinal smooth muscle, in contrast to a significantly decreased 
mutation loads in the mitotic spleen, the epithelium of the gastric pylorus and the small 
intestine, suggesting the selection against the m.5024C>T mutation in the mitotic tissue of the 
tRNAAla mutant mice. This is in accordance with the selective loss of the m.3243A>G mt-
tRNA point mutation in mitotic blood and epithelial tissues in patients (discussed in Chapter 
3) (Olsson et al., 2001; Frederiksen et al., 2006; de Laat et al., 2012; Grady et al., 2018). The 
strong selection against the m.5024C>T mutation only shows in the mitotic tissue that is 
rapidly renewed by somatic stem cells, whereas in organs that contain a mix of mitotic and 
post-mitotic tissues or/and are in a mitotically quiescent status physiologically, such as the 
kidney (Benigni et al., 2010), pancreas (Zhou and Melton, 2018), lung (Kotton and Morrisey, 
2014) and liver (Forbes and Newsome, 2016), the age-related selective loss is undetectable. 
This possibly accounts for the emerging or sustained symptoms relevant to these organs in 
patients with age (Taylor and Turnbull, 2005). The heteroplasmy level of the kidney and the 
gastric smooth muscle in the tRNAAla mutant mice slightly drifted up from 10 weeks to 50 
weeks, possibly as a result of the clonal expansion (Elson et al., 2001), but this process is not 
obvious in these mice, as the rest of the post-mitotic tissues/organs consistently shows no age-
dependent change in their mutation loads. 
The genetic analysis of the single intestinal crypt demonstrates a tight distribution of the 
m.5024C>T mutation in individual crypts of the young mice. In contrast, the old tRNAAla 
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mutant mice show a considerable variation in the heteroplasmy level between individual 
crypts with some crypts harbouring extremely low levels of the mutation (≈ 3%), suggesting 
the involvement of stem cells. The skewed population of the crypt heteroplasmy with the 
mean deviating from the heteroplasmy of the three-week ear notch in the old mutant mice and 
an upper threshold of the mutation (≈ 83%) found in the intestinal crypts suggest the selection 
against the m.5024C>T mutation in the intestinal epithelium prevents the mutation level from 
drifting above the limit. These findings are analogous to the case in the patients with inherited 
m.3243A>G mutation (Chapter 3).  
The genetic upper limit of the mutation load in crypts (≈ 83%) is different from the 
histochemical threshold of COX deficiency in the intestinal epithelium (≈ 70%) (Baines, 
2014), suggesting that the biochemical defect does not solely regulate the elimination of the 
mutation. The similar distribution of the m.5024C>T in individual intestinal crypts and 
pyloric units implies that different GI epithelial tissues might share the same mechanism of 
the selective loss. In addition, the investigation of the individual mouse of two age groups 
with different initial mutation burdens delineates a gradual process of the segregation of the 
m.5024C>T mutation in individual crypts over time. The tight normal distribution of the 
heteroplasmy in the crypts with the mean value the same as that of the smooth muscle and the 
three-week ear notch in two young tRNAAla mutant mice with intermediate-high mutation 
burdens suggests that all the intestinal crypts initially harbour the same quantity of mutations 
which segregate symmetrically to both directions with age until they meet the limit where the 
selection arrests this process.  
The only mitotic tissue that does not have a detectable selective loss of the m.5024C>T 
mutation in the tRNAAla mutant mice is the epithelium of the gastric fundus. This is 
unexpected, as the fundic epithelium is regularly renewed by gastric stem cells that are 
primarily located in the isthmian area of a gastric unit (Hoffmann, 2008). In contrast, the loss 
of the m.5024C>T mutation was observed in the antral epithelium of the gastric pylorus, 
revealing a difference in the selective pressure within the different epithelial tissues. The 
fundic and pyloric units have different cell components and are morphologically and 
functionally distinct (reviewed in 1.7.2 of Chapter 1). Many reasons could potentially account 
for the difference in the selection between them. One likely explanation is that the turnover 
rate of the fundic epithelium is much longer than that of the antral epithelium (Hansen et al., 
1976; Patel et al., 1993; Hoffmann, 2008). In particular, the renewal timescale of the 
zymogenic cells that are the main cell type in the fundic gland is three times longer than that 
of the antral gland cells (Karam, 1999). Moreover, lineage tracing in hemizygous lacZ 
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transgenic mice with induced mutations that can hamper the expression of lacZ enzyme shows 
that despite homogeneous stem cell populations that lack lacZ activity, the mature parietal and 
zymogenic cells with normal lacZ function can last for a long time, resulting in the mosaic 
lacZ activity in some fundic units (Bjerknes and Cheng, 2002). Hence, though the gastric 
stem cells undergo a monoclonal conversion that might have lost the mutation (Thompson et 
al., 1990; Nomura et al., 1998; Bjerknes and Cheng, 2002), the heteroplasmy level of single 
fundic units can still be enormously affected by the slowly renewed mature glandular cells 
with high levels of mutated mtDNA. The difference in the heteroplasmy in the two epithelial 
tissues of the stomach with comparatively similar unit structure but different turnover rates 
suggests the involvement of transit-amplifying cells and differentiated epithelial cells in the 
selective loss of the m.5024C>T mutation in the mitotic tissue of the tRNAAla mutant mice.  
This study shows that the loss of the m.5024C>T mutation is more evident in young mice 
with high initial mutation levels compared with those with intermediate-high mutation loads. 
This is compatible with the data of patients’ blood showing that most of the individuals with a 
heavy mutation burden in the first examination lost the m.3243A>G mutation in blood over 
time, whereas the heteroplasmy level does not tend to decrease in blood in those with the 
mutation load less than 20% (Grady et al., 2018). However, despite a trend of correlation 
between the initial mutation burden and the rate of losing the m.5024C>T mutation in the 
small intestinal epithelium of the 10-week mice, the 50-week mice do not show any such 
evidence. This may be due to the small numbers of mice in the study. Therefore, further 
investigations are required using more mice with low, intermediate and high mutation load in 
the three-week ear. 
 
4.5.1 Future work 
Here I have genetically characterised the tRNAAla mutant mouse model and demonstrated the 
dynamics of the m.5024C>T mutation in different tissues with age; however, the biochemical 
and histochemical consequence of the age-related change in the heteroplasmy level is 
unknown. It is interesting to study whether the phenotype of the mitotic tissue is reversible 
concomitant with the age-dependent decrease in the mutation load, which is observed in the 
blood of the patients with large-scale deletions (Larsson et al., 1990; McShane et al., 1991; 
Nørby et al., 1994). Hence, it is essential to determine the biochemical and histochemical 
phenotype in the intestinal epithelium that loses the mutation most rapidly among all mitotic 
tissues at multiple stages of the lifespan to validate whether this mouse model is 
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phenotypically ideal for studying the selection against inherited mtDNA mutations. This will 
be discussed in Chapter 5. 
Other questions that would be crucial to understanding the dynamics of mtDNA mutations 
and the tissue heterogeneity in mtDNA disease are what the loss rates of the mutation in 
different mitotic tissues are and whether they are consistent or variable with age. In this study, 
I have only characterised the mice at 10 weeks and 50 weeks. Answering these questions 
needs a further genetic characterisation of different mitotic tissues at multiple ages, for 
example, 30 weeks and 70 weeks. The subsequent establishment of the regression models 
using these data would reveal the relationship between the rate of losing the mutation and age.  
Many factors might be associated with the loss rate of the m.5024C>T mutation. The data in 
this study illustrate a potential relationship between the initial mutation burden and the rate of 
the selective loss in the intestinal epithelium of the 10-week tRNAAla mutant mice, which is 
overturned by the result showing they are not correlated in the 50-week mice. Nevertheless, a 
conclusion cannot be drawn considering the small number of mice included in the study that 
all carry similarly high levels of the mutation. Future work to elucidate this question should 
involve the investigations of an increased number of the tRNAAla mutant mice with different 
initial levels of mutated mtDNA, for instance, “< 20%”, “20% - 40%”, “40%-60%” and “> 
60%”. 
The different dynamics of the m.5024C>T mutation in the fundic and the antral epithelium 
with different turnover rates of the glandular cells in the mutants’ stomach suggests the 
contributions of transit-amplifying cells and differentiated epithelial cells to the loss of the 
inherited mutation in mitotic tissue in addition to that of the stem cells. It is undoubtedly 
crucial to investigate the mechanism underpinning this phenomenon. Cell proliferation and 
apoptosis manipulate the turnover the stem cell progenies, and mitochondria play an 
important role in their regulation (Lu et al., 2009; Mishra and Chan, 2014). In addition, 
studies have shown that apoptosis reacts differently to respiratory chain deficiency in normal 
ageing individuals and patients with mtDNA disease (Auré et al., 2006; Nooteboom et al., 
2010), suggesting that this difference might contribute to the difference in the selective 
pressure on the somatic and the inherited mtDNA mutations. Thus, it would be valuable to 
investigate the balance of the cell proliferation and apoptosis in the fast-renewing intestinal 
crypt using corresponding markers, such as Ki-67 and cleaved caspase-3, for 
immunofluorescence (Chapter 6). Meanwhile, it is essential to confirm the contribution of the 
stem cells in the process of losing the mutation by pyrosequencing individual stem cells that 
are isolated by fluorescence-activated cell sorting at different ages. 
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Finally, it would be worth thoroughly characterising the histochemical and biochemical 
phenotypes, mitochondrial proliferation and abnormalities of mitochondrial microstructure in 
different tissues of the tRNAAla mutant mice by sequential COX/SDH histochemistry, 
immunofluorescence and electron microscopy to verify whether this mouse model is ideal for 
studying the mechanism of mtDNA disease in other aspects. 
 
4.6 Conclusions 
In this study, I have genetically characterised tRNAAla mutant mice with the inherited 
m.5024C>T mutation and demonstrated the dynamics of this mutation in a variety of tissues 
with different regeneration capability. I have shown that the heteroplasmy levels remain 
steady with age in the majority of tissues/organs of the tRNAAla mutant mice that are post-
mitotic, contain post-mitotic cells or mitotically quiescent. In contrast, I have found a 
selective loss in the mitotic spleen, pyloric epithelium of the stomach and intestinal 
epithelium. Moreover, I have illustrated that the distribution of m.5024C>T mutation in the 
individual intestinal crypts of the tRNAAla mutant mice is very similar to what I found in the 
GI epithelium of patients with the m.3243A>G and the m.8344A>G mutation, which shows 
some crypts harbouring extremely low levels of the mutation and an upper threshold of the 
heteroplasmy level, suggesting the involvement of stem cells and a selective loss of the 
mutation above the upper limit. Furthermore, I have shown that the fundic unit of the tRNAAla 
mutant mice maintains the mutation load over time probably because of the low turnover rate 
of the differentiated glandular cells, suggesting the involvement of the progenies of stem cells 
in the process of losing the m.5024C>T mutation in mitotic tissue. These results have 
corroborated that the tRNAAla mouse model is genetically ideal for studying the mechanism 
underlying the selective pressure against the inherited mtDNA mutations. To date, this is the 
only mouse model of mtDNA disease that shows such tissue-specific distribution of the 
mutation and the age-dependent selective loss of the mtDNA mutation in mitotic tissue, which 
perfectly recapitulates the findings of the patients with certain mtDNA disease. 
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Chapter 5 Characterisation of the OXPHOS level in the gastrointestinal 
epithelium of the tRNAAla mutant mice 
5.1 Introduction  
As previously discussed in Chapter 3, I found a significantly lower mutation load of the 
m.3243A>G mt-tRNA point mutation in the mitotic gastrointestinal (GI) epithelium 
compared with that in the post-mitotic smooth muscle of patients with mtDNA disease. This 
correlated with normal COX activity and the protein level of respiratory chain (RC) 
complexes I and IV in the epithelium but defective COX function and decreased complex I 
protein subunit levels in the muscle. However, as it is a cross-sectional study, the effect of the 
age-dependent loss of inherited pathogenic mtDNA mutations on OXPHOS function needs 
further investigation.  
In Chapter 4, I have shown a significant decrease in the heteroplasmy of the m.5024C>T mt-
tRNA point mutation in the mitotic intestinal epithelium of the old tRNAAla mutant mice 
compared with the young mutants. Previously Dr Holly Baines has characterised COX 
activity in the colonic epithelium of the young and old mutant mice using sequential 
COX/SDH histochemistry. She found partial COX deficiency in the colonic epithelium of all 
tRNAAla mutant mice (Baines, 2014). Around a quarter of crypts (≤ 27%) were found to have 
defective COX activity (Figure 5.1) (Baines, 2014). However, complete loss of COX activity 
is rare: two thirds of the mutant mice with a high tail heteroplasmy level (≥ 60%) 
(representing the initial mutation load similar to the ear notch) did not have any crypts with 
complete COX deficiency; and a very low level of complete COX deficiency (≤ 5% crypts) 
was detected in the rest of the mice (Baines, 2014). The heteroplasmy level of the m.5024C>T 
mutation segregated with COX activity in the colonic crypts, where crypts with defective 
COX activity harbour high m.5024C>T heteroplasmy and those with normal COX function 
carry low levels of the mutation (Baines, 2014). This has confirmed the pathogenicity of the 
m.5024C>T mutation and its correlation with COX function in the tRNAAla mutant mice 
(Baines, 2014). Surprisingly, even with the lower mutation load in the colonic epithelium 
compared with the smooth muscle in the aged mutant mice, there was no difference in the 
percentage of the colonic crypts with COX defects, including both entire and partial COX 
deficiency, between the young and old mutant mice (Figure 5.1) (Baines, 2014). However, the 
percentage of COX defective colonic crypts did correlate with the tail heteroplasmy in the 
young but not the old mutant mice (Baines, 2014). Since the sequential COX/SDH assay is 
for determining COX enzyme function and is semi-quantitative, further characterisation of the 
protein expression of the RC complexes using immunofluorescence was required. Moreover, 
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it is unknown whether other fast-renewing tissue, for example, the epithelium of small 
intestine, has any change in OXPHOS function with age correlating with the decrease in the 
m.5024C>T heteroplasmy level.  
 
 
Figure 5.1 Defective COX activity in the colonic epithelium of the young and old tRNAAla mutant mice. 
Sequential COX/SDH histochemistry was carried out on colon sections of the 20-week and 70-week 
tRNAAla mutant mice. The percentage of COX defects is quantified as the ratio of the number of the 
COX defective crypts, including those with complete and partial loss of the COX activity, and the total 
number of colonic crypts (~500 crypts per sample). Raw data was obtained by Dr Holly Baines for the 
analysis (p = 0.15, unpaired t-test). 
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5.2 Aims 
This study aimed to investigate the effect of the age-related decrease in the heteroplasmy level 
of the m.5024C>T mutation on OXPHOS function in the gastrointestinal epithelium of 
tRNAAla mutant mice. This was achieved by detailed characterisation of OXPHOS protein 
expression, including: 
1. Determine COX activity in the small intestinal epithelium in the young (10 weeks) 
and old (50 weeks) mutant mice by sequential COX/SDH histochemistry. 
2. Determine COX activity in the epithelium of the gastric fundus and pylorus in the old 
mutant mice by sequential COX/SDH histochemistry for the reason that the age-
related dynamics of the m.5024C>T mutation in these epithelial cells are different 
compared with that in the intestinal epithelium and it is worth investigating whether 
biochemical phenotypes of these tissues reflect the difference at the genetic level.  
3. Determine the protein level of the respiratory chain complex I and IV, and the level of 
mitochondrial mass in the colonic epithelium of young and old mutant mice by 
immunofluorescence. 
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5.3 Methods 
5.3.1 Sequential COX/SDH histochemistry and semi-quantification of COX defects 
Frozen small intestines of seven 10-week tRNAAla mutant mice and six 50-week mutants and 
stomach tissue of seven 50-week mice were sectioned in a cryostat at 10 µm. Each age group 
includes two mice with intermediately high ear m.5024C>T heteroplasmy (60% - 69%) and 
the remainder with high ear heteroplasmy (71% - 79%). COX and SDH histochemistry assays 
were optimised individually for use in the sequential COX/SDH assay. The optimisation 
strategy is shown in Figure 5.2. For the COX assay, sections were incubated in the COX 
solution for a sequential period of time (11 min, 15 min, 19 min, 22 min and 25 min). For 
SDH assay, sections were incubated in the SDH solution for 5 min, 10 min, 15 min, 20 min 
and 25 min. The timespan for each assay that provided cells with strong labelling and avoided 
over-pigmentation was selected for the sequential assay. The optimal incubation time for the 
COX/SDH assay is cell-specific, which is summarised in Table 2.6.  
Sequential COX/SDH histochemistry was performed on sections. Crypts were analysed in a 
semi-quantitative manner using the following criteria: “complete deficiency” (blue), “partial 
deficiency” (bluish brown or containing blue/bluish brown cells) and “normal activity” 
(brown). Longitudinally and obliquely sectioned epithelial tissue, where the small intestinal 
crypts at the base of the mucosa could be identified, was included for the semi-quantification. 
A total number of approximately 120 crypts were examined in each mouse. The number of 
crypts with defective COX activity, including crypts with complete COX deficiency and 
partial COX deficiency, were counted. The percentage of crypts with COX defects was 
calculated as the number of COX defective crypts over the number of total examined crypts. 
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Figure 5.2 Optimisation of the incubation time for COX and SDH assays. For the COX assay, sections 
of the fundic epithelium were incubated in the COX solution for (A) 11 min, (B) 15 min, (C) 19 min, 
(D) 22 min and (E) 25 min. (A) 11 min was selected for the sequential COX/SDH assay. For the SDH 
assay, sections were incubated in the SDH solution for (A) 5 min, (B) 10 min, (C) 15 min, (D) 20 min 
and (E) 25 min. (A) 5 min was chosen for the final sequential assay. Scale bar = 200 µm. 
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5.3.2 Immunofluorescence 
Formalin-fixed and paraffin-embedded (FFPE) colon tissue (4 µm) from tRNAAla mutant 
mice was sectioned by myself for the optimisation of the immunofluorescence (IF) assay and 
by Anna Smith for final experiments. The optimised combination of antibodies in the IF study 
is in Table 5.1. Five mutant mice with high m.5024C>T heteroplasmy in the ear (71% - 80%) 
were examined in each age group (10 weeks and 50 weeks) and compared with three age-
matched wild-type mice. Information about the mice included in the IF study and the number 
of colonic crypts scrutinised is summarised in Table 5.2. Due to a shortage of frozen colon 
tissue from the 10-week tRNAAla mutant mice for determining the mutation level in the 
colonic epithelium, the heteroplasmy in intestinal crypts used in the analyses of this study was 
the average mutation level of individual small intestinal crypts from Chapter 4. Paired t-tests 
showed no difference in the mutation load in the small and large intestinal crypts in five 50-
week mutants, proving the reliability of substituting heteroplasmy of small intestinal crypts 
for that of colonic crypts in the analyses (Figure 5.3).   
 
Antibody combination 
Primary antibody Secondary antibody Tertiary antibody 
Anti-NDUFB8 (ab110242) Biotin-XX (A10519) 
Streptavidin, Alexa Fluor 647 
conjugate (S21374) 
Anti-MTCO1 (ab14705) Alexa Fluor 546 (A21133) N/A 
Anti-TOM20 (ab186734) Alexa Fluor 488 (A21141) N/A 
Table 5.1 Information about the antibodies used for the immunofluorescence. Antibodies in the same 
row are the matching primary and secondary/tertiary antibodies. Details of each antibody and their 
optimised concentration are summarised in the Table 2.7 and Table 2.8. 
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10 weeks 
Mouse ID Ear mut% Intestinal E mut% N of crypts 
B933 79 70.63 150 
B934 77 63.69 148 
B938 77 67.57 154 
B945 74 68.71 152 
B948 71 58.17 146 
B988 WT n/a 144 
B994 WT n/a 142 
B995 WT n/a 145 
50 weeks 
Mouse ID Ear mut% Intestinal E mut% N of crypts 
372 80 55.99 158 
365 79 55.04 157 
353 73 51.49 147 
370 73 55.07 145 
369 71 51.78 135 
24283 WT n/a 155 
24769 WT n/a 126 
WT210 WT n/a 144 
Table 5.2 A summary of the mouse information and the number of examined colonic crypts in each 
mouse in the immunofluorescence study. Colon tissue of five tRNAAla mutant mice with high 
m.5024C>T heteroplasmy and three age-matched wild-type mice in each group was used. Mut, 
mutation. N, number. 
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Figure 5.3 Mutation load in the crypts of small and large intestines from five 50-week tRNAAla mutant 
mice (mouse 351 353 365 369 and 373). Heteroplasmy of 10 small and large intestinal crypts of each 
mouse was determined by pyrosequencing and averaged for comparison. Each square signifies a mouse.  
 
5.3.3 Imaging and statistical analysis 
As the 10-week and the 50-week mouse tissue was fixed by Dr Laura Greaves and Dr James 
Stewart respectively, the fixation conditions of the tissue were slightly different. All blocks of 
tissue were sectioned and collected using adhesive glass slides by Anna Smith. However, 
possibly due to different fixation conditions, under an epifluorescence microscope, some cells 
of the 50-week sections slightly floated above the focal panel of the majority of the cells. To 
fix this issue, sections that were labelled by fluorophore-conjugated antibodies were imaged 
using an upright Confocal Laser Microscope System in a z-stack fashion, which covered a 
range of focal panels (detailed in 2.9.3). The stacked images were then incorporated to acquire 
the maximum projection at each pixel site, which represents the pixel intensity at the optimal 
focus of the tissue at each pixel point. Individual crypts were drawn on the images as regions 
of interest (ROI) covered with a mask defining the minimum pixel intensity to remove the 
lumen of the crypts. Mean pixel intensity within the ROI was measured using NIS-Element 
AR Imaging software (detailed in 2.9.3).  
Three independent experiments were performed on non-serial sections to comprehensively 
determine the level of RC complexes and mitochondrial mass in the colonic crypts of the 
tRNAAla mutant mice. The raw data of the pixel intensity in each crypt was background 
corrected and log-transformed to fit the R-script written by Dr John Grady for calculating z-
scores (specified in 2.12.1). Transforming data into z-scores allows the integration of the data 
of the three experiments. The z-scores of the absolute protein level of RC complexes and the 
level of Tom20 in individual crypts were calculated according to the parameters (mean and 
SD) of the control population that was established by randomly sampling an equal number of 
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measurements of the 10-week wild-type controls (described in 2.12.1). For calculating the z-
scores of the relative level of RC complexes to the mitochondrial mass marked by Tom20 
antibodies, a linear regression was established between the data of the RC complexes and 
Tom20 to provide a predicted level of RC complexes based on the Tom20 level. An estimate 
of the deviation of the level of RC complexes against Tom20 level from the predicted level 
was presented as the z-scores. The classification of the z-scores is shown in Table 5.3, which 
is based on the confidence level (detailed in section 2.12.1).  
To determine the relationship between age, mouse genotype, the absolute/relative level of 
complex I/IV and the level of mitochondrial mass, mixed-effect generalised linear models 
were established by Dr Alasdair Blain. Random factors accounting for the variation between 
experimental sets and mouse individuals were added to enable the best fitness of the model 
(tested using Akaike Information Criterion).  
 
Classification  z-score boundaries  
Tom20  
Very low  z < -3.0  
Low  -3.0 ≤ z < -2.0  
Normal  -2.0 ≤ z ≤ 2.0  
High  2.0 < z ≤ 3.0  
Very high  3.0 < z  
NDUFB8 and MTCO1 
Positive  -2.0 ≤ z  
Intermediate positive  -2.6 ≤ z < -2.0  
Intermediate negative  -3.3 ≤ z < -2.6  
Negative  z < -3.3  
Table 5.3 Categorisation of the boundaries of the z-score. The z-scores of the absolute level and the 
relative level of RC complexes share the same classification. 
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5.4 Results 
5.4.1 Defective COX function in the small intestine and stomach 
Previously, Dr Holly Baines found no difference in the percentage of the COX defective 
colonic crypts between the young and old tRNAAla mutant mice (Baines, 2014). As the 
m.5024C>T mutation load significantly decreased in the small intestinal epithelium of the old 
mutants compared with the young mice (Chapter 4), I performed sequential COX/SDH 
histochemistry on the sections of the small intestinal crypts of the 10-week (n = 7) and 50-
week (n = 6) tRNAAla mutant mice to investigate whether there is any change in the COX 
function concomitant with the reduced mutation load. Each age group consisted of two mice 
with intermediately high heteroplasmy in the ear (60% - 69%) and the remaining mice with 
high ear heteroplasmy (71% - 79%). Villi of the small intestine were excluded since the cells 
of each villus stem from several stem cells niches, whereas each crypt comprises of a single 
stem cell niche that undergoes monoclonal conversion, a few Paneth cells and the transit-
amplifying cells that originate from these stem cells (Barker, 2014). Partial COX deficiency 
(bluish brown crypts or crypts containing blue/bluish brown cells) was detected in all the 
mutant mice, but complete COX deficiency (blue crypts) was barely observed in the intestinal 
epithelium (<2%) (Figure 5.4A). No difference in the percentage of the COX-defective small 
intestinal crypts, including those with complete and partial loss of the COX activity, was 
found between the 10-week and 50-week tRNAAla mutant mice (Figure 5.4B). No correlation 
was found between the level of COX defects and the m.5024C>T heteroplasmy level in the 
ear or crypts in either 10-week or 50-week tRNAAla mutant mice (p > 0.05, Spearman’s rank 
analysis). 
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Figure 5.4 COX defects in the small intestinal epithelium of the 10-week and 50-week tRNAAla mutant 
mice labelled by sequential COX/SDH histochemistry. (A) Example images of COX defective crypts in 
the 10-week and 50-week mice with high and intermediately high ear heteroplasmy level. Black arrows 
indicate small intestinal crypts with partial COX deficiency that contain bluish brown or blue cells. Scale 
bar = 200 µm (B) Quantification of the percentage of the crypts with COX defect (entire and partial loss 
of COX activity). Seven 10-week mice (B933, B934, B938, B945, B948, B949 and B952) and six 50-
week mice (365, 353, 370, 369, 373 and 351) were included for statistical analysis. Each square 
represents a single mouse. 
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The mutation load of fundic epithelium remained high from 10 weeks to 50 weeks in the 
tRNAAla mutant mice, which was in contrast to the pyloric epithelium in which the mutation 
level decreased with age (Chapter 4). To ascertain whether the genetic finding is correlated 
with the COX activity in these two types of epithelial tissues in the stomach, I performed 
sequential COX/SDH histochemistry on the sections of gastric fundus (n = 6) and pylorus (n 
= 3) of the 50-week tRNAAla mutant mice. Gastric epithelium of the 10-week mutant mice 
was not examined in this study, since the mutation level was similar in all tissues of the 10-
week mutants. Both the fundic and pyloric units of all examined mice contained many evident 
blue cells that had a complete absence of COX activity (Figure 5.5 and Figure 5.6), which is 
in contrast to the milder COX defect in the small intestinal crypts with lower mutation load 
(Figure 5.4). Due to the distinct cell component between the fundic, pyloric and small 
intestinal epithelium, the semi-quantification by subjective colour differentiation and manual 
counting would be unreliable. The indefinite boundaries of the fundic units would further 
lessen the accuracy of the semi-quantification. Thus, semi-quantification was not carried out 
on the images of the fundic and pyloric epithelium. Quantitative immunofluorescence would 
be required for precise determination of the OXPHOS level in these tissues in the future. 
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Figure 5.5 Images showing COX deficiency in the epithelium of the gastric fundus in the 50-week 
tRNAAla mutant mice. Sections were labelled using sequential COX/SDH assay. Six mice were 
examined: (A) 365 (ear m.5024C>T% = 79%), (B) 353 (ear m.5024C>T% = 73%), (C) 370 (ear 
m.5024C>T% = 73%), (D) 369 (ear m.5024C>T% = 71%), (E) 373 (ear m.5024C>T% = 69%) and 
(F) 351 (ear m.5024C>T% = 71%). Cells with complete COX deficiency are blue (red arrows), and 
those with partial COX deficiency are bluish-brown (yellow arrows). Scale bar = 200 µm. 
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Figure 5.6 Images showing the COX defects in the epithelium of the gastric pylorus of the 50-week 
tRNAAla mutant mice. Sequential COX/SDH assay was performed on the sections. Three mice were 
examined: (A) 372 (ear m.5024C>T% = 80%), (B) 365 (ear m.5024C>T% = 79%) and (C) 353 (ear 
m.5024C>T% = 73%). Cells that entirely lost COX function are blue (red arrows), and those with 
partial COX deficiency are bluish-brown (yellow arrows). Scale bar = 200 µm. 
  
157 
 
5.4.2 Quantification of absolute level of RC complexes in the colonic crypts 
5.4.2.1 Absolute level of complex I 
As the semi-quantification of COX function was based on subjective assessment of COX and 
SDH labels, I performed a more reliable quantitative immunofluorescence to investigate the 
expression of RC complexes on sections of the colonic epithelium of the tRNAAla mutant 
mice. I performed three independent experiments on non-serial colon sections of 10-week and 
50-week wild-type (n = 3 in each age group) and tRNAAla mutant mice (n = 5 in each age 
group) and examined approximately 150 crypts in total in each mouse. The 10-week and 50-
week mutants both displayed complex I deficiency (labelled by NDUFB8 antibody) compared 
with the age-matched wild-type controls (Figure 5.7 complex I panel). The 10-week mice 
displayed a general decrease in complex I expression, whereas the 50-week mice had some 
crypts with strong complex I labelling and some crypts that had completely lost complex I 
expression (Figure 5.7 complex I panel), possibly as a result of the monoclonal conversion. 
Pixel intensity of individual crypts was measured in each independent experiment, which was 
transformed into z-scores and pooled for statistical analysis (detailed in 5.3.3). The level of 
RC complexes was classified into four groups: “positive”, “intermediate positive”, 
“intermediate negative” and “negative” with the boundaries corresponding to 95%, 99% and 
99.9% confidence level (detailed in 5.3.3). Categorical quantification of the absolute protein 
level of complex I showed mild complex I deficiency in the 10-week mutant mice (3.20% CI-
negative and 3.33% CI-intermediate-negative) similar to that in the 50-week mutant mice 
(3.91% CI-negative and 3.37% CI-intermediate-negative crypts) (Figure 5.8A). Analysis of 
the z-score distribution revealed a higher median level of complex I in the 50-week mutants 
(median = 1.33) than the 10-week mutants (median = 0.44), suggesting an improvement of 
complex I expression in the mitotic colonic epithelium of the tRNAAla mutant mice with age 
(Figure 5.9B).  
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Figure 5.8 Quantification of the absolute complex I protein level (labelled by NDUFB8) in the colonic 
epithelium of the tRNAAla mutant mice. (A) Categorical z-scores of complex I levels in the tRNAAla 
mutants compared with the wild-type controls at 10 weeks and 50 weeks. The complex I level was 
classified as “positive”, “intermediate positive”, “intermediate negative” and “negative”. The 
boundaries of the z-scores for each category are summarised in the Table 5.3. (B) Whisker-and-box plot 
of the z-NDUFB8 showing the median and distribution of the complex I level in the colonic epithelium. 
Each point signifies a measurement of an individual crypt. The dotted lines are the boundaries for 
defining “intermediate negative” and “negative”. 
 
An overview of the absolute complex I level in individual mice is shown in Figure 5.9. 
Modelling of the whole dataset with factors “variation in experiment sets” and “variation in 
individual mice” included (detailed in 5.3.3) showed a negative linear relationship between 
the ear heteroplasmy and the z-scores of complex I in the colonic crypts of both 10-week (p < 
0.001) and 50-week (p < 0.001) mutants, indicating a decrease in the absolute complex I level 
in the colonic epithelium concomitant with an increase in the initial mutation load. The 
relationship was much stronger in the 10-week mice (r = 0.418) compared with the 50-week 
mice (r = 0.140), suggesting a weakened influence of the initial mutation burden m.5024C>T 
with age on the complex I level. In addition, it showed a weak negative linear relationship 
between the complex I level and the average mutation level in intestinal crypts (Table 5.2) in 
the 10-week mutants (r = 0.086, p = 0.013), which became stronger in the 50-week mutants (r 
= 0.117, p < 0.001), suggesting that the association of the mutation level and the absolute 
complex I level in the colonic crypts increased with age.  
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Figure 5.9 Quantification of the respiratory chain complex I level in the colonic epithelium of individual 
tRNAAla mutant mice. (A) Categorical z-scores of the complex I level. Complex I level was classified 
as “positive”, “intermediate positive”, “intermediate negative” and “negative”. The boundaries of the z-
scores for each category are summarised in the Table 5.3. (B) An overview of z-NDUFB8 showing the 
median and the distribution of the complex I level in the colonic epithelium. Each point represents a 
measurement of an individual crypt. The 10-week mutant mice, B933, B934, B938, B945 and B952 
carried 79%, 77%, 77%, 74% and 71% m.5024C>T in the ear respectively. The 50-week mutants, 372, 
365, 353, 370 and 369 carried 80%, 79%, 73%, 73% and 71% m.5024C>T in the ear respectively.  
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5.4.2.2 Absolute level of complex IV 
Since COX deficiency was observed in all the examined tRNAAla mutant mice, in addition to 
RC complex I, I also measured RC complex IV level (labelled by the MTCO1 antibody) in 
the colonic epithelium by quantitative immunofluorescence assay. I observed no difference in 
the complex IV level between the 10-week wild-type controls, 10-week tRNAAla mutants and 
50-week mutants, but a notably decreased complex IV level in the 50-week wild-type controls 
on the images (Figure 5.7 complex IV panel). Quantification of the z-scores revealed 10.59% 
complex IV-negative and 6.12% intermediate-negative colonic crypts in the aged controls 
(Figure 5.10A). In contrast, there were barely any crypts with a complex IV defect in either 
10-week (0.54% negative and 0.93% intermediate negative) or 50-week (0.67% negative and 
3.24% intermediate negative) tRNAAla mutants (Figure 5.10A). The distribution of the z-
MTCO1 showed that the median level of complex IV was slightly higher at 10 weeks than 50 
weeks in both controls and tRNAAla mutants (Figure 5.10B). The data of the 50-week wild-
type mice had a marked larger variation with the z-MTCO1 of numerous crypts below the 
“negative” line (< 3.3) (Figure 5.10B), suggesting an effect of ageing on OXPHOS function. 
This is in contrast to the other groups where the z-MTCO1 of most of the crypts was within 
the normal range (quartiles between -2 and 2) (Figure 5.10B).  
Individual mouse analysis confirmed that the absolute complex IV level was not affected in 
the 10-week mutant mice, and was slightly decreased in the 50-week mutants (Figure 5.11). In 
contrast, the categorical data showed a significantly reduced complex IV level in two aged 
wild-type mice (23.27% CIV-negative and 5.81% intermediate-negative crypts in 24283; 
6.25% negative and 11.81% intermediate negative in WT201), which was confirmed by the 
distribution data (Figure 5.11). No complex IV deficiency was found in the other 50-week 
wild-type mouse 24769. More aged wild-type mice will be included to confirm these findings 
in the future.  
These results indicate that the aged tRNAAla mutants with inherited m.5024C>T mutation did 
not display as pronounced a complex IV defect as the aged wild-type mice did. 
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Figure 5.10 Quantification of the respiratory chain complex IV level in the colonic crypts of the tRNAAla 
mutant mice. (A) Categorical z-scores of the complex IV level in the 10-week and 50-week tRNAAla 
mutants compared with the age-matched wild-type controls. The complex IV level was classified as 
“positive”, “intermediate positive”, “intermediate negative” and “negative”. The boundaries of the z-
scores for each category are summarised in the Table 5.3. (B) Whisker-and-box plot of the z-MTCO1 
showing the median and distribution of the complex IV level in the colonic crypts. Each point denotes 
a measurement of an individual crypt. The dotted lines are the limits for the “intermediate negative” and 
“negative” categories. 
 
The modelling demonstrated a linear relationship between the absolute level of complex IV in 
the colonic crypts and the ear heteroplasmy of the 10-week mutants (r = 0.164, p < 0.001) but 
not in the 50-week mutants (p > 0.05), suggesting a loss of influence of initial mutation 
burden on the absolute complex IV level with age in the colonic epithelium. In addition, the 
modelling revealed a stronger correlation between the absolute complex IV level and crypt 
heteroplasmy in the 50-week mutants (r = 0.142, p < 0.001) compared with the 10-week 
mutants (r = 0.081, p = 0.020), suggesting an age-related increase in the association of 
heteroplasmy with absolute complex IV level in the crypts. 
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Figure 5.11 Quantification of the absolute complex IV protein level in the colonic epithelium of 
individual mice. (A) Categorical z-scores of the absolute complex IV level. Complex I level was 
classified as “positive”, “intermediate positive”, “intermediate negative” and “negative”. The limits of 
the z-scores for each category are summarised in the Table 5.3. (B) An overview of z-MTCO1 showing 
the median and the distribution of the absolute complex IV level in the colonic crypts. Each point 
represents a measurement of an individual crypt. The 10-week mutant mice, B933, B934, B938, B945 
and B952 carried 79%, 77%, 77%, 74% and 71% m.5024C>T in the ear respectively. The 50-week 
mutants, 372, 365, 353, 370 and 369 carried 80%, 79%, 73%, 73% and 71% m.5024C>T in the ear 
respectively. The dotted lines are the boundaries for the classification of “intermediate negative” and 
“negative”. 
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5.4.2.3 Absolute OXPHOS level 
To investigate the total level of OXPHOS deficiency in the colonic epithelium of the tRNAAla 
mutant mice, profiles of RC complexes were plotted in Figure 5.12, where z-scores of the 
absolute level of complex I were drawn against those of the complex IV with the colour of the 
dots denoting the mitochondrial mass (MM) level. These results showed that isolated complex 
I deficiency (dots in the top left section) was the primary type of OXPHOS deficiency in the 
mutant mice with inherited m.5024C>T mutation, whereas isolated complex IV deficiency 
(dots in the bottom right section) was evident in the ageing wild-type mice (Figure 5.12). 
Most of the crypts with high MM level (orange and red for high and very high Tom20 level 
respectively) had normal OXPHOS function (dots in the top right section), regardless of the 
genotype and age, whereas complex IV defective crypts in the ageing wild-type mice had 
normal to low level of MM (beige, light blue and blue for normal, low and very low Tom20 
level) (Figure 5.12). 
Quantification of the total level of OXPHOS defect involved sorting the crypts into four 
groups: “complex I and complex IV both positive”, “isolated complex I defect”, “isolated 
complex IV defect” and “joint complexes I and IV defect”. The defective crypts were the 
pooled data of the crypts with intermediate-negative and negative RC complex level in the 
previous study of individual RC complexes. The proportion of OXPHOS defective crypts was 
the aggregative percentage of the crypts with isolated complex I or IV defect and joint defect. 
The analysis showed a slightly higher percentage of OXPHOS-defective colonic crypts in the 
50-week (9.84%) compared with the 10-week tRNAAla mutant mice (8.00%) (Figure 5.13A). 
In addition, the 50-week mutants had a small percentage of crypts with joint complex defects 
that was not observed in the 10-week mutants (Figure 5.13). Isolated complex I defect was the 
main type of OXPHOS defect in the tRNAAla mutant mice, whereas isolated complex IV 
defect was the primary phenotype of the aged wild-type mice (Figure 5.13).  
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Figure 5.12 Profiles of the level of the RC complexes and mitochondrial mass in the colonic crypts of 
the wild-type and tRNAAla mutant mice at 10 weeks and 50 weeks. Z-scores of NDUFB8 labelling 
complex I (horizontal axis) was drawn against the z-scores of MTCO1 labelling the RC complex IV 
(vertical axis). The colour indicates the classification of the Tom20 (marking MM) level: “very high” 
in red, “high” in orange, “normal” in beige, “low” in light blue and “very low” in blue. The boundaries 
for each class is summarised in Table 5.3. Each point signifies data of an individual crypt. 
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Figure 5.13 Absolute OXPHOS level in the colonic crypts of the (A) grouped and (B) individual 10-
week and 50-week tRNAAla mutant and wild-type mice. OXPHOS defect was classified into “both 
complex I and complex IV positive”, “isolated complex I defective”, “isolated complex IV defective” 
and “joint complex I and IV defective”. Z-scores of the absolute complex I/IV level below “-2.6” was 
defined as defects in the complex I and IV. The 10-week mutant mice include B933, B934, B938, B945 
and B952 with 79%, 77%, 77%, 74% and 71% m.5024C>T in the ear respectively. The 50-week mutants 
include 372, 365, 353, 370 and 369 with 80%, 79%, 73%, 73% and 71% m.5024C>T in the ear 
respectively. 
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The percentage of the OXPHOS-defective crypts in the 10-week mutants was correlated with 
the m.5024C>T heteroplasmy level in the three-week ear notch (presumed initial mutation 
load) (p = 0.03, rs = 0.975, Spearman’s rank correlation) (Figure 5.13B and Figure 5.14A). 
However, such a correlation was not found in the 50-week mutants (p = 0.43, Spearman’s 
rank correlation) (Figure 5.13B and Figure 5.14B). Additionally, no correlation between the 
percentage of the OXPHOS-deficient crypts and the crypt heteroplasmy level was found in 
the 10-week, the 50-week mutants and the pooled mice of both age groups.  
 
 
 
Figure 5.14 Correlation between the percentage of the OXPHOS-defective crypts and the m.5024C>T 
heteroplasmy level in the ear notch obtained at 3 weeks in the (A) 10-week and (B) 50-week tRNAAla 
mutant mice. The percentage of the OXPHOS defective crypts was the pooled data of the “isolated 
complex I/IV defective” and the “joint complex I and IV defective”. Each square represents an 
individual mutant mouse. Full line, p = 0.03; dotted line, p = 0.43, Spearman’s rank correlation. 
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5.4.3 Quantification of relative levels of RC complexes to mitochondrial mass 
5.4.3.1 Complex I level relative to mitochondrial mass 
Defects in RC complexes caused by inherited mtDNA mutations are often associated with 
mitochondrial proliferation (Egger et al., 1981; DiMauro et al., 1985; Moraes et al., 1992). To 
date, it is still unknown whether cellular function is affected by the total amount of RC 
complex proteins or the level relative to mitochondria mass in a cell. Thus, it is important to 
investigate the relative level of RC complexes against mitochondrial mass (MM). Tom20 is a 
nuclear-encoded peripheral subunit of the TOM (translocase of the outer mitochondrial 
membrane) complex for mediating the transportation of nuclear-encoded proteins into 
mitochondria (Yamano et al., 2008; Yamamoto et al., 2011), which is often used as a 
mitochondrial mass marker (Jourdain et al., 2013; Contino et al., 2017). Immunofluorescent 
co-labelling the RC complexes with the Tom20 antibody demonstrated a relative complex I 
deficiency in the colonic epithelium of the mutants in both age groups, and it was more 
pronounced in the 50-week mutants compared with the 10-week mutants (Figure 5.7 CI & 
Tom20 panel). Z-scores of the level of complex I/IV against Tom20 were calculated and 
categorised (specified in 5.3.3). Categorical data showed a slightly higher percentage of the 
crypts with relative complex I deficiency in the 50-week mutants (13.21% CI-negative and 
4.99% CI intermediate-negative crypts) compared with the 10-week mutants (10.00% CI-
negative and 6.27% CI-intermediate-negative) (Figure 5.15A). However, the median complex 
I level in the colonic epithelium of the 50-week mutants was slightly higher than that in the 
10-week mutants (median difference = 0.26) (Figure 5.15A). These analyses revealed more 
crypts with relative complex I deficiency to MM (Figure 5.15) rather than the absolute 
deficiency (Figure 5.8) in the tRNAAla mutant mice; however, they showed no pronounced 
difference in the relative complex I level between the 10-week and 50-week tRNAAla mutant 
mice.  
Data of the relative complex I level in individual mice is summarised in Figure 5.16. 
Modelling of the data showed a stronger linear relationship between the relative complex I 
level and the ear heteroplasmy in the colonic epithelium of the 10-week mutants (r = 0.394, p 
< 0.001) compared with the 50-week mutants (r = 0.102, p = 0.003). The relative complex I 
level also had a negative linear correlation with the crypt heteroplasmy in both 10-week (r = 
0.125, p<0.001) and 50-week (r = 0.105, p=0.002) tRNAAla mutant mice, though the 
relationships were weak. 
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Figure 5.15 Respiratory chain complex I level (labelled by NDUFB8) relative to the mitochondrial mass 
(labelled by Tom20) in the colonic epithelium of the tRNAAla mutant mice. (A) Categorical z-scores of 
the relative complex I level in the 10-week and 50-week tRNAAla mutants compared with the age-
matched wild-type controls. The relative complex I level was classified as “positive”, “intermediate 
positive”, “intermediate negative” and “negative”. The borders of the z-scores for each group is 
summarised in the Table 5.3. (B) Whisker-and-box plot of the z-NDUFB8/Tom20 showing the median 
and distribution of the relative complex I level in the colonic crypts in the mutants and controls. Each 
point signifies a measurement of a single crypt. The dotted lines are the boundaries for the categorisation 
of “intermediate negative” and “negative”. 
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Figure 5.16 Relative complex I level to the mitochondrial mass in the intestinal crypts of individual 
tRNAAla mutant mice. (A) Categorical z-scores of the complex I level (marked by NDUFB8) relative to 
MM (marked by Tom20). Relative complex I level was categorised as “positive”, “intermediate 
positive”, “intermediate negative” and “negative”. The borders for each category are summarised in the 
Table 5.3. (B) An overview of the continuous data showing the median and the distribution of the 
relative complex I level in the colonic epithelium. Each point is a read-out of a single crypt. The 10-
week mutant mice include B933, B934, B938, B945 and B952 (79%, 77%, 77%, 74% and 71% 
m.5024C>T in the ear respectively). The 50-week mutants include 372, 365, 353, 370 and 369 (80%, 
79%, 73%, 73% and 71% m.5024C>T in the ear respectively). 
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5.4.3.2 Complex IV level relative to mitochondrial mass 
Although the absolute complex IV level (labelled by MTCO1 antibody) seemed not affected 
in the colonic epithelium of the tRNAAla mutant mice on the image (Figure 5.7 complex IV 
panel), co-labelling with the mitochondrial mass marker Tom20 showed severe relative 
complex IV deficiency (crypts in orange) in the 50-week wild-type and mutant mice (Figure 
5.7 CIV & Tom20 panel). Quantification of the z-MTCO1 against the Tom20 level revealed a 
decrease in the relative complex IV level with age, regardless of the genotype (Figure 5.17). 
Although the relative complex IV level was significantly reduced in the 50-week mutants 
(52.83% CIV-negative crypts) compared with the 10-week mutants (6.67% “negative”) and 
even 50-week wild-type mice (18.35% “negative”) (Figure 5.17A), the rate of the decrease 
with age was very similar between the wild-type and the tRNAAla mutant mice (median 
difference (10 and 50 weeks) = 2.570 and 2.575 in the wild-type and mutant mice 
respectively).  
Data from individual mice confirmed the findings of the grouped data (Figure 5.18). 
Modelling revealed that the relative complex IV level was inversely correlated with the ear 
heteroplasmy in the 10-week (r = 0.152, p < 0.001) but not the 50-week mutants. As with the 
relative complex I level, the relative complex IV level had similar weak linear relationships 
with the crypt heteroplasmy in the 10-week (r = 0.131, p < 0.001) and 50-week (r = 0.126, p < 
0.001) tRNAAla mutant mice. 
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Figure 5.17 Respiratory chain complex IV level (labelled by MTCO-1) relative to the mitochondrial 
mass (labelled by Tom20) in the colonic crypts of the 10-week and 50-week tRNAAla mutant and 
control mice. (A) Categorical z-scores of the relative complex IV level in the tRNAAla mutants and the 
age-matched wild-type controls. The relative complex IV level was categorised as “positive”, 
“intermediate positive”, “intermediate negative” and “negative”. The borders of the z-scores for each 
category are summarised in the Table 5.3. (B) Whisker-and-box plot of the z-MTCO1 against Tom20 
level showing the median and distribution of the relative complex IV level in the colonic crypts in the 
mutants and controls. Each point signifies a measurement of a single crypt. The dotted lines are the 
boundaries for the categorisation of “intermediate negative” and “negative”. 
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Figure 5.18 Relative complex IV level (labelled by MTCO1) to MM (labelled by Tom20) in the colonic 
epithelium of individual mouse. (A) Categorical data of z-MTCO1/Tom20. Relative complex IV level 
was classified as “positive”, “intermediate positive”, “intermediate negative” and “negative”. The limits 
for each category are summarised in the Table 5.3. (B) An overview of the continuous z-MTCO1/Tom20 
showing the median and the distribution of the relative complex IV level in the colonic crypts. Each 
point is a measurement of a single crypt. The 10-week mutant mice include B933, B934, B938, B945 
and B952 (79%, 77%, 77%, 74% and 71% m.5024C>T in the ear respectively). The 50-week mutants 
include 372, 365, 353, 370 and 369 (80%, 79%, 73%, 73% and 71% m.5024C>T in the ear respectively). 
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5.4.3.3 OXPHOS level relative to mitochondrial mass 
The immunofluorescent images revealed some crypts with normal complex IV level (Figure 
5.7 complex IV panel) having a joint complex I and complex IV deficiency relative to 
mitochondrial mass in the 50-week mutants (yellow circles in Figure 5.7). Therefore, I further 
extensively investigated the OXPHOS level relative to the MM in the colonic epithelium of 
the tRNAAla mutant mice. Z-scores of the relative complex I and CIV level against Tom20 
were plotted in Figure 5.19. The crypts in the 10-week mutants mostly had relative complex I 
deficiency (top left sector), whereas crypts in the 50-week mutants were dominated by 
relatively isolated complex IV deficiency (bottom right sector) and joint defects in complex I 
and IV (bottom left sector) (Figure 5.19). The aged wild-type mice only had crypts with 
isolated complex IV deficiency (bottom right sector) (Figure 5.19). Quantification of the 
relative OXPHOS level to MM revealed an increase in the isolated complex IV defect with 
age in the colonic crypts of both wild-type and mutant mice (Figure 5.20). Isolated complex I 
defect was the main type of OXPHOS defect in the 10-week mutants, whereas the isolated 
complex IV defect prevailed in the crypts in the 50-week mutants (Figure 5.20). A decrease in 
the proportion of isolated complex I defective crypts was observed in the mutant mice with 
age, which was concomitant with an increase in the proportion of crypts with joint defects in 
the RC complexes (Figure 5.20). The relative OXPHOS deficiency was not correlated with 
the ear and the crypt heteroplasmy in either 10-week or 50-week tRNAAla mutants, possibly 
because of the small sample size for this specific analysis method without modelling.  
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Figure 5.19 Profiles of the OXPHOS level relative to mitochondrial mass (marked by Tom20) in 
colonic epithelium of the 10-week and 50-week tRNAAla mutant and wild-type mice. Z-scores of the 
relative complex I level to Tom20 (horizontal axis) was drawn against the z-scores of the relative 
complex IV level (vertical axis). The colour indicates the categorisation of the MM level: “very high” 
in red, “high” in orange, “normal” in beige, “low” in light blue and “very low” in blue. The borders for 
grouping is summarised in Table 5.3. Each dot is data of an individual crypt. 
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Figure 5.20 Relative OXPHOS deficiency in the colonic epithelium of the (A) grouped and (B) 
individual 10-week and 50-week tRNAAla mutant and wild-type mice. Relative OXPHOS defect was 
categorised into “both complex I and IV positive”, “isolated complex I defective”, “isolated complex 
IV defective” and “joint complex I and IV defective”. The z-scores of the complex I/IV relative to MM 
below “-2.6” was defined as defects in the RC complex I/IV. The 10-week mutant mice included in this 
study were B933, B934, B938, B945 and B952 with 79%, 77%, 77%, 74% and 71% m.5024C>T in the 
ear notch obtained at 3 weeks respectively. The 50-week mutants were 372, 365, 353, 370 and 369 with 
80%, 79%, 73%, 73% and 71% m.5024C>T in the ear notch respectively. 
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5.4.4 Level of mitochondrial mass in colonic crypts 
The immunofluorescence images and the OXPHOS profiles have shown a significant increase 
in the mitochondrial mass (marked by Tom20) in the colonic epithelium of the 50-week 
tRNAAla mutants and a mild increase in the 10-week mutants and 50-week wild-type mice 
(Figure 5.7 Tom20 panel and Figure 5.12). Pixel intensity of the Tom20 channel was 
quantified and transformed into z-scores, which were grouped into “very low”, “low”, 
“normal”, “high” and “very high” based on the approximate 95% and 99% confidence level 
(detailed in 5.3.3). Further quantification of the Tom20 z-scores demonstrated an increase in 
the percentage of the crypts with a high level of mitochondrial mass with age in both tRNAAla 
mutant and wild-type mice (Figure 5.21A). The tRNAAla mutants had a larger proportion of 
crypts with high mitochondrial mass than the age-matched wild-type controls at both 10 
weeks and 50 weeks (Figure 5.21A). The categorical results were then confirmed by the 
distribution data (Figure 5.21B). A significant interaction was found between the mouse 
genotype and age, showing a more rapid increase in the Tom20 level in the tRNAAla mutants 
compared with wild-types with age (p < 0.001, two-way ANOVA).  
 
Figure 5.21 Level of the mitochondrial mass (labelled by Tom20) in the colonic crypts of the grouped 
10-week and 50-week tRNAAla mutant and wild-type mice. (A) Categorical z-scores of the Tom20 level 
in the 10-week and 50-week tRNAAla mutants compared with the age-matched wild-type controls. The 
tom20 level was classified as “very high”, “high”, “normal”, “low” and “very low”. The boundaries of 
the z-scores for each group is summarised in the Table 5.3. (B) Whisker-and-box plot of the Tom20 z-
scores showing the median and distribution of the MM level in the colonic crypts. Each point denotes a 
measurement of an individual crypt. The dotted lines are the boundaries of the categories. 
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Individual mouse analysis showed a consistent and pronounced increase in the Tom20 level in 
all 50-week mutants with approximately a half of the crypts having elevated mitochondrial 
mass (Figure 5.22A), which was significantly higher compared with the 10-week tRNA 
mutants (Figure 5.22). Of note, one aged wild-type mouse (24769) showed a marked 
mitochondrial proliferation (Figure 5.22), and it was the only mouse with no absolute 
complex IV deficiency in the aged wild-type group, suggesting a protective effect of 
mitochondrial proliferation during ageing (Figure 5.11).  
Modelling of the data showed that Tom20 had a positive correlation with the crypt 
heteroplasmy in the 10-week mutants (r = 0.130, p < 0.001) but a negative correlation in the 
50-week mutants (r = 0.049, p = 0.018). No correlation was found between the level of 
Tom20 in the colonic epithelium with the ear heteroplasmy in the 10-week mutants (p = 
0.933). Whereas in 50-week mutants, Tom20 was negatively correlated with the heteroplasmy 
level in the ear (r = 0.126, p < 0.001). However, all these correlations were very weak as 
shown by the small r values, possibly due to the small sample size or due to the closeness of 
the heteroplasmy level between the examined mice.   
The level of Tom20 was positively correlated with the absolute level of complex I in the 
colonic epithelium of all examined mice (p < 0.0001 in wild-type controls; p = 0.028 and 
0.021 in 10-week and 50-week mutants respectively, Pearson correlation) (Figure 5.23A). The 
correlation was stronger in the wild-type mice compared with the mutants at both 10 weeks 
and 50 weeks but was similar within the same genotype (r = 0.569 and 0.479 in 10-week and 
50-week wild-type mice; r = 0.080 and 0.084 in the mutants at 10 weeks and 50 weeks) 
(Figure 5.23A). The level of Tom20 was also positively correlated with the absolute level of 
complex IV in all mice (p < 0.0001 in all mouse groups, Pearson correlation), which was 
overall stronger than its correlation with complex I level (Figure 5.23). The correlation in the 
wild-type mice was stronger than the mutants in both age groups, and was slightly stronger at 
50 weeks than 10 weeks within the same genotype (r = 0.790 and 0.827 in 10-week and 50-
week wild-types; r = 0.268 and 0.438 in mutants at 10 weeks and 50 weeks) (Figure 5.23B).  
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Figure 5.22 Mitochondrial mass level (labelled by Tom20) in the colonic epithelium in individual 10-
week and 50-week tRNAAla mutant and wild-type mice. (A) Categorical z-scores of Tom20 level. 
Tom20 level was categorised as “very high”, “high”, “normal”, “low” and “very low”. The limits for 
each category is summarised in the Table 5.3. (B) An overview of z-Tom20 showing the median and 
the distribution of the MM level. Each point represents a measurement of an individual crypt. The 10-
week mutants, B933, B934, B938, B945 and B952 (79%, 77%, 77%, 74% and 71% m.5024C>T in the 
ear respectively) and the 50-week mutants, 372, 365, 353, 370 and 369 (80%, 79%, 73%, 73% and 71% 
m.5024C>T in the ear respectively) were included in this study. The dotted lines are the boundaries for 
the classification of the z-Tom20. 
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Figure 5.23 Linear relationships between the level of Tom20 and absolute (A) complexes I and (B) IV 
in the colonic crypts of the 10-week and 50-week wild-type and tRNAAla mutant mice. (A) Equations 
for the linear relationship: 10-week wild-types, Y = 0.5685*X - 7.164e-00, R2 = 0.323; 10-week mutants, 
Y = 0.1328*X + 0.1172, R2 = 0.006; 50-week wild-types, Y = 0.5611*X + 1.387, R2 = 0.230; 50-week 
mutants, Y = 0.1367*X + 0.5841, R2 = 0.007. (B) 10-week wild-types, Y = 0.7901*X + 3.437e-008, R2 
= 0.624; 10-week mutants, Y = 0.2733*X + 0.07519, R2 = 0.072; 50-week wild-types, Y = 1.125*X - 
1.849, R2 = 0.683; 50-week mutants, Y = 0.3877*X - 1.343, R2 = 0.192; Pearson correlation analysis. 
WT, wild-type. 
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5.5 Discussion 
Mitochondrial DNA disease is characterised by tissue-specific heterogeneous phenotypes 
(Taylor and Turnbull, 2005). Investigating the effect of dynamics of mtDNA mutations on 
biochemical phenotypes of tissue is vital to the understanding of the progression of mtDNA 
disease. I have found a normal OXPHOS function correlating with a decreased mutation load 
in mitotic GI epithelium in comparison to the post-mitotic smooth muscle of patients with 
inherited m.3243A>G mutation (Chapter 3). However, this study is cross-sectional, due to 
limitations in obtaining human samples at multiple stages of lifespan. Consequently, it is 
unable to show the age-related change in heteroplasmy level and its outcome in mitotic tissue. 
The establishment of the tRNAAla mutant mice with inherited m.5024C>T mutations allows 
me to screen tissue in animals at different ages. I have demonstrated a significant reduction in 
the mutation load in the mitotic intestinal epithelium of the old mutant mice compared with 
the young mutants (Chapter 4). To understand the biochemical effect of this decrease at the 
genetic level with age, in this study, I have characterised the OXPHOS function of the mitotic 
GI epithelium in the 10-week and 50-week mutant mice using sequential COX/SDH 
histochemistry and quantitative immunofluorescence assay. For the latter study, I have 
investigated the absolute level of RC complexes I and IV and relative level to a mitochondrial 
mass marker, Tom20, in the colonic epithelium of the mutant mice. 
OXPHOS function is affected by the inherited m.5024C>T mutation in the intestinal 
epithelium of the mutant mice. This is indicated by a proportion of small intestinal crypts (< 
30%) with defects in COX activity in the mutants with high ear mutation load. The 
immunofluorescence study of the absolute protein level of RC complexes then confirms that a 
maximum of 16.55% colonic crypts are OXPHOS-defective, with complex I deficiency 
predominating over complex IV deficiency. In comparison, no obvious OXPHOS deficiency 
has been found in the young wild-type controls, suggesting that the OXPHOS deficiency in 
the mutants is caused by inherited m.5024C>T mutation. Isolated complex I defect is the main 
biochemical phenotype in the young mutants, in which I detect no crypts with joint defects in 
complexes I and IV, but the latter becomes evident with age. I have also detected a complex 
IV defect with no complex I deficiency in the old wild-type mice, suggesting that complex IV 
is more sensitive to ageing than complex I in the colonic crypts. This is in accordance with 
human studies showing that a vast majority of colonic crypts have isolated complex IV 
deficiency and joint defects in complex IV and other complexes in ageing humans, whereas 
only a small proportion of colonic crypts have isolated complex I deficiency (Greaves et al., 
2010). 
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In the young mutants, the level of OXPHOS defect is correlated with mutation load in the ear 
sampled at 3 weeks, a reference of initial mutation level, where mice with high ear 
heteroplasmy have a high level of OXPHOS deficiency in the colonic epithelium, indicating 
the pathogenicity of the m.5024C>T mutation. Such correlation is substantially weakened in 
the old mutants, suggesting a loss of influence of the initial mutation load on OXPHOS 
function in the colonic epithelium with age. On the contrary, I found a stronger correlation 
between the crypt heteroplasmy and the absolute level of RC complexes I and IV in the old 
mutants than that in the young mutants, suggesting an increase in the correlation between the 
expression of RC complexes and in situ tissue heteroplasmy with age. The results discussed 
above suggest that the OXPHOS level is closely correlated with inherited m.5024C>T 
mutation and is a good reflection of the variation in the heteroplasmy level in this mouse 
model. 
OXPHOS defects, in particular, defects in complexes I and IV, increase in tissue with age due 
to accumulated somatic mtDNA mutations (Taylor et al., 2003; Greaves et al., 2010). In 
contrast, I found no difference in the COX activity between the young and old mutants in the 
small intestinal epithelium, which is consistent with the previous finding of COX function in 
the colonic epithelium (Baines, 2014). In addition, the absolute protein level of RC complexes 
did not decrease with age in the colonic epithelium of the tRNAAla mutant mice. On the 
contrary, the absolute complex I level slightly increased in the old mutants compared with the 
young mutants. This is consistent with the decrease in the mutation load of inherited 
m.5024C>T mutation in the intestinal epithelium (Chapter 4). In addition, in comparison to 
the pronounced complex IV deficiency in the colonic crypts of the ageing wild-type mice, the 
tRNAAla mutant mice barely had any crypts with absolute complex IV deficiency, suggesting 
that the tRNAAla mutant mice might have a response to the inherited m.5024C>T mutation 
that has a protective effect which maintains OXPHOS function during ageing. This is in 
contrast to some studies where different breeding strategies of mtDNA-mutator mice were 
used to show that maternally transmitted mtDNA mutations play a synergistic role with the 
accumulation of somatic mtDNA mutations during ageing, which aggravate the deterioration 
of the phenotypes of the mitotic (colon and testis) and post-mitotic (heart and brain) tissue 
(Ross et al., 2013). However, these maternally transmitted mtDNA mutations were low levels 
of miscellaneous pathogenic and non-pathogenic mtDNA variants due to mtDNA 
mutagenesis of the mother mice (Ross et al., 2013). Whereas inherited mtDNA mutations that 
cause mtDNA diseases are specific mutations that are at a high level in symptomatic patients 
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(Craven et al., 2017). It is possible that a high mutation load is needed at the beginning to 
trigger the protective mechanism.  
Furthermore, I found a significantly elevated level of mitochondrial mass (labelled by Tom20) 
in the tRNAAla mutant mice compared with the wild-type controls. Although age has an effect 
on upregulating MM in both mutant and wild-type mice, it interacts with the mouse genotype. 
As a result, the protein level of Tom20 increased faster with age in the tRNAAla mutants than 
in the wild-type mice. Tom20 is a common mitochondrial mass marker encoded by nuclear 
DNA, which is not directly affected by defects in mtDNA (Yamano et al., 2008; Jourdain et 
al., 2013). The level of MM reflects the dynamics of mitochondrial biogenesis and 
mitophagy. The increase in the MM in the colonic epithelium of the tRNAAla mutant mice 
could be a compensatory response to the OXPHOS deficiency caused by inherited mtDNA 
mutations, but also could be a reflection of machinery that actively removes the inherited 
mtDNA mutations by regulating mitochondrial biogenesis and mitophagy. In addition, despite 
less OXPHOS defects in the old mutants compared with the wild-type mice, the level of MM 
is still markedly higher in the mutants compared with the wild-types, suggesting a role of 
mitochondrial proliferation relevant to inherited mtDNA mutations rather than a simple 
compensatory response to OXPHOS deficiency. The findings of MM here are consistent with 
the increased level of nuclear-encoded mitochondrial markers, COX4 and SDHA, in the 
gastrointestinal epithelium from patients with m.3243A>G mutation (Chapter 3).  
The modelling has provided information about the correlations between the MM and different 
factors, such as the level of complexes I and IV and the heteroplasmy of ears and crypts in the 
young and old mice. Complex IV level is positively correlated with Tom20 in the mutants, 
accounting for the preserved absolute complex IV protein level in the mutants with the 
elevated MM. The correlation of the MM with the level of complex IV is much stronger than 
its correlation with the level of complex I, which explains why the level of complex IV rather 
than the complex I relative to the MM is significantly dropped with the elevation in the MM. 
The linear relationship between the level of RC complex expression is stronger in wild-type 
mice compared with the tRNAAla mutants, indicated by the higher correlation coefficient and 
steeper gradient of the regression equation. This might be a reason why the MM significantly 
increased in the mutants if it is a compensatory response to defective RC complexes. As a 
smaller increase in the level of RC complexes is concomitant with an increase in the MM in 
the mutants compared with the wild-type mice, the mutant mice may have to produce more 
mitochondria to elevate the OXPHOS level compared with wild-type mice. With reference to 
complex IV, its correlation with MM is slightly stronger in the old mice compared with the 
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young mice, suggesting an increment in the influence of MM on complex IV with age. The 
correlation between MM and ear or crypt heteroplasmy is very weak, even if the modelling 
tremendously reduces the loss of information from the data. This may be because the MM is a 
secondary parameter, regardless of whether it is a compensatory response or operating 
machinery. There is no correlation between ear heteroplasmy and the level of Tom20 in the 
colonic epithelium of the young mice but a weak negative correlation in the old mutants. The 
level of MM is positively correlated with crypt heteroplasmy in the young mutants, 
suggesting that mitochondrial proliferation might increase in response to high in situ mutation 
load. Their correlation turns to negative, which might be a consequence of the above 
hypothesis. With age, crypts in which mitochondrial proliferation fails to elevate to contribute 
to removing the mutation will have higher mutation load. However, as correlations cannot 
reflex any causal relationship, there could be various interpretations of these results, and it 
should be careful to draw any conclusions.  
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5.5.1 Future work 
One limitation of this study is that the GI samples are obtained via resection from different 
mice in the two age groups, making it a multiple cross-sectional study rather than a 
longitudinal study. In this case, measurements at different ages cannot be compared within 
each mouse directly, increasing the complexity of data analysis to reduce the variation 
between individual mice. Colonoscopy technique in live mice could be used in the future to 
acquire biopsies within individual mouse at different time points (Becker et al., 2007), which 
would facilitate the dynamic screening of samples in all aspects. 
Crypts with OXPHOS deficiency caused by accumulated somatic mtDNA mutation only 
occupy a few percents of the whole crypt population in middle-aged individuals, which 
become obvious at a very late stage of lifespan (Taylor et al., 2003). In this study, I have only 
examined the 10-week and the 50-week mice. However, a minimum age of 18 months (~ 70 
weeks) is considered senescence for mice (Dutta and Sengupta, 2016). Including old mice in 
further studies could possibly reveal a more obvious age-related change in the biochemical 
phenotype in the tRNAAla mutants and a larger difference between the wild-type and mutant 
mice during ageing to benefit the understanding of the process of ageing and mtDNA disease. 
In this study, I have correlated the m.5024C>T heteroplasmy in the intestinal epithelial 
homogenate with the overall biochemical defect in the colonic epithelium. It would be 
worthwhile to determine the heteroplasmy in individual crypts and correlate it with the protein 
level of RC complexes in the crypt to gain in-depth knowledge of the association between the 
mutation load and OXPHOS function and validate the biochemical threshold previously 
determined via sequential COX/SDH histochemistry. In addition, as I have only studied the 
heteroplasmy of the m.5024C>T mutation, there is still possibility that the biochemical defect 
in the 50-week tRNAAla mutant mice is caused by the age-related accumulation of somatic 
mtDNA mutations. Thus, next-generation sequencing to screen the whole mtDNA genome 
would be necessary in the future work. 
Although sequential COX/SDH histochemistry is irreplaceable for examining the enzyme 
activity of COX on tissue specimens, semi-quantification based on label colours is more 
subjective compared with quantitative immunofluorescence assay, especially for tissue with 
partial OXPHOS deficiency. In this study, the COX/SDH histochemical assay reveals 
numerous COX-defective cells in the fundic and pyloric epithelium of the stomach in the 
tRNAAla mutant mice. The semi-quantification methodology for comparatively homogenous 
intestinal crypts would not be applicable to gastric units with heterogeneous cell components 
that naturally have distinct COX activity. In addition, for investigating whether the difference 
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in the mutation load between the fundic and pyloric epithelium can cause any difference in the 
OXPHOS function, due to the cell components and structure of the two types of gastric units, 
it would be inappropriate to compare the number of COX-deficient cells directly. As 
discussed above, quantitative immunofluorescence or western blot would be a more stringent 
technique for determination of the OXPHOS function in the gastric epithelium and should be 
employed in the further study. 
This study has shown elevated mitochondrial proliferation in the colonic epithelium of the 
tRNAAla mutant, which is correlated with the OXPHOS level in crypts, suggesting a change in 
mitochondrial biogenesis and quality control. mtDNA copy number is also an index of these 
processes (Lee and Wei, 2005). It is worthy of investigating the level of mtDNA copy number 
and its association with OXPHOS level in intestinal crypts of the mutants. Fluorophore 
labelled individual crypts whose OXPHOS level are determined could be laser-microdissected 
for the further determination of mtDNA copy number by real-time PCR (Phillips et al., 2014). 
In addition, it is also important to investigate mitochondrial biogenesis and mitophagy 
individually and their relationship with OXPHOS level by co-labelling immunofluorescence 
markers for mitochondrial biogenesis, e.g. PCG-1 alpha (Fernandez-Marcos and Auwerx, 
2011), and mitophagy, e.g. Parkin and PINK1 (McWilliams and Muqit, 2017), with markers 
for RC complexes. 
This study reveals a difference in the absolute protein level of RC complexes and relative 
level of RC complexes to mitochondrial mass in the colonic crypts of the tRNAAla mutant 
particularly when the mice age. However, their effect on cellular function is unknown. It 
would be intriguing to investigate this by comparing the functionality of cells in intestinal 
crypts with normal absolute and relative OXPHOS level, those with normal absolute 
OXPHOS level but low relative level and those with low absolute and relative level. 
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5.6 Conclusions 
In this study, I have characterised the OXPHOS function in the gastrointestinal epithelium of 
the tRNAAla mutant mice. I have found an OXPHOS deficiency in the intestinal crypts of the 
mutants caused by the inherited m.5024C>T mutation, which maintains or slightly improves 
with age. This is in accordance with the age-related decrease in the mutation load in the 
intestinal crypts of the tRNAAla mutants with age but in contrast to the deterioration of 
OXPHOS deficiency in wild-type controls. In addition, I have found an increase in 
mitochondrial proliferation in the mutants compared with the wild-type controls, which 
interacts with age and correlates with the protein level of RC complexes I and IV. These 
findings prove that the tRNAAla mutant mice can be a good animal model for investigating the 
mechanism underpinning the age-related selective loss of inherited mtDNA mutations and 
suggest that this process might be associated with mitochondrial biogenesis and quality 
control. 
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Chapter 6 Investigating the cellular mechanism underlying the selective loss 
of inherited mtDNA mutations in the intestinal epithelium 
6.1 Introduction 
I have previously shown in Chapter 2 that the turnover of stem cell progenies may affect the 
rate of age-related selective loss of the inherited m.5024C>T mutation in the gastrointestinal 
epithelium of tRNAAla mutant mice. Cell turnover is determined by cell proliferation and cell 
death, particularly apoptosis, the delicately programmed suicide of cells (Pellettieri and 
Alvarado, 2007). Mitochondria contribute to a variety of cellular and metabolic events in 
addition to the generation of ATP, which is intimately involved in the regulation of cell 
proliferation and apoptosis (Tait and Green, 2010; Antico Arciuch et al., 2012; Lopez and 
Tait, 2015; Salazar-Roa and Malumbres, 2017). Mutations in mtDNA can cause 
mitochondrial malformation and dysfunction, which can lead to dysregulated renewal of 
mitotic tissue. The age-related somatic mtDNA mutations can affect the turnover of stem cell 
progenies by indirectly affecting somatic stem cell function (Su et al., 2018) or directly 
affecting the proliferation and apoptosis of the daughter cells (Nooteboom et al., 2010; Fox et 
al., 2012). In ageing humans, downregulated cell proliferation and upregulated apoptosis have 
been found in colonic crypts with OXPHOS deficiency caused by the accumulation of 
somatic mtDNA mutations, resulting in a loss of cell population in these crypts (Nooteboom 
et al., 2010). The establishment of the progeroid mtDNA-mutator mouse model further 
confirms the effect of somatic mtDNA mutations on cell cycle and apoptosis in mitotic tissue 
(Kujoth et al., 2005; Fox et al., 2012). Studies have shown an elevated level of apoptosis in 
the small intestinal villi of mtDNA-mutator mice compared with wild-type mice (Kujoth et 
al., 2005). In addition, abundant apoptotic cells are observed in crypts of the small intestine 
from mtDNA-mutator mice, where intestinal stem cells and transit-amplifying cells are 
located, which is rarely seen in wild-type mice (Fox et al., 2012). Furthermore, studies report 
reduced DNA synthesis that compromises cell proliferation, and an altered cell cycle in the 
small intestinal crypts, concomitant with a compromised regeneration ability of isolated 
crypts in vitro and a deceleration of cell migration toward the tip of the villus (Fox et al., 
2012). These studies demonstrate that somatic mtDNA mutations can affect the proliferation 
and apoptosis of intestinal epithelial cells, resulting in abnormal cell turnover of the tissue.  
Despite a body of research on the association between the somatic mtDNA mutations and 
apoptosis (Lin and Beal, 2006; Liu et al., 2009), the study of the effect of disease-causing 
mitochondrial DNA mutations on apoptosis is still in its infancy. Relevant studies are chiefly 
concerned with and limited to post-mitotic muscles of patients harbouring large-scale 
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deletions and common mt-tRNA mutations, such as m.3243A>G and m.8344A>G mutations, 
and the findings are in conflicts (Mirabella et al., 2000; Ikezoe et al., 2002; Umaki et al., 
2002; Auré et al., 2006). Some reports show no sign of apoptosis in the muscle of the patients 
(Sciacco et al., 2001), whereas others show enhanced apoptosis in the patients (Mirabella et 
al., 2000; Ikezoe et al., 2002; Umaki et al., 2002; Auré et al., 2006). In addition, the level of 
apoptosis seems to be mutation-specific, as in patients carrying point mutations in protein-
encoding genes causing NARP and LHON, little to no apoptosis is found (Mirabella et al., 
2000). Some studies report that apoptosis primarily occurs in muscle fibres with RC 
deficiency and no difference in apoptosis is found between RRF and non-RRFs. In contrast, 
other studies report that apoptosis mainly occurs in muscle fibres with mitochondrial 
proliferation (Ikezoe et al., 2002; Umaki et al., 2002), irrespective of RC function (Auré et 
al., 2006). One consistent finding is that the presence of apoptosis is associated with a high 
mutation load (Mirabella et al., 2000; Auré et al., 2006). Although these investigations were 
carried out on post-mitotic tissues, they suggest an association between apoptosis and disease-
causing mtDNA mutations, and possible effects of the genetic and biochemical features of 
mtDNA diseases, including mutation load, OXPHOS defects and mitochondrial proliferation, 
on the level of apoptosis in tissue. 
For mitotic cells, the studies on the impact of disease-causing mtDNA mutations on apoptosis 
are primarily in vitro, in either cybrid or patient fibroblasts (Geromel et al., 2001; Liu et al., 
2009). Studies have shown that large-scale deletions (Liu et al., 2004; Schoeler et al., 2005; 
Lee et al., 2006; Liu et al., 2007), m.3243A>G (Liu et al., 2004), m.8344A>G (Liu et al., 
2004) and point mutations in mtDNA protein-encoding genes (Geromel et al., 2001; 
Danielson et al., 2002; Carrozzo et al., 2004; Ghelli et al., 2008) cause oxidative stress in 
cells and predispose them to apoptosis. Despite no reports on apoptosis in fast-renewing 
mitotic tissue of patients with mtDNA disease, one study shows that in mice with high levels 
of large-scale deletions (Inoue et al., 2000), enhanced apoptosis of dysfunctional 
spermatogenetic cells with RC defects leads to oligospermia and asthenozoospermia, resulting 
in male infertility of these mice (Nakada et al., 2006). These studies have provided 
preliminary evidence that disease-causing mtDNA mutations can affect apoptosis of mitotic 
cells, which might lead to a reduced number and defective function of stem cell progenies.  
As discussed above, the cell proliferation and apoptosis that regulate the turnover of mitotic 
tissue are closely associated with mitochondrial function and mtDNA mutations and might 
play a role in the selective loss of disease-causing mtDNA mutations. 
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6.2 Aims 
This study aimed to determine whether cell proliferation and apoptosis of stem cell progenies 
are associated with the selective loss of inherited mtDNA mutations in mitotic tissue using the 
tRNAAla mouse model. Specifically, this study aims to: 
1. Determine whether there is any difference in the overall level of cell proliferation in 
the colonic crypts of 10-week and 50-week wild-type and tRNAAla mutant mice, and 
ascertain whether there is any difference in cell proliferation within the crypts with 
different OXPHOS functions and levels of mitochondrial mass. 
2. Determine the apoptosis level in the 10-week and 50-week colonic crypts of the 
tRNAAla mutant mice in comparison to that in the wild-type controls. 
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6.3 Methods 
6.3.1 Immunofluorescence and imaging 
FFPE colon tissue of the tRNAAla mutant mice was sectioned at a thickness of 4µm by myself 
for assay optimisation and by Anna Smith for the final experiments. Sections were 
deparaffinised, subjected to antigen retrieval and incubated in antibody cocktails (detailed in 
2.8.2). Dewaxing timespan, antigen retrieval buffer and methodology, and antibody 
concentrations in the immunofluorescence assay were optimised for the formal experiment. 
Antibody combinations used in this study are shown in Table 6.1. Information about the 
antibodies and the optimised concentration thereof is summarised in Table 2.7 and Table 2.8. 
Five tRNAAla mutant mice with high ear heteroplasmy (71% - 80%) and three wild-type 
controls at 10 weeks and 50 weeks were employed in this study, which is the same group of 
mice described in Chapter 5. For the study of cell proliferation, sections were counterstained 
using Hoechst to label the nuclei of cells in colonic crypts (described in 2.8.3). For the study 
of the apoptosis level, sections were counterstained with β-catenin, a cell surface marker, to 
facilitate the cell counting. For both studies, sections were co-labelled with the markers for 
the RC complex I (NDUFB8) and mitochondrial mass (Porin) to determine OXPHOS 
function in colonic epithelial cells. Sections were imaged using the Confocal Laser 
Microscope System in a z-stack fashion (detailed in 2.9.3).  
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Antibody combination for cell proliferation study 
Primary antibody Secondary antibody Tertiary antibody 
Anti-NDUFB8 (ab110242) Biotin-XX (A10519) 
Streptavidin, Alexa Fluor 
647 conjugate (S21374) 
Anti-VDAC1 (ab14734) Alexa Fluor 488 (A21141) N/A 
Anti-Ki-67 (#12202) Alexa Fluor 546 (A11010) N/A 
Antibody combination for apoptosis study 
Primary antibody Secondary antibody Tertiary antibody 
Anti-NDUFB8 (ab110242) Biotin-XX (A10519) 
Streptavidin, Alexa Fluor 405 
conjugate S32351 
Anti-TOM22 (ab57523) Alexa Fluor 488 (A21131) N/A 
Anti-Caspase 3, active 
(cleaved) form (AB3623) 
Alexa Fluor 546 (A11010) N/A 
Anti-β-catenin (sc-393501) Alexa Fluor 647 (A21242) N/A 
Table 6.1 Antibody cocktails for the immunofluorescence assay in the studies of cell proliferation and 
apoptosis. EDTA was used as antigen retrieval buffer to obtain the optimal labelling effect of these 
antibodies. Details of the antibodies and their optimised concentrations are summarised in Table 2.7 and 
Table 2.8. 
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6.3.2 Image analysis 
Z-stack images were incorporated for maximum intensity projection and pixel intensity of the 
markers for complex I and mitochondrial mass in each colonic crypt was measured as 
described in 2.9.3. Absolute and relative level of complex I is determined as z-scores (detailed 
in 5.3.3).  
In the study of cell proliferation, the number of Ki-67 signals and nuclei (labelled by Hoechst) 
in each colonic crypt was manually counted. Non-specific binding of antibodies in the Ki-67 
channel that were not overlapping with the signals of the nuclei were excluded (Figure 6.1). 
The level of cell proliferation in each crypt was defined as the percentage of proliferating 
cells, which is the number of Ki-67 positive nuclei over the number of Hoechst positive 
nuclei. In this situation, the integrity of the crypt structure is important. Therefore, counting 
was only performed on longitudinal crypts whose base and apex could be defined. 
For quantifying the level of apoptosis, cells containing the signals of active caspase-3 were 
counted. The level of apoptosis was described by the number of signal-positive cells per 
hundred crypts. As apoptosis primarily occurs at the apex of a crypt, only longitudinal crypts 
with intact apical epithelium and apoptotic cells in these crypts were counted. Cells in the 
lumen were excluded.   
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6.4 Results  
6.4.1 Cell proliferation and mouse genotype 
Ki-67 is a common marker for proliferating cells for the reason that it is present in the nuclei 
of cells during all active phases of a cell cycle (G1, S, G2 and mitosis) but not in resting cells 
(G0) (Gerdes et al., 1984; Scholzen and Gerdes, 2000). To determine whether the inherited 
m.5024C>T mutation combined with age has any effect on cell proliferation in the mitotic 
epithelium, I performed immunofluorescence on sections of colonic epithelium from the 10-
week and 50-week wild-type and tRNAAla mutant mice using markers for Ki-67 and DNA to 
label the proliferating cells and the nuclei respectively (Figure 6.1). In addition, I co-labelled 
the RC complex I and mitochondrial mass using antibodies against NDUFB8 and Porin to 
further study the association between the OXPHOS level, mitochondrial proliferation and cell 
proliferation (described in 6.4.2) (Figure 6.1). I then quantified the proportion of proliferating 
cells in individual colonic crypts of each mutant and compared it with that in the wild-type 
mice (6.3.2). Crypts were randomly selected regardless of the complex I level for the 
quantification to obtain an objective overall measure of the level of cell proliferation in each 
group. A total number of ~30 crypts in each group was examined with an approximately equal 
number of crypts selected in each mouse of each group. The overall percentage of the 
proliferating cells in individual crypts increased with age, irrespective of the genotype (p = 
0.022, two-way ANOVA) (Figure 6.2A). However, no statistically significant difference in 
cell proliferation was found between the tRNAAla and the wild-type genotype (Figure 6.2). 
The analysis of individual mice showed no difference in the percentage of proliferating cells 
in crypts of different mice within the same group based on the genotype and age, indicating 
consistency in counting (one-way ANOVA) (Figure 6.2B). 
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Figure 6.1 Representative immunofluorescence images for proliferating cells (Ki-67), RC complex I 
(NDUFB8), mitochondrial mass (Porin) and nuclei (Hoechst). Signals due to non-specific binding of 
the antibody at the Ki-67 channel that are not superimposed with nuclear labels were excluded from 
counting (white arrows). Scale bar = 50µm. 
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Figure 6.2 Cell proliferation level in the colonic crypts of (A) the grouped and (B) the individual 10-
week and 50-week wild-type and tRNAAla mutant mice. Five tRNAAla mutant mice and three wild-type 
controls in each age group were examined. The level of cell proliferation is presented as the percentage 
of proliferating cells (the number of the Ki-67 immunofluorescence signals / the number of the nucleus 
signals). (A) n (10-week wildtypes) = 30, n (10-week mutants) = 31, n (50-week wildtypes) = 30, n (50-
week mutants) = 25. (B) The 10-week mutant mice, B933, B934, B938, B945 and B952 carried 79%, 
77%, 77%, 74% and 71% m.5024C>T in the ear respectively. The 50-week mutants, 372, 365, 353, 370 
and 369 carried 80%, 79%, 73%, 73% and 71% m.5024C>T in the ear respectively. The number of 
crypts analysed: n (B988) = 10, n (B994) = 10, n (B995) = 10, n (B933) = 7, n (B934) = 7, n (B938) = 
6, n (B945) = 6, n (B948) = 5, n (24283) = 10, n (24769) = 10, n (WT201) = 10, n (372) = 5, n (365) 
= 7, n (353) = 4, n (370) = 5 and n (369) = 4.   
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6.4.2 Cell proliferation, OXPHOS level and mitochondrial mass 
6.4.2.1 Cell proliferation and absolute complex I 
In colonic crypts of ageing humans, OXPHOS deficiency caused by the accumulation of 
somatic mtDNA mutations is associated with decreased cell proliferation and increased 
apoptosis (Nooteboom et al., 2010). To investigate the effect of OXPHOS deficiency caused 
by the inherited m.5024C>T mutation with age on cell proliferation in colonic crypts, I 
measured the absolute protein level of complex I (CI) in individual colonic crypts of the 
tRNAAla mutant mice and investigated the cell proliferation level in crypts with different 
absolute CI levels. The raw data of the measurement was transformed into z-scores using the 
data of the 10-week wild-type mice as the control group, and categorised into “positive”, 
“intermediate positive”, “intermediate negative” and “negative” according to the 95%, 99% 
and 99.9% confidence levels (detailed in Chapter 5). In line with the data in Chapter 5, 
quantification of the CI level showed CI defects in mutants but not in wild-type controls; and 
that the proportion of colonic crypts with CI deficiency slightly decreased in the 50-week 
mutants compared with the 10-week mutants, suggesting an improvement of the OXPHOS 
phenotype. In this study, only the “positive” and “negative” groups were included to increase 
the power of comparison. The percentage of proliferating cells in approximately 60 CI-
positive crypts and 15 CI-negative crypts in each age group were analysed. No significant 
difference in the level of cell proliferation was found between the crypts with different 
OXPHOS classifications at either 10 weeks or 50 weeks (two-way ANOVA) (Figure 6.3A). 
The CI-positive crypts appeared to have a higher level of cell proliferation than the CI-
negative crypts in the 50-week tRNAAla mutant mice, but it is not statistically significant 
(Figure 6.3A). No correlation was found between the proportion of proliferating cells and the 
absolute complex I level in either wild-type or mutant mice at 10 nor 50 weeks (p > 0.05, 
Pearson correlation test). However, the analysis revealed a markedly increased cell 
proliferation in the CI-positive crypts at 50 weeks compared with that at 10 weeks (p = 0.006, 
two-way ANOVA) (Figure 6.3A). Due to the mild OXPHOS phenotype of the tRNAAla 
mutant mice, there were only a limited number of crypts with absolute complex I deficiency 
in the images taken. For individual analysis, the data of one 10-week mutant and one 50-week 
mutant that contain ≥ five CI-negative crypts in each were analysed. Despite a trend showing 
a higher level of cell proliferation in the CI-positive crypts compared with the CI-negative 
crypts in each mouse, it was not statistically significant (p > 0.05, unpaired t-test) (Figure 
6.3B). 
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Figure 6.3 Cell proliferation in colonic crypts of tRNAAla mutant mice with absolute positive and 
negative complex I function. (A) Percentages of proliferating cells in the CI-positive and CI-negative 
crypts of the 10-week and 50-week mutants. n (CI-positive crypts at 10 weeks) = 61, n (CI-negative 
crypts at 10 weeks) = 15, n (CI-positive crypts at 50 weeks) = 59, n (CI-negative crypts at 50 weeks) = 
14. **, p < 0.01, Sidak’s multiple comparison, two-way ANOVA. (B) The proportion of proliferating 
cells in colonic crypts of B933 (10 weeks, ear heteroplasmy = 79%) and 365 (50 weeks, ear 
heteroplasmy = 79%). n (CI-positive crypts of B933) = 11, n (CI-negative crypts of B933) = 10, n (CI-
positive crypts of 365) = 11, n (CI-negative crypts of 365) = 6. 
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6.4.2.2 Cell proliferation and relative complex I level 
In Chapter 5, I have shown a higher percentage of colonic crypts with OXPHOS deficiency 
relative to mitochondrial mass compared with those with absolute OXPHOS deficiency, and a 
distinct change in the absolute and relative complex IV level with age in crypts of tRNAAla 
mutant mice. Thus, I also investigated the association between cell proliferation and the 
relative complex I level. Z-scores of the relative complex I level was calculated as absolute 
NDUFB8 level normalised by Porin level and categorised (detailed in Chapter 5). The data 
showed a decrease in the percentage of crypts with relative CI defects in the 50-week mutants 
compared with the 10-week mutants. The analysis of cell proliferation showed an overall 
higher level of cell proliferation in colonic crypts at 50 weeks compared with 10 weeks, 
irrespective of the OXPHOS level (p = 0.005, two-way ANOVA) (Figure 6.4A). In 
accordance with the results regarding the absolute complex I level, the percentage of 
proliferating cells was higher at 50 weeks compared with 10 weeks in colonic crypts with 
relatively normal CI level (p = 0.006, two-way ANOVA), whereas no change in cell 
proliferation was observed in crypts with relative CI deficiency with age (Figure 6.4A). In 
addition, no correlation was found between the cell proliferation level and the relative CI level 
in either wild-type or tRNAAla mutant mice at 10 weeks or 50 weeks, which is in accordance 
with the data of absolute CI level (p > 0.05, Pearson correlation test). The analysis of 
individual mice revealed a higher level of cell proliferation in the CI-positive crypts compared 
with the CI-negative crypts in one 10-week mouse B938 and one 50-week mouse 372 (p = 
0.034 and 0.012 respectively, unpaired t-test) (Figure 6.4B). However, no significant 
difference in cell proliferation was found between the crypts with different CI levels in the 
rest of the mice (Figure 6.4B).  
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Figure 6.4 Cell proliferation in colonic crypts of tRNAAla mutant mice with positive and negative 
complex I functions relative to mitochondrial mass (Porin). (A) Percentages of proliferating cells in 
relative CI-positive and CI-negative crypts of the 10-week and 50-week mutants. n (CI-positive crypts 
at 10 weeks) = 45, n (CI-negative crypts at 10 weeks) = 31, n (CI-positive crypts at 50 weeks) = 49, n 
(CI-negative crypts at 50 weeks) = 27. **, p < 0.01, Sidak’s multiple comparisons, two-way ANOVA. 
(B) The proportion of proliferating cells in colonic crypts in individual mice at 10 weeks and 50 weeks. 
10-week mutants: B933 (ear heteroplasmy = 79%), n (CI-positive crypts) = 5, n (CI-negative crypts) = 
14; B934 (ear heteroplasmy = 77%), n (CI-positive crypts) = 10, n (CI-negative crypts) = 7; B938 (ear 
heteroplasmy = 77%), n (CI-positive crypts) = 10, n (CI-negative crypts) = 7; and 50-week 372 (ear 
heteroplasmy = 80%), n (CI-positive crypts) = 10, n (CI-negative crypts) = 7; 365 (ear heteroplasmy = 
79%), n (CI-positive crypts) = 10, n (CI-negative crypts) = 7; and 370 (ear heteroplasmy = 73). n (CI-
positive crypts) = 9, n (CI-negative crypts) = 6. *, p < 0.05, unpaired t-test. 
  
201 
 
6.4.2.3 Cell proliferation and porin level 
Due to conflicts between the isotypes of the antibodies against Tom20 and Ki-67, I used porin 
as the mitochondrial mass marker for immunofluorescence in this study. I quantified the porin 
level in the colonic crypts of the 10-week and 50-week mutant and wild-type mice for marker 
verification (~20 crypts for each mouse). As with Tom20, porin was significantly upregulated 
in the tRNAAla mutants compared with the wildtype mice at 10 weeks (Figure 6.5). The 50-
week mutant mice also showed a larger percentage of colonic crypts with enhanced 
expression of porin compared with the aged wildtype mice (Figure 6.5A), despite no 
statistical significance in the continuous data (Figure 6.5B). As with Tom20, the protein level 
of porin increased with age in wild-type controls (Figure 6.5). However, this did not happen 
in the tRNAAla mutant mice. Categorical data indicated a declined proportion of crypts with 
“very high” porin level in the 50-week mutants compared with the 10-week mutants (Figure 
6.5A), whereas continuous data showed no difference in porin expression between the young 
and old mutants (Figure 6.5B), both of which contradict the findings of Tom20 in Chapter 5.   
 
Figure 6.5 Protein levels of porin in wild-type and tRNAAla mutant mice at 10 weeks and 50 weeks. (A) 
Categorical z-scores of the porin protein level. Data were classified into “very high”, “high”, “normal”, 
“low” and “very low”. The boundaries of the z-scores for each group were set according to the 95% and 
99% confidence level (Table 5.3). (B) Whisker-and-box plot of the porin z-scores showing the median 
and distribution of the mitochondrial mass in the colonic crypts. Each point denotes a measurement of 
an individual crypt. The dotted lines are the boundaries of the categories. The number of examined 
crypts: n (10-week wild-type) = 77, n (10-week mutants) = 114, n (50-week wild-type) = 60, n (50-week 
mutants) =112; ~20 crypts in each mouse. ****, p < 0.0001, Kruskal-Wallis test.  
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To determine whether porin has any age-related effect on cell proliferation in colonic crypts, I 
compared the level of cell proliferation between the crypts with normal and high porin levels 
in 10-week and 50-week tRNAAla mutant mice. The “high porin” group was the pooled group 
of crypts with “high” and “very high” porin level from Figure 6.5. The overall level of cell 
proliferation increased with age, irrespective of the porin level (p < 0.001, two-way 
ANOVA); however, no difference in the percentage of proliferating cells was found between 
the two porin categories in each age group (Figure 6.6A). Multiple comparisons revealed a 
significant increase in cell proliferation in the crypts with a high porin level in the 50-week 
mutants compared with the 10-week mutants (p = 0.007, two-way ANOVA) (Figure 6.6A).  
To uncover whether the inherited m.5024C>T mutation has any impact on the age-related 
increase in cell proliferation with the high porin level, I compared the percentage of dividing 
cells in the colonic crypts with normal and high levels of porin in 50-week wild-type and 
tRNAAla mutant mice. No difference in the level of cell proliferation was found between the 
genotypes or between the crypts with different porin classifications (two-way ANOVA) 
(Figure 6.6B). As the current data only includes a limited number of crypts with a high porin 
level in the aged wild-type mice, which may bias the result, the cell proliferation level of 
crypts with high porin levels should be examined in greater numbers in future analysis. 
Despite no difference in the response of cell proliferation to porin between the aged wild-type 
and the tRNAAla mutant mice, the level of porin and cell proliferation had opposite linear 
relationships in controls and mutants at 10 weeks (Figure 6.7). The percentage of proliferating 
cells in crypts was positively correlated with the porin level in the 10-week wildtype mice (r = 
0.4553, p = 0.012), whereas it was negatively correlated with porin in 10-week mutant mice (r 
= -0.2645, p = 0.016) (Pearson correlation analysis) (Figure 6.7). However, for 50-week mice, 
despite the same trend within the same genotype as the 10-week mice, the linear relationships 
between cell proliferation and porin was not statistically significant in either wild-type or 
tRNAAla mutant mice (Pearson correlation analysis) (Figure 6.7). 
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Figure 6.6 Associations between the level of cell proliferation and porin in colonic crypts. (A) The 
percentage of proliferating cells in the crypts of the 10-week and 50-week tRNAAla mutants with normal 
and high porin levels. The number of crypts with normal and high porin level = 52 and 31 (10 weeks), 
50 and 27 (50 weeks) respectively. **, p < 0,01, two-way ANOVA. (B) The fraction of proliferating 
cells in crypts with normal and high porin levels in the 50-week wild-type and tRNAAla mutant mice. 
The “high porin” group in this figure include the crypts with “high” and “very high” porin level in Figure 
6.5A. The number of crypts with normal and high porin = 25 and 5 (WT), 50 and 27 (tRNAAla mutants) 
respectively. 
 
Figure 6.7 Linear relationships between the level of cell proliferation and porin in colonic crypts of the 
10-week and 50-week wild-type and tRNAAla mutant mice. Linear relationships between the percentages 
of proliferating cells and the z-scores of porin protein level in each crypt are shown as lines. Full and 
dotted lines indicate statistically significant and non-significant linear relationships (Pearson correlation 
analysis). Significant equations for linear regression are: 10-week wildtypes,Y = 6.702*X + 38.19, R2 
= 0.207 and 10-week mutants, Y = -3.427*X + 46.08, R2 = 0.070. The number of crypts analysed: n 
(10-week wildtypes) = 30, n (10-week mutants) = 83, n (50-week wildtypes) = 30, n (50-week mutants) 
= 77. 
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6.4.3 Cell population in colonic crypts 
Despite no significant difference in the frequency of proliferating cells in colonic crypts 
between the wild-type and the tRNAAla mutant mice, a slight change in cell proliferation 
might result in massive alteration in the cell population. Therefore, I quantified the number of 
cells (labelled by Hoechst) in individual crypts in the tRNAAla mutant mice and compared it 
with that in the wild-type mice at 10 and 50 weeks. The results showed a significantly lower 
number of cells in crypts of the tRNAAla mutants compared with the wildtypes, regardless of 
age (p = 0.001, two-way ANOVA) (Figure 6.8A). Nevertheless, the difference between the 
genotypes within the same age group was not of statistical significance (two-way ANOVA) 
(Figure 6.8A). This is probably due to the small sample size. The individual analysis 
confirmed consistent counting between the individuals within the group of the 10-week wild-
type and mutant mice and 50-week mutants; however, the cell population in mouse 24283 
was markedly lower than that in the other two 50-week wild-type mice, leading to significant 
intra-group variations (p < 0.001, one-way ANOVA) (Figure 6.8B). In order to determine if 
this is a robust observation, a larger number of mice will be examined in the future study. 
To determine whether CI is associated with increased colonic crypt cell populations, I 
compared the number of cells in crypts with different absolute and relative levels of CI in the 
tRNAAla mutant mice at 10 and 50 weeks. However, I found no statistically significant 
difference in the cell population between crypts with different CI levels at any age (two-way 
ANOVA). In addition, I found no correlation between the absolute and relative CI level and 
the number of cells in crypts in any group of mice (Pearson correlation analysis). I also 
investigated whether the mitochondrial mass is associated with the crypt cell population. 
However, I found no statistically significant difference in the number of cells in crypts 
between the crypts with normal and high levels of porin in the tRNAAla mutant mice (two-way 
ANOVA) nor any correlation between the porin level and the population of colonic epithelial 
cells in any groups of mice (Pearson correlation analysis).    
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Figure 6.8 Colonic epithelial cell population in the (A) grouped and (B) individual wild-type and 
tRNAAla mutant mice at 10 weeks and 50 weeks. The number of cells whose nuclei were labelled by 
Hoechst was counted in individual crypts. (A) The number of crypts examined: n (10-week wildtypes) 
= 30, n (10-week mutants) = 31, n (50-week wildtypes) = 30, n (50-week mutants) = 25. (B) The 10-
week mutant mice, B933, B934, B938, B945 and B952 carried 79%, 77%, 77%, 74% and 71% 
m.5024C>T in the ear respectively. The 50-week mutants, 372, 365, 353, 370 and 369 carried 80%, 
79%, 73%, 73% and 71% m.5024C>T in the ear respectively. The number of crypts investigated: n 
(B988) = 10, n (B994) = 10, n (B995) = 10, n (B933) = 7, n (B934) = 7, n (B938) = 6, n (B945) = 6, n 
(B948) = 5, n (24283) = 10, n (24769) = 10, n (WT201) = 10, n (372) = 5, n (365) = 7, n (353) = 4, n 
(370) = 5 and n (369) = 4. 
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6.4.4 Verification of mitochondrial mass markers 
As shown in 6.4.2.3, though the porin level in the tRNAAla mutant mice was higher than that 
in the wild-type controls, which was in line with the Tom20 level, it decreased with age in the 
mutants, unlike the Tom20. This might be due to the different sections that I examined or 
different attributes of mitochondrial mass markers. In addition, the porin antibody was 
unstable and presented unspecific bindings and uneven labelling on some sections in the 
presence of the apoptosis marker (cleaved caspase-3). Moreover, the isotype of the Tom20 
antibody conflicted with that of the apoptosis marker. Thus, neither porin nor Tom20 was 
suitable for the apoptosis study. Therefore, it is necessary to assess different mitochondrial 
markers for ascertaining the difference between the findings of porin and Tom20 and for the 
investigation into the association between apoptosis and mitochondrial mass. I firstly tried 
COX4, which is a nuclear-encoded subunit used in the human studies (Chapter 3). I 
performed immunofluorescence to compare the protein levels of COX4 and Tom20, and their 
relationship with the level of CI (NDUFB8). However, I found crypts with COX defects often 
concomitant with CI deficiency in both 10-week and 50-week tRNAAla mutant mice but not in 
age-matched wild-type controls, suggesting that COX4 expression was affected by the 
inherited m.5024C>T mutation and should not be used as a mitochondrial marker for this 
study (Figure 6.9).  
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Tom22 is a key subunit of the translocase of the outer mitochondrial membrane (TOM) 
complex mediating the import of cytosolic proteins into mitochondria with Tom20 and 
Tom40 subunits (Saeki et al., 2000; Yano et al., 2000; Yamano et al., 2008; Wiedemann and 
Pfanner, 2017), which has been used as a mitochondrial mass marker in many studies (Latil et 
al., 2012; Shi et al., 2014). Tim23 is a crucial channel-forming protein of the presequence 
translocase of the inner mitochondrial membrane (TIM23 complex) that accepts proteins with 
presequence and manipulates their transportation into mitochondria (Truscott et al., 2001; 
Wiedemann and Pfanner, 2017). Tim23 has also been used to label mitochondria and has 
proved to be consistent with other mitochondrial mass markers such as porin and Tom20 
(Tang et al., 2013). To verify different mitochondrial markers, I performed 
immunofluorescence to determine the expression of SDHA, Tom20, Tom22 and Tim23 on 
colon sections of the 10-week and 50-week wild-type and tRNAAla mutant mice. The images 
show notably stronger signals of all four markers in the mutants compared with the wild-type 
controls, though the contrast at 50 weeks was not as obvious as that at 10 weeks (Figure 6.10).  
The pixel intensity of approximately 105 crypts in each mouse was quantified and 
transformed into z-scores, allowing precise comparison of the protein levels of the four 
markers. For categorical analysis, z-scores were sorted into “very low”, “low, “normal”, 
“high” and “very high” as described in Chapter 5. The results of Tom20 was consistent with 
the findings in  Chapter 5, showing that the mutants had a higher level of Tom20 in the 
colonic crypts than the wildtypes and that the expression of Tom20 increased with age in both 
wild-type and mutant mice (Figure 6.11). The expression of Tim23 showed the same trend 
with that of the Tom20 (Figure 6.11). A minor difference was that Tim23 expression elevated 
in more crypts of the 10-week mutants compared with Tom20 (Figure 6.11). The level of 
SDHA and Tom22 presented the same tendency as porin in the tRNAAla mutant mice, where 
the 50-week mutants had lower levels of SDHA, Tom22 and porin in crypts compared with 
the 10-week mutants (Figure 6.11 and Figure 6.5). These results confirmed an increase in 
mitochondrial mass in the colonic crypts of the tRNAAla mutants compared with the wild-type 
controls and revealed different trends in the expression of different mitochondrial markers 
with age in the tRNAAla mutants.  
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Figure 6.10 Example immunofluorescence images for four mitochondrial markers SDHA, Tom22, 
Tom20 and Tim23 in colonic crypts of the 10-week and 50-week wild-type and tRNAAla mutant mice. 
Z-stack pictures covering the equal scanning thickness were taken using a confocal microscope and 
integrated as a single picture for each field of view. Scale bar = 50µm. 
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Figure 6.11 Protein levels of four mitochondrial markers SDHA, Tom22, Tom20 and Tim23 in the 
colonic crypts of the wild-type and tRNAAla mutant mice at 10 weeks and 50 weeks. (A) Data were 
categorised into “very low”, “low”, “normal”, “high” and “very high” with boundaries “-3, -2, 2 and 3” 
corresponding to the 95% and 99% confidence level. (B) An overview of the median and the distribution 
of the level of mitochondrial markers. Each point signifies a single crypt. The dotted lines are the borders 
of categories in the categorical data. The number of crypts examined: n (10-week wildtypes) = 313, n 
(10-week mutants) = 544, n (50-week wildtypes) = 307 and n (50-week mutants) = 557. 
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6.4.5 Apoptosis and mouse genotype 
Mitochondria are intimately associated with the intrinsic pathway of apoptosis (Tait and 
Green, 2010). Dysregulated apoptosis has been found related to somatic mtDNA mutations 
and OXPHOS deficiency in mitotic colonic epithelium (Nooteboom et al., 2010). Apoptosis 
is conducted through cleaving and activating caspase-3, and antibodies against cleaved 
caspase-3 (active form) are commonly used as an apoptosis marker (Kujoth et al., 2005; Tait 
and Green, 2010). To determine whether apoptosis is affected in the colonic crypts of the 
tRNAAla mutant mice and whether it is involved in the selective loss of the m.5024C>T 
mutation in mitotic intestinal epithelium, I performed immunofluorescence labelling complex 
I, mitochondrial mass and apoptotic epithelial cells with antibodies against NDUFB8, Tom22 
and cleaved caspase-3 respectively (Figure 6.12). Tom22 was selected as the mitochondrial 
marker in this section because its isotype was compatible with the other antibodies. Confocal 
images were taken and processed as described in 2.9.3. Diffuse or punctate signals of cleaved 
caspase-3 were observed mainly in the cytoplasm of the colonic epithelial cells (Figure 6.12) 
(Bressenot et al., 2009). Signals that partially overlapped the nuclear area (the region with no 
Tom22 labelling in a cell) were occasionally observed, indicating nuclear translocation of the 
active caspase-3 during apoptosis (Kamada et al., 2005; Bressenot et al., 2009). Beta-catenin 
(β-catenin) is a component of the cadherin-catenin adhesion complex that is predominantly 
expressed at the cell membrane in normal colonic epithelium (Iwamoto et al., 2000; 
Brembeck et al., 2006). To facilitate the counting of apoptotic cells, I co-labelled the section 
using β-catenin as a cell surface marker (Figure 6.12). I counted the number of all 
longitudinal crypts with a definitive base and apex in a section and the number of apoptotic 
cells within them, and transformed the data to the number of apoptotic cells in a hundred 
crypts as an index of the apoptosis level. 
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Figure 6.12 Representative immunofluorescence images for apoptotic cells (cleaved caspase-3), 
complex I (NDUFB8), mitochondria (Tom22) and epithelial cell membrane (β-catenin) in colonic crypts 
of a wild-type mouse. The merged view of the β-catenin and the cleaved caspase-3 channels facilitate 
the counting of the apoptotic cells. Scale bar = 50µm. 
 
The apoptosis level in the crypts of the tRNAAla mutant mice was lower at 10 weeks but 
slightly higher at 50 weeks compared with the wild-type mice, though no statistical 
significance was found (two-way ANOVA) (Figure 6.13A). The apoptosis level did not 
change in the wild-type mice with age, whereas it increased in the tRNAAla mutant mice with 
age; however, the latter was not statistically significant (Figure 6.13A). Individual analysis 
showed notable variations between each mouse; nevertheless, it showed that most of the 10-
week mutant mice had a lower level of apoptosis in the crypts compared with the 50-week 
mutant mice (Figure 6.13B). One limitation of this study was the small sample size, which 
weakened the power of statistical analysis. To strengthen the power of the experiment, a 
greater number of mice will need to be examined in future studies. Due to the restricted 
timespan of this PhD, I was not able to complete the quantification of the complex I and the 
Tom22 level to study their relationship with the apoptosis level in the colonic epithelium of 
the tRNAAla mutant mice, but this will be carried out in future work. 
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Figure 6.13 Apoptosis level in the colonic crypts of the (A) grouped and (B) individual wild-type and 
tRNAAla mutant mice at 10 weeks and 50 weeks. The apoptosis level is denoted as the number of 
apoptotic cells in a hundred of crypts. The 10-week mutant mice, B933, B934, B938, B945 and B952 
carried 79%, 77%, 77%, 74% and 71% m.5024C>T in the ear respectively. The 50-week mutants, 372, 
365, 353, 370 and 369 carried 80%, 79%, 73%, 73% and 71% m.5024C>T in the ear respectively. 
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6.5 Discussion 
The turnover rate of gastrointestinal epithelial cells may affect the rate of losing inherited 
mtDNA mutations (discussed in Chapter 4). Cell proliferation and apoptosis affect the cell 
turnover in mitotic tissue and are intimately associated with mitochondrial functionality (Tait 
and Green, 2010; Antico Arciuch et al., 2012; Lopez and Tait, 2015; Salazar-Roa and 
Malumbres, 2017), making them potential candidates that contribute to the selective loss of 
inherited mtDNA mutations. Therefore, I have investigated the level of cell proliferation and 
apoptosis and their relationship to OXPHOS function and mitochondrial mass in the colonic 
crypts of 10-week and 50-week tRNAAla mutant mice in comparison to wild-type controls. 
I have demonstrated an increased level of cell proliferation in colonic crypts with age, 
regardless of the genotype and the OXPHOS function, which is in line with previous studies 
(Atillasoy and Holt, 1993; Nalapareddy et al., 2017). However, I found no difference in the 
frequency of proliferating colonic epithelial cells between the tRNAAla mutant and wild-type 
mice. This is in accordance with the findings in mice with accumulated somatic mtDNA 
mutations, where similar percentages of Ki-67 labelled proliferating cells in colonic crypts are 
found in ~ 50-week mtDNA-mutator mice and wild-type mice (Stamp, 2016), suggesting that 
the frequency of cells in the active cell cycle is unlikely to be affected by mtDNA mutations, 
regardless of whether they are inherited or somatic. Nonetheless, this does not rule out the 
possibility of changes in cell proliferation in the tRNAAla mutant mice, as other facets of cell 
proliferation, such as the frequency of cells in each active phase of a cell cycle (e.g. G1, S, G2 
and mitosis phase) and the rate of entering a cell cycle, have not been investigated to this 
point and are worth studying in the future. Of note, ageing is a systemic and perplex process 
with many factors changing continuously and dynamically. For example, mutations in nuclear 
oncogenes, such as K-ras and c-myc, might occur during ageing and affect cellular 
proliferation in intestines (Pappou and Ahuja, 2010; Liu et al., 2011). The finding regarding 
the 50-week mice in this study is an integrated effect of mtDNA mutations with all the other 
age-related systemic changes. 
The frequency of dividing cells in colonic crypts has no correlation with either the absolute CI 
level or the relative CI level to porin in either young or old wild-type or tRNAAla mutant mice. 
In addition, I found no difference in the proportion of dividing cells between the CI-positive 
and CI-negative crypts in the young mutant mice. However, I found a significant increase in 
the frequency of proliferating cells in the CI-positive crypts with age, resulting in a higher 
level of cell proliferation in the CI-positive crypts compared with the CI-negative crypts in the 
50-week tRNAAla mutant mice. Although the latter is not statistically significant, possibly due 
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to the small sample size, it is in line with former studies on ageing human colon samples 
which shows a decreased cell proliferation in the crypts with COX defects compared with 
those with normal COX expression (Nooteboom et al., 2010), suggesting that OXPHOS 
deficiency caused by inherited and somatic mtDNA mutations may have the same impact on 
cell proliferation in colonic crypts. In addition, this study illustrates that it is probably the 
enhanced cell proliferation in the OXPHOS-normal crypts rather than weakened proliferation 
in the OXPHOS-defective crypts with age that results in different levels of cell proliferation 
between the crypts with different OXPHOS functions in aged individuals. Overall, these 
results suggest that OXPHOS function may have an effect on cell proliferation in colonic 
crypts with age over time, but at a cross-sectional time point, it is not correlated with the level 
of cell proliferation within individuals. 
I found no significant difference in the percentage of proliferating cells in crypts with a 
normal porin level compared with those with a high porin level in tRNAAla mutant mice at 50 
weeks, though in the 10-week mutants, the level of cell proliferation is slightly lower in crypts 
with high porin level compared with crypts with normal porin level. The frequency of 
dividing cells is significantly elevated in the crypts with a high porin level at 50 weeks 
compared with that at 10 weeks, whereas it is stable in crypts with a normal level of porin 
with age, suggesting an age-related influence of mitochondrial mass on cell proliferation. 
Despite an overlapping population of crypts with high porin level and normal CI function, this 
result is unlikely to be biased by the complex I level, since similar numbers of CI-positive and 
CI-negative crypts within the population of crypts with high porin level have been analysed. 
In addition, the majority of crypts with normal porin level are CI-positive, but they do not 
show increased cell proliferation with age as the crypts with normal CI expression do. 
Furthermore, I have found opposite linear relationships between the frequency of dividing 
cells and the level of porin in colonic crypts between the 10-week wild-type and tRNAAla 
mutant mice. The cell proliferation level is positively correlated with mitochondrial mass in 
the young wild-type mice, whereas it is negatively correlated with mitochondrial mass in the 
young tRNAAla mutant mice, which is consistent with the finding regarding the crypts with 
grouped porin level in the young mutants. This suggests a distinct response of colonic 
epithelial cell proliferation to mitochondrial mass or vice versa in mutant mice with inherited 
mtDNA mutations compared with wildtype mice. Although the regression line still shows an 
opposite trend between the wild-type and the tRNAAla mutant mice, the correlation loses 
statistical significance in the old mice. This is in line with the finding that the cell 
proliferation level in the crypts with the same level of porin is not different between the 50-
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week wild-type and tRNAAla mutant mice, suggesting that age mitigates the effect of the 
inherited m.5024C>T mutation on the relationship between cell proliferation and 
mitochondrial mass.  
Despite no significant difference in the proportion of proliferating cells between the wild-type 
and the tRNAAla mutant mice, the crypt cell population is significantly smaller in the mutants 
compared with the wild-type controls, suggesting an effect of the inherited m.5024C>T 
mutation on colonic cell populations. This is in contrast to the findings in normal ageing mice 
and mtDNA-mutator mice with accumulated somatic mtDNA mutations, where the number of 
cells in crypts is higher than that in wild-type mice (Stamp, 2016; Nalapareddy et al., 2017). 
In addition to cell proliferation, populations of cells can also be altered by changes in 
apoptosis. However, analysis of the apoptosis level revealed no significant difference in the 
number of apoptotic cells in colonic crypts between the wild-type and tRNAAla mutant mice at 
either 10 weeks or 50 weeks. In fact, the apoptosis level seems lower in the mutants compared 
with controls at 10 weeks. Although cell proliferation and apoptosis are essential for 
maintaining cell populations, they do not regulate cell populations exclusively. Intestinal 
crypts in ageing animals have compromised cell proliferation and increased apoptosis, but 
they have more cells than those in young animals (Nalapareddy et al., 2017), which is also the 
case in mtDNA-mutator mice (Fox et al., 2012; Stamp, 2016). In this study, the shrinkage of 
the colonic epithelial cell population in the tRNAAla mutant mice might be a consequence of 
the small change in the frequency of dividing cells in crypts and apoptosis, which is amplified 
with age. However, it may be associated with changes in cell cycles and/or crypt structure. 
The functions and number of stem cells, as well as the signals emitted from the stem cell 
niche, may also play a role. In addition, as I have only been able to investigate the apoptosis 
level in the whole crypt cell population at present using the available tissue, it is unknown 
whether intestinal stem cells undergo enhanced apoptosis, which could be selective and 
rapidly remove the mutation in the intestinal epithelium as well as change the whole crypt cell 
population. Further investigations are required to ascertain how inherited mtDNA mutations 
affect the cell population of intestinal crypts.  
As expected, the porin level is higher in the colonic crypts of mutants compared with the 
wild-type mice in each age group. However, it is lower in the 50-week mutants than the 10-
week mutants, contrary to Tom20. Hence, I have compared the levels of different 
mitochondrial markers, including SDHA, Tom22, Tom20 and Tim23, in the colonic 
epithelium in the wild-type and tRNAAla mutant mice. All of them are upregulated in the 
mutants compared with the wildtypes in each age group, confirming that the tRNAAla mutant 
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mice indeed have a higher mitochondrial mass in the colonic epithelium than the wild-type 
mice. The 50-week mutants have a lower level of porin, SDHA and Tom22 but a higher level 
of Tom20 and Tim23 in colonic crypts compared with the 10-week mutants, suggesting 
differential effects of age on the regulation of different mitochondrial markers in the tRNAAla 
mutant mice. It is surprising that Tom22 and Tom20 change differently with age because they 
are both subunits of the TOM complex and they are functionally similar (Yamano et al., 
2008; Wiedemann and Pfanner, 2017). These findings suggest that inherited mtDNA 
mutations may have an indirect impact on the protein levels of the nuclear-encoded 
mitochondrial markers with age, which is highly protein-specific. It also reminds the 
researchers that the levels of mitochondrial markers have limits in reflecting the actual level 
of mitochondrial mass as it is dynamic and may have a specific age-related secondary 
response to mtDNA mutations.  
 
6.5.1 Future work 
One limitation of this study is the small sample size, especially the small number of the wild-
type controls. This could reduce the power of statistical analyses. More mice will undoubtedly 
be examined for the study of the frequency of proliferating cells and apoptosis in the future. 
Due to the limited period of the PhD, I have not been able to investigate the relationship 
between the apoptosis level, the OXPHOS function and the mitochondrial mass at this stage. 
This will be carried out in future work.  
Mitochondrial function and the regulation of cell cycles are mutually affected (Salazar-Roa 
and Malumbres, 2017). Key regulators of the cell cycle, for example, cyclin-Cdk complexes 
and cell cycle ubiquitin ligases, play an important role in the regulation of mitochondrial 
energy generation and biogenesis (Salazar-Roa and Malumbres, 2017). Future work will 
involve investigating the effect of inherited mtDNA mutations and OXPHOS defects on cell 
cycles using the tRNAAla mutant mice, which will include the number of cells at different 
stages of the cell cycle, the rate of entering the cell cycle and the level of cell cycle regulators.  
The shrinkage of the population of colonic epithelial cells might be associated with 
abnormalities of crypt morphology and stem cell regeneration. Wnt signalling pathway is 
crucial to the maintenance of intestinal mucosal homeostasis, crypt structure and function of 
stem cells (Fevr et al., 2007; Nalapareddy et al., 2017). Beta-catenin is a critical effector in 
Wnt signalling and is upregulated in colonic cancer (Korinek et al., 1997; Morin et al., 1997; 
Fevr et al., 2007). β-catenin has been used in this study as a cell surface marker to facilitate 
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the counting of apoptotic cells, thus its protein level can be directly measured on the images in 
place to study whether Wnt/β catenin is affected by the m.5024C>T mutation. In addition to 
the reduced crypt cell population, it is also intriguing to know whether other aspects of 
epithelial proliferation, for example, the number of crypts is reduced in the tRNAAla mutant 
mice. 
Due to the lack of reliable stem cell markers for immunofluorescence, I have been unable to 
investigate the proportion of dividing intestinal stem cells or apoptosis level in stem cells on 
the tissue samples that I currently have. Ultimately, it would be vital to investigate the impact 
of inherited mtDNA mutations on the number and function of stem cells to ascertain the 
mechanism of the selective loss of inherited mtDNA mutations. This could be achieved by 
crossing the tRNAAla mutant mice with Lgr5-EGFP-IRES-creERT2 mice (Barker et al., 2007) 
or by isolating stem cells by fluorescence-activated cell sorting using combinations of cell 
surface markers (Wang et al., 2013a; Nefzger C  et al., 2016). 
 
6.6 Conclusion 
In this study, I have investigated the frequency of proliferating cells and its association with 
the OXPHOS function and the mitochondrial mass in the colonic epithelium of the tRNAAla 
mutant mice. I have confirmed the interaction between mitochondrial functions and cell 
proliferation in these mice. I have also shown that changes in the OXPHOS function and the 
mitochondrial mass caused by inherited and somatic mtDNA mutations might have the same 
impact on cell proliferation in aged individuals. In addition, I have demonstrated a possible 
effect of the inherited m.5024C>T mutation on cell populations and the interaction between 
the mitochondrial mass and cell proliferation in colonic crypts. Finally, I have verified 
different mitochondrial markers and confirmed mitochondrial proliferation in the tRNAAla 
mutant mice compared with the wildtypes. These preliminary findings have provided ideas for 
investigating the mechanism of the selection against inherited mtDNA mutations in mitotic 
tissue and advanced the understanding of the mtDNA disease progression and phenotype 
development. However, the exact mechanism underlying the selective loss of inherited 
mtDNA mutations in dividing cells is still unknown and requires further studies. 
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Chapter 7 Final discussion 
Mitochondrial DNA diseases are characterised by highly heterogeneous clinical 
manifestations with tissue-specific distribution and phenotypic expression of mtDNA 
mutations (Taylor and Turnbull, 2005). Mitotic segregation is believed to be amongst the 
factors that affect the dynamics of mtDNA mutations in mitotic tissue, contributing to the 
heterogeneity of mtDNA disorders (Taylor and Turnbull, 2005). However, different types of 
mtDNA mutations can have opposite outcomes over time in mitotic tissue. During ageing, a 
variety of mtDNA mutations occur somatically, and clonally expand to high levels in cells, 
with no evidence suggesting any selective pressures promoting or impeding their 
accumulation (Taylor et al., 2003; Greaves et al., 2012a). In mitotic tissue, such accumulation 
of somatic mtDNA mutations initiates in adult stem cells (Taylor et al., 2003; Su et al., 2018). 
In contrast, patients with mtDNA disease lose specific inherited mtDNA mutations in mitotic 
blood and certain epithelial cells, including buccal mucosa, urine and cervical smears, 
suggesting selective pressures against inherited mtDNA mutations in mitotic cell populations 
(Olsson et al., 2001; Rahman et al., 2001; de Laat et al., 2012; Grady et al., 2018). However, 
the loss of inherited mtDNA mutations is mostly unexplored. It is unknown whether such loss 
is a universal phenomenon occurring across all types of mitotic tissues, where it occurs in 
tissue, what effects it has on tissue phenotypes and the mechanisms underlying it. 
Understanding this process is critical not only to understanding the phenotype and progression 
of mtDNA disease but also to understanding the behaviour of somatic mtDNA mutations in 
ageing. Therefore, this work aims to further the understanding of the loss of inherited mtDNA 
mutations in mitotic tissue. 
 
7.1 Gastrointestinal epithelial cells lose inherited m.3243A>G and m.8344A>G mutations 
GI epithelium is a mitotic tissue that is rapidly renewed by somatic stem cells. The genetic 
assessment of different segments of the GI tracts from patients with the common inherited 
m.3243A>G and m.8344A>G mutations revealed a significantly lower mutation load in the 
epithelium of oesophagus, stomach, small intestine and colon compared with the post-mitotic 
smooth muscle in the same segment. However, in foetuses, the inherited m.3243A>G 
mutation is evenly distributed in mitotic and post-mitotic tissues (Matthews et al., 1994; 
Cardaioli et al., 2000; Monnot et al., 2011). As there is no evidence suggesting any age-
related increase in the mutation load in muscles, the finding suggests a loss of these mutations 
in mitotic GI epithelium. In addition, there is a substantial variation in heteroplasmy levels 
between intestinal crypts, where some crypts carry no mutations. A typical feature of 
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intestinal crypts is that they undergo monoclonal conversion, which allows a single stem cell 
to dominate the stem cell niche of a crypt and renew all cells in the crypt (Kim and Shibata, 
2002; Snippert et al., 2010; Kozar et al., 2013). Therefore, these findings suggest that the loss 
of mutations occurs in intestinal stem cells, as the selection at any other level of the 
differentiation process could not result in crypts with no mutation. The selective loss of the 
inherited m.3243A>G mutation is correlated with an absence of OXPHOS deficiency in the 
GI epithelium, in contrast to the severe complex I defect in colonic smooth muscles. As 
previous studies have shown OXPHOS defects in both mitotic and post-mitotic tissues of 
teratomas that derive from iPSCs with high levels of m.3243A>G mutation (Hämäläinen et 
al., 2013), it is reasonable to assume that patients may harbour OXPHOS defects in their GI 
epithelium in the first place and the loss of mutations may recover the OXPHOS function. 
However, the effect of the mutation loss on biochemical phenotypes needs to be confirmed by 
longitudinal studies or multiple cross-sectional studies. Due to the difficulties of obtaining 
human samples, it is necessary to use an animal model for further investigations.  
 
7.2 tRNAAla mutant mice: a good model to study selective loss of inherited mtDNA mutations 
Previously, none of the mouse models with inherited mtDNA mutations have proven suitable 
for investigating the tissue-specific segregation of mtDNA mutations (reviewed in 1.6.3 of 
Chapter 1). In collaboration with Dr James Stewart and Prof Nils-Göran Larsson, Max Planck 
Institute for Biology of Ageing, Cologne, Germany, Dr Laura Greaves’ team has developed a 
novel mouse model with an inherited m.5024C>T mutation in the mitochondrial tRNAAla 
gene (Kauppila et al., 2016). These mice are suggested to be a candidate to study the loss of 
inherited mtDNA mutations as mice with a high mutation load show an age-related decline in 
m.5024C>T heteroplasmy in blood (Kauppila et al., 2016). Thorough genetic characterisation 
of these mice in two age groups reveals a loss of the m.5024C>T mutation in the mitotic 
spleen, pyloric epithelium of stomach and intestinal crypts. Such loss is absent in the post-
mitotic heart, skeletal muscle, brain and GI smooth muscles of the mutants. The considerable 
variation in m.5024C>T mutation levels between individual intestinal crypts and the presence 
of some crypts harbouring extremely low levels of mutations recapitulate the findings in 
patients with mtDNA disease. Young mutant mice present different levels of OXPHOS 
deficiency in their colonic epithelium with the magnitude of deficiency closely correlated 
with their initial mutation loads. Despite no significant changes in COX activity with age, RC 
complex I defect is slightly recovered in the old mice, which is concomitant with the decrease 
in the level of inherited m.5024C>T mutations, suggesting a beneficial effect of the loss of 
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pathogenic m.5024C>T mutations on biochemical phenotypes. In addition, these mice display 
many features the same as the patients in the human study, such as the enhanced expression of 
mitochondrial markers and the upper limit of heteroplasmy levels in the intestinal epithelium, 
and tissue-specific loss rates of mutations, which are discussed in the next two sections. In 
brief, tRNAAla mutant mice indeed have a loss of inherited m.5024C>T mutations in mitotic 
tissue. Their genetic and biochemical features recapitulate the findings in the human study, 
proving them a good model to investigate the mechanism underlying the loss of inherited 
mtDNA mutations. In addition, the examination of the mice in two age groups have provided 
useful information about the age-related genetic and biochemical changes in mitotic tissue.  
 
7.3 Upper limits in mutation levels of inherited mtDNA mutations 
In the human study, patients show an upper limit of inherited mtDNA mutations in the 
OXPHOS-normal GI epithelium, which varies between the epithelium of different GI 
segments and between the same types of epithelium in different individuals. This limit never 
exceeds the mutation level in the OXPHOS-defective smooth muscle of the same segment. 
Although the biochemical thresholds of mutations in GI epithelium and smooth muscles are 
likely to be slightly different, these results lead to an assumption that this upper limit might be 
associated with the biochemical threshold, where epithelial cells harbouring mutations beyond 
the limit may have OXPHOS defects and are eliminated by cellular quality control systems to 
decrease the mutation level in tissue. The upper limit of heteroplasmy is recapitulated in the 
intestinal and pyloric epithelium of the tRNAAla mutant mice; however, it is higher than the 
biochemical threshold for m.5024C>T to cause COX deficiency in the mouse intestinal 
epithelium (Baines, 2014), suggesting that factors in addition to OXPHOS function contribute 
to the selective loss of inherited mutations. Moreover, the genetic examination of the young 
and old tRNAAla mutant mice shows a dynamic change in m.5024C>T heteroplasmy in 
individual crypts and further confirms the existence of an upper limit. Heteroplasmy levels of 
the m.5024C>T mutation in all crypts are considerably similar in the young mice. The 
mutation levels of individual crypts drift symmetrically in both directions over time from the 
initial level until they reach the upper limit, leading to the considerable variation in crypt 
heteroplasmy in the old mutants. This results in a significant decline in the overall mutation 
level in the intestinal epithelium of the mutant mice with high initial mutation burdens, which 
is shown in this thesis, whereas in mutants with a low mutation burden from the start, such an 
effect may not be obvious. On the contrary, it might lead to an increase in the average 
mutation level of tissue. This might be able to account for the lack of mutation loss in blood 
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and increased numbers of COX-defective colonic crypts in the tRNAAla mutants with low 
initial mutation levels (Baines, 2014; Kauppila et al., 2016). It would be important to examine 
the mice with low mutation loads to advance the understanding of the dynamics of inherited 
mtDNA mutations in individual crypts with age. Upper limits of mutation heteroplasmy is a 
critical feature associated with the loss of inherited mtDNA mutations, which is absent for 
somatic mtDNA mutations as they accumulate to homoplasmy in the colonic epithelium of 
ageing humans. However, factors that determine the upper limit and mechanisms that prevent 
heteroplasmy from surpassing the limit is still unknown.  
 
7.4 Tissue-specific rates of losing inherited mtDNA mutations 
Another characteristic of the loss of inherited mtDNA mutations is the tissue-specific loss 
rate. In the human study, mutation levels of m.3243A>G in the epithelium of oesophagus, 
stomach and small intestine are different within the same patient, suggesting a different rate of 
losing the mutation. This is corroborated using the tRNAAla mutant mice, which shows a 
lower loss rate of the m.5024C>T mutation in the epithelium of gastric pylorus compared 
with the epithelium of small intestine and no significant loss of the mutation in the epithelium 
of gastric fundus. This difference might be associated with different turnover rates of different 
types of epithelial cells, as the turnover of fundic epithelial cells is markedly slower than that 
of pyloric epithelial cells, which is both slower than the epithelial turnover of intestines 
(Hoffmann, 2008). However, the lower heteroplasmy in the oesophageal epithelium compared 
with the intestinal epithelium in patients suggests that the rate of losing inherited mtDNA 
mutations is unlikely to be determined exclusively by physiological turnover rates of mitotic 
tissue, as the regeneration of oesophageal epithelium is slower than that of intestinal 
epithelium (Creamer et al., 1961; Squier and Kremer, 2001). It might also be associated with 
wound healing and repair of lesions in injured GI epithelium, considering oesophagal 
epithelium might have a higher risk of acute injuries compared with intestinal epithelium due 
to its frequent damage from food that may be of high temperature and hardness (Doupé et al., 
2012). However, the mechanism of the tissue-specific loss rate of inherited mtDNA mutations 
is still an enigma. It is also unknown whether the loss rate changes with age in tissue. Given 
that I only have the samples of mice in only two age groups in this project, it would be useful 
to examine tRNAAla mutant mice at multiple stages of lifespan in the future. 
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7.5 Hypotheses for potential mechanisms underlying the selective loss of inherited mtDNA 
mutations in mitotic cells 
The ultimate question of this project is how inherited mtDNA mutations are lost in mitotic 
tissue and why somatic mtDNA mutations lack such selective pressure and accumulate with 
age. Due to the limited time of this PhD, a number of questions remain unanswered. 
However, this work has provided important clues for the proposal of hypotheses and further 
investigations. 
Regarding the distinct dynamics of inherited and somatic mtDNA mutations in mitotic tissue 
of patients with mtDNA disease and normal aged humans, one hypothesis is that mtDNA 
mutations are in essence under no selective pressures until they have reached a high level 
(Figure 7.1). Patients with mtDNA disease harbour high levels of mtDNA mutations from the 
start thus selection occurs earlier in patients compared with normal individuals who 
accumulate high levels of mutations only when they age (Figure 7.1). In this project, the old 
tRNAAla mutant mice show no severe complex IV defects in colonic epithelium similar to the 
young mice whereas the age-matched wild-type mice present a significant complex IV 
deficiency in colonic crypts due to the aggregation of somatic mtDNA mutations. Previous 
studies show that low levels of inherited mtDNA mutations actually exacerbate OXPHOS 
defects caused by the amassing of somatic mutations (Ross et al., 2013). These results suggest 
that high levels of m.5024C>T mutation might be required to trigger a protective effect that 
impedes the accumulation of somatic mtDNA mutations and maintains the OXPHOS function 
in mitotic tissue, which in part supports this hypothesis. However, a caveat to this hypothesis 
is that only specific inherited mtDNA mutations are lost in mitotic tissue of patients with age, 
suggesting that the selective pressures might only be induced by particular mutations, whereas 
normal individuals accumulate random mtDNA mutations during ageing. 
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Figure 7.1 Mitochondrial DNA mutations are hypothesised under no selective pressures until they have 
reached a high level. By then, they trigger certain mechanisms to remove the mutations in the mitotic 
intestinal epithelium. Patients or tRNAAla mutant mice harbour high levels of mutations from the start. 
Thus the selection occurs early. Whereas normal ageing individuals accumulate somatic mutations to a 
high level when they are aged, activating the selection late in life. If they live immortally, they might 
eventually lose somatic mutations as patients with mtDNA disease. 
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Both patients and mutant mice with inherited mtDNA mutations show an upregulated 
expression of different mitochondrial markers in GI epithelium. These markers include 
nuclear-encoded subunits of RC complexes and mitochondrial outer/inner membrane proteins. 
In tRNAAla mutant mice, despite a different change in levels with age, all of these markers 
show enhanced expressions in mutants compared with controls. These findings suggest 
increased mitochondrial proliferation in individuals with inherited mtDNA mutations. The 
aged wild-type mice also have elevated mitochondrial content compared with the young wild-
type mice, suggesting that mitochondrial proliferation might be a shared compensatory 
response to mtDNA mutations and/or OXPHOS dysfunction; however, mitochondrial 
proliferation in wild-type mice is not as strong as in the tRNAAla mutant mice. It is as yet 
unknown what determines the magnitude of mitochondrial proliferation. Mitochondrial 
content is a combined result of mitochondrial biogenesis and degradation and is intimately 
associated with mitochondrial dynamics. Three possibilities can account for a net elevated 
mitochondrial level: (1) biogenesis and degradation both increase with a stronger effect of the 
former; (2) enhanced biogenesis with reduced degradation; (3) and both decrease with a larger 
magnitude of degradation. Mitophagy is a vital process in the mitochondrial quality control 
system, which mediates the selective degradation of dysfunctional mitochondria (Youle and 
Narendra, 2011). Mitochondrial biogenesis is generally thought to non-selectively increase 
mitochondrial content (Durham et al., 2007). Based on current knowledge, the first and the 
last possibilities are more likely to facilitate the loss of inherited mtDNA mutations. 
Investigating mitochondrial biogenesis and mitophagy is crucial to the understanding of the 
mechanisms underlying the selective loss of inherited mtDNA mutations and should be 
included in future work. 
Post-mitotic tissue does not lose inherited mtDNA mutations with age. The selective loss of 
inherited mtDNA mutations is undeniably associated with mitotic attributes of tissue and 
likely adult stem cells, which is supported by the presence of intestinal crypts with no 
detectable mutations. In addition, preliminary data in this project show a decreased crypt cell 
population in colonic crypts of tRNAAla mutant mice and different age-related changes in cell 
proliferation between CI-positive and CI-negative crypts, suggesting mutation-related 
alteration in regeneration of colonic epithelial cells in tRNAAla mutant mice, which might be 
associated with dysfunction of stem cells and dividing daughter cells. However, no 
conclusions can be drawn currently, and the role that stem cells play in the mutation loss 
needs to be further investigated. 
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Here I discuss a few hypotheses about how stem cells and progenitor cells are involved in the 
loss of inherited mtDNA mutations. First, mitochondria play an important role in the 
regulation of stem cell homeostasis, and mitochondrial dysfunction caused by mtDNA 
mutagenesis can enormously affect stem cell self-renewal and differentiation (Ahlqvist et al., 
2012). Therefore, intestinal stem cells with heavy mutation load might not be able to divide to 
renew themselves and produce progeny (Figure 7.2). In addition, high levels of mtDNA 
mutations cause mitochondrial dysfunction and predispose stem cells to apoptosis, depletion 
and senescence (Figure 7.2) (Su et al., 2018). Together, these can lead to a loss of stem cells 
with high levels of mtDNA mutations in the stem cell pool, allowing stem cells with fewer 
mutations to dominate the stem cell niche and replenish the tissue, which entails a decline in 
the average mutation level of tissue. 
 
 
 
Figure 7.2 Hypothesis one: intestinal stem cells and progenitor cells with a high mtDNA mutation level 
undergo apoptosis; the function of stem cells with high mutation load might be compromised and unable 
to divide to renew themselves or generate daughter cells. As a result, stem cells with high mutation load 
will eventually be replaced by those with fewer mutations in the stem cell pool. 
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Second, some in vitro studies demonstrate that stem cells can asymmetrically segregate aged 
mitochondria into daughter cells and those with fewer aged mitochondria display more stem 
cell properties (Katajisto et al., 2015). It is possible that stem cells also have a system to 
identify dysfunctional mitochondria with high levels of inherited mutations and segregate 
them during division for self-renewal or differentiation. The daughter cells (stem cells or 
progenitor cells) with fewer dysfunctional mitochondria regenerate the tissue, whilst those 
with more dysfunctional mitochondria undergo extinction (Figure 7.3).  
 
 
 
Figure 7.3 Hypothesis two: stem cells might have ability to identify and segregate dysfunctional 
mitochondria with high mutation load in one of their daughter cells in order to reduce the mutation load 
and maintain the cellular function of the other. The one that inherits most of the dysfunctional 
mitochondria from the mother cell will undergo cell death. Defective mitochondria are red. Normal 
mitochondria are beige. Mitochondria in the transitional status are pink. 
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Third, mitophagy is essential for stem cells to maintain their identity against senescence 
(García-Prat et al., 2016). Stem cells might have a stringent quality control system to degrade 
dysfunctional mitochondria with high levels of inherited mtDNA mutations, enabling the 
biogenesis of normal mitochondria, which together decreases the mutation load in stem cells 
and their progenies (Figure 7.4). These hypothesised mechanisms might be impaired in 
normal ageing individuals, leading to the accumulation of somatic mtDNA mutations in stem 
cell populations. It would be critical to investigate the gene expression in isolated stem cells 
from tRNAAla mutant mice and compare it with that in those isolated from young and aged 
wild-type mice to understand the mechanism whereby stem cells contribute to the loss of 
inherited mutations and whether it is associated with the presence of the upper heteroplasmy 
limit of inherited mtDNA mutations.  
 
 
 
Figure 7.4 Hypothesis three: stem cells might be able to remove excessive mtDNA mutations by 
mitophagy and repopulate healthy mitochondria with enhanced mitochondrial biogenesis. 
Mitochondrial fission is required to isolate the impaired part of mitochondria for the subsequent 
mitophagy. Defective mitochondria are red. Normal mitochondria are beige. Sub-healthy mitochondria 
are pink. 
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7.6 Final conclusion 
To summarise, this work has advanced the understanding of the loss of inherited mtDNA 
mutations and its effect on biochemical phenotypes in mitotic tissue, highlighting the 
contrasting selective pressures on inherited and somatic mtDNA mutations. The tRNAAla 
mouse model has proved to be a good model for investigating the selective pressures against 
inherited mutations. Characterisation of these mice has provided important information about 
the development of the non-random distribution of inherited mtDNA mutations in different 
types of tissues and have furthered the understanding of mtDNA disease progression. This 
work has revealed important features of the selective loss of inherited mtDNA mutations and 
has demonstrated the requirement for mechanistic investigations, which are critical to 
understanding the development of mtDNA disease and ageing as well as its association with 
stem cell biology.  
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Chapter 8 Appendices 
8.1 Appendix 1 Case history of patients with mtDNA disease 
Patient 1, harbouring the m.3243A>G mutation, is a 33-year-old female with deafness, ataxia 
and GI dysmotility. Patient 2, carrying the m.3243A>G mutation, had progressive 
mitochondrial disease with deafness, diabetes, stroke-like episodes, cognitive impairment, 
cardiac abnormality, epilepsy and GI dysmotility. She died at the age of 36. Patient 3 with the 
m.3243A>G mutation, was the aunt of patient 2. She progressively developed symptoms of 
mitochondrial disease, including cognitive impairment, deafness and GI dysmotility. She died 
at the age of 64. Patient 4 harboured the m.8344A>G mutation with progressive development 
of mitochondrial disorders involving myoclonus, epilepsy, cognitive impairment and cardiac 
abnormalities. He died at age 56 years.  
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8.2 Appendix 2 Histochemical assays on colonic epithelium of the patient 4 
 
Figure 8.1 Haematoxylin and eosin staining, COX and SDH histochemical assays on colonic 
epithelium of the patient 4. Colonic crypts are severely degraded as is shown by the H and E staining. 
The morphology of cells is unidentifiable within the crypts. No tissue is labelled with the COX 
histochemical assay, which is likely due to tissue degradation. SDH assay reveals the presence of SDH 
activity in the smooth muscle; however, the labelling in the colonic crypts is possibly unspecific 
chemical precipitates on cell debris. 
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8.3 Appendix 3 “Inherited pathogenic mitochondrial DNA mutations and gastrointestinal stem 
cell populations.”   
Su, Tianhong, Grady, John P., Afshar, Sorena, McDonald, Stuart A. C., Taylor, Robert W., 
Turnbull, Doug M., & Greaves, Laura C. (2018). Inherited pathogenic mitochondrial DNA 
mutations and gastrointestinal stem cell populations. The Journal of Pathology, 246(4), 427-
432.  
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8.4 Appendix 4 “Roles of Mitochondrial DNA Mutations in Stem Cell Ageing.” 
Su, Tianhong, Turnbull, Doug, & Greaves, Laura. (2018). Roles of Mitochondrial DNA 
Mutations in Stem Cell Ageing. Genes, 9(4), 182.  
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